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Abstract 
The hormonal control of 5a- reductase activity in 
DMBA ( 7 ,12- dimethylbenz[a]anthracene)- induced rat 
mammary tumours and its relationship to tumour growth 
have been studied by measuring tumour growth, tumour 
metabolism of testosterone and plasma hormone levels 
in rats of differing endocrine status. 
Female Sprague -Dawley rats bearing actively grow- 
ing tumours, induced by an intragastric administration 
of 30 mg DMBA at 50 days of age, were allocated to one 
of the following treatment groups : - 1) Intact Control (IC), 
2) Intact + Perphenazine (IP), 3) Intact + Bromocryptine 
methanesulphonate (IB), 4) Ovariectomised Control (OC), 
5) Ovariectomised + Perphenazine (OP). Animals received 
a daily s.c. dose of drug (5 mg /kg body weight) or corn 
oil vehicle (controls), over an average treatment period 
of 12 days. The effects of the treatment regimes on 
pl4sma prolactin and plasma oestradiol levels were 
measured in the individual tumour -bearing rats and also 
in greater detail in non -tumour -bearing rats. At the 
end of treatment (dioestrus in cycling rats), a whole 
tissue homogenate of tumour was incubated under fixed 
conditions with [7a -3H] testosterone in the presence 
of an NADPH -generating system. 5a- Reduction was deter- 
mined as the sum of 5a- dihydrotestosterone and total 
5a- androstanediol production. Plasma prolactin levels 
were raised to the same extent in both IP and OP groups 
and were lowered in IB and OC groups. Plasma oestradiol 
levels were lowered in the OC, OP and IP groups, but 
not the IB group. The OC, OP and IP groups were in 
constant dioestrus, whereas rats in the IB group cycled 
normally. Tumour growth was, on average, inhibited in 
the IB group and tumours regressed rapidly in the OC 
group. Tumour growth was stimulated in the IP group, 
but, in general, was not maintained in the OP group. 
In comparison with the IC group tumour 5a- reduction was 
significantly higher in the IP group, unaltered in the 
IB group, and numerically but not significantly lower 
in the OC group. Whilst tumour 5a- reductase in the OP 
group was significantly higher than that of the OC group 
it did not differ significantly from that of the IC group 
and was significantly less than that of the IP group. 
Although, in comparison with their respective control 
groups, the groups with elevated plasma prolactin levels 
showed a higher capacity for tumour 5a- reduction, other 
intergroup comparisons indicate that ovarian hormones 
may also be involved in regulating tumour 5a- reductase 
activity. A study of testosterone metabolism in actively 
growing DMBA- induced mammary tumours, taken from un- 
treated rats at different stages of a 4 -day oestrous 
cycle, revealed that 5a- reductase was highest in tumours 
removed in metoestrus and lowest in tumours removed in 
proestrus. However the differences in 5a- reduction 
levels between tumours from the 4 stages of the cycle 
did not attain significance. Evidence is presented to 
indicate that DMBA -induced rat mammary tumours convert 
testosterone to 4- androstene- 3a,17ß -diol. The daily 
s.c. administration (1 mg /rat) of 5a- dihydrotestosterone 
and 5a- androstane- 3a,17ß -diol but not 5u.- androstane- 
3ß,17ß -diol induced a state of constant dioestrus and 
regression of DMBA- induced rat mammary tumours. The 
effects may be associated with a decreased secretion 
of oestradiol and prolactin - Tumour incidence was 
higher in rats given DMBA in proestrus and lower in 
those given DMBA in dioestrus. At all stages of the 
cycle the mean plasma prolactin levels at the time of 
DMBA administration were higher in rats which subsequently 
bore tumours than in those which did not. 
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Abbreviations Full names 
ACTH adrenocorticotrophic hormone 
ave average. 
CB 154 (B) bromocryptine (2-bromo-12'-hydroxy- 
2'- (1- methylethyl) -5/a- (2- methyl- 
propyl) ergotaman- 3',6',18 -trione) 
methanesulphonate 
c.p.m. counts per minute 
d.f. degrees of freedom 
DMBA 7,12 -dimethylbenz a anthracene 
DNA deoxyribonucleic acid(s) 
d.p.m. disintegrations per minute 
g.l.c. gas liquid chromatography 
In logarithm to the base e 
3 -MC 3- methylcholanthrene 
NADH nicotinamide- adenine dinucleotide 
(reduced form) 
NADP +, NADPH nicotinamide- adenine dinucleotide 
phosphate (oxidised and reduced 
forms) 
perphenazine (P) 4- 3- (2- chlorophenothiazin- 10 -y1) 
(also Fentazin) propyl - 1- piperazineethanol 
5a- reductase 4-ene-3-ketosteroid,5a- oxido- 
reductase 
RNA ribonucleic acid(s) 
r.p.m. revolutions per minute 
S.A. specific activity 
s.c. subcutaneous(ly) 
s.d. standard deviation of observed values 
N -4 
Abbreviations Full names 
s.e. mean standard error of estimate of 
mean values 
t.l.c. thin layer chromatography 
u.v. ultraviolet 
v/v volume by volume 












These names were used to denote the position of 
the tumours on palpation and do not necessarily corres- 
pond to particular mammary glands. 
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INTRODUCTION 
I. Breast cancer 
Early medical records suggest that cancer of the breast has occurred in the 
human species for at least 2,000 years (from Lewison, 1955). At present it is 
the most common form of malignancy in women of North America and Western 
Europe (Doll, Muir & Waterhouse, 1970; Campbell, 1971). The proportion of 
women in the UK and USA who contract the disease has been estimated at 
around 1 in 17 and 1 in 15 respectively (Forrest, 1971; Tormey & Carbone, 1976). 
The incidence of male breast cancer is less than 1% of that of females (Visfeldt 
& Scheike, 1973). Furthermore it has recently been reported that the incidence 
of breast cancer in women may be increasing (Grace, Gaudette & Burns, 1977; 
Devesa & Silverman, 1978), but the mortality rate due to the disease has not 
been markedly altered over the last three decades (Shimkin, 1967; Tormey & 
Carbone, 1976; Devesa & Silverman, 1978). 
The study of breast cancer as a distinct form of malignancy has arisen 
from observations that, to varying degrees, tumours of the breast and subsequent 
metastases retain certain properties of their tissue of origin. Just as the 
development and growth of the "normal" female breast is under hormonal control 
(Lyons, 1958; Hilgers, 1971; Ceriani, Contesso & Nataf, 1972; Ceriani, 1974), 
evidence has accumulated to indicate that the development and growth of 
cancerous tumours within this tissue may be influenced by similar hormonal 
factors. 
The distribution pattern of the world -wide incidence of breast cancer has 
been useful in studying the aetiology of the disease. Women in the USA and 
Western Europe exhibit a higher rate of breast cancer than women in other areas 
such as developing countries and Japan. There is some evidence that hormones 
may be involved in differences in breast cancer incidence between countries. 
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The markedly lower incidence of breast cancer found in postmenopausal 
Japanese women compared to their "western" counterparts (de Waard, 1964) has 
been associated with certain hormonal differences which exist between the two 
populations. MacMahon, Cole and Brown (1971) observed that high ratios of 
oestriol to oestrone plus oestradiol occur in the urine of Japanese women 
compared to American women. Based on this observation and the fact that early 
pregnancy, which protects against breast cancer, is associated with high oestriol 
excretion (Cole & MacMahon, 1969), it has been proposed that a lower risk of 
breast cancer is associated with an elevated excretion of oestriol (MacMahon, 
Cole, Brown, Aoki, Lin, Morgan & Woo, 1974). This theory has been criticised 
by Lipsett (1971) and Adams (1977), on the basis of the poor correlation between 
plasma and urinary oestrogen levels, and by Pratt and Longcope (1978), who were 
unable to find differences in oestriol production after oestradiol infusion in 
normal women and women with breast cancer. These criticisms have been 
further justified by the report that plasma levels of oestradiol and progesterone 
were unrelated to breast cancer risk in postmenopausal women (Bulbrook, Moore, 
Clark, Wang, Tong & Hayward, 1978). 
Alternatively, Adams (1977) has proposed that the high levels of serum 
DHASO4 and urinary androgen metabolites in British women compared to 
Japanese women are implicated in the higher incidence of postmenopausal breast 
cancer in western countries. This proposal is in alignment with the hypothesis 
that the "western" incidence of breast cancer is associated with overnutrition 
(de Waard, 1964). There is a strong world -wide correlation between breast 
cancer incidence and nutritional status, particularly fat intake (Lea, 1966; 
Drasar & Irving, 1973), and dietary factors, possibly involving fat, may contrib- 
ute to the increase in breast cancer incidence towards "western" levels found 
amongst second generation Japanese born in the United States (Wynder, 1968; 
Buell, 1973). The levels of urinary androsterone and aetiocholanolone, both 
being important metabolites of DHA and DHASO4 (van de Wiele & Lieberman, 
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1960), are high in obese women and are lowered during fasting as is the 
production rate of DHASO4 (Borth, Linder & Riondel, 1957; Hendrikx, Heyns & 
de Moor, 1968). However it is also true that, as opposed to the situation in 
undeveloped areas, in the western countries of the world the menarche occurs 
earlier and first pregnancy later (Marshall, 1975), both factors being conducive 
to a higher incidence of breast cancer (MacMahon, Cole & Brown, 1973). 
It might be argued that these results are equivocal because of the 
retrospective nature of the investigations. However, on the basis of a long term 
prospective study in Guernsey involving a population of approximately 5,000 
women, apparently healthy at the start of the study, it has been demonstrated 
that premenopausal women with low excretory rates of androsterone and 
aetiocholanolone, which correlate with plasma levels of DHA, DHASO4 and 
5- androstenediol (Bulbrook, Hayward & Spicer, 1971; Wang, Moore, Thomas, 
Bulbrook, Hoare, Tong & Hayward, 1979), experience an increased risk of breast 
cancer. 
The risk of breast cancer in premenopausal women also correlates with 
subnormal excretion levels of progesterone in the luteal phase of the menstrual 
cycle, but is unrelated to oestradiol levels (Bulbrook, Moore, Clark, Wang, Tong 
& Hayward, 1978). These findings agree with the suggestion of Wallace, 
Sherman, Bean, Leeper and Treloor (1978), that the increased breast cancer risk 
associated with early menarche, deferred pregnancy and late menopause 
(MacMahon, Cole & Brown, 1973; Juret, Couette & Mandard, 1976) may be due to 
a relative oestrogen excess unopposed by progesterone as reflected by longer and 
more varied cyclic patterns, at early and late stages of the reproductive period. 
Furthermore it has been reported that women undergoing hysterectomy and 
bilateral ovariectomy before the age of 40 had a reduced risk of contracting 
breast cancer (Trichopoulos, MacMahon (St Cole, 1972; Hill, Wynder, Kumar, 
Helman, Rona and Kuno, 1976), and that the breast cancer incidence rate was 
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increased in postmenopausal women who received prolonged oestrogen replace- 
ment therapy (Hoover, Gray, Cole & MacMahon, 1976). 
High prolactin levels have been found in association with a family history 
of breast cancer (Kwa, de Jong- Bakker, Engelsman & Cleton, 1974; Henderson, 
Gerkins, Rosario, Casagrande & Pike, 1975; Kwa, Cleton, de Jong- Bakker, 
Bulbrook, Hayward & Wang, 1976), but, in general, a lack of correlation between 
plasma prolactin levels and the presence or absence of breast cancer hasd been 
reported (Boyns, Cole, Griffiths, Roberts, Buchan, Wilson & Forrest, 1973; Sheth, 
Ranadive, Suraiya & Sheth, 1975; Franks, Ralphs, Seagroatt & Jacobs, 1974)ì 
Despite the fact that the period of neoplastic change cannot yet be 
determined, present evidence would suggest that hormones may play a role in the 
development of breast cancer. The questions as to which hormones are 
important and whether, in the human, these hormones can act directly as 
carcinogens or whether their effect is to render the tissue more susceptible to as 
yet unidentified carcinogenic agents remain to be answered. 
The first indication that the growth of established mammary cancers may 
be controlled in some cases by endocrine manipulation was provided as early as 
1896 by Beatson who reported the regression of breast tumours in premenopausal 
women following ovariectomy. Later it was shown that adrenalectomy (Huggins 
& Bergenstal, 1952; Dao, 1972) and pituitary ablation (Luft & Olivecrona, 1953; 
Forrest & Stewart, 1967) were of benefit to a proportion of postmenopausal 
women with breast cancer. In addition certain groups of breast cancer patients 
have derived benefit from the administration of androgens (Co- operative Breast 
Cancer Group, 1964; Kennedy & Yarbro, 1968; Hayward, 1970), progesterone 
(Jones, 1962; Briggs, Caldwell & Pitchford, 1967), large doses of oestrogens 
(Hayward, 1970; Stoll, 1973) and anti- oestrogens (Cole, Jones & Todd, 1971; 
EORTC, 1972; Ward, 1973). Amelioration of the disease has also been reported 
following treatment with drugs which interfere with the secretion of adrenal 
steroids such as aminoglutethimide (Wells, Haagensen, Misbin, Lipton, Smart & 
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Santen, 1976; Smith & Powles, 1978) and dexamethasone (Borkowski, L'Hermite, 
Dor, Longeval, Rozencweig, Muquardt & van Cauter, 1977). 
Whilst certain breast cancers in experimental animals have been shown to 
be dependent upon circulating levels of prolactin (Welsch & Nagasawa, 1977), and 
a role for prolactin in human breast cancer has also been proposed (McGuire, 
Chamness, Costlow & Shepherd, 1974; Minton, 1974 a; Smithline, Sherman & 
Kolodny, 1975; Nagasawa, 1979), the use of drugs such as L -Dopa and CB 154 
which inhibit prolactin release from the anterior pituitary have generally 
provided disappointing results in the treatment of breast cancer although 
remissions have been observed in a few individuals (Dickey & Minton, 1972; 
Heuson, Coune & Staquet, 1972; Murray, Mozaffarian & Pearson, 1972; Schulz, 
Czygan, del Pozo & Friesen, 1973; Minton, 1974 b). 
Although some primary breast cancers and metastases retain their respons- 
iveness to the hormones which regulate the growth and function of their tissue of 
origin, this property appears absent or is eventually lost by a large proportion of 
tumours. Since a positive response to hormone or ablative endocrine therapy is 
seen in less than half of the women presenting with breast cancer, it is important 
to be able to recognise these patients so that the most appropriate form of 
therapy can be given. Much effort has therefore been directed towards the use 
of in vitro methods to demonstrate hormonal sensitivity in excised tumours. 
The discovery that oestrogen target tissues possess cytoplasmic and 
nuclear receptors exhibiting a high specificity and high affinity towards oest- 
radiol (Talwar, Segal, Evans & Davidson, 1964; Toft & Gorski, 1966; Jungblut, 
Hatzel, de Sombre & Jensen, 1967) explained the earlier observation of oestrogen 
retention by target tissues (Glascock & Hoekstra, 1959; Jensen & Jacobsen, 1960 
& 1962), and provided evidence that the action of steroids was mediated by 
attachment to specific receptors. 
In keeping with the observation that some breast cancers exhibit sensitivity 
to oestrogens, appreciable levels of specific, high- affinity oestradiol receptors 
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have been found in the cytosol and nuclei prepared from breast cancers (Jensen, 
de Sombre & Jungblut, 1967; Terenius, 1968; Sander, 1969; Brooks, Locke & 
Soule, 1973). Moreover, the presence of specific cytosol and nuclear receptors 
for progesterone (Terenius, 1973; Horowitz & McGuire, 1975), androgens 
(Wagner, Gorlich & Jungblut, 1973; Maass, Engel, Trams, Nowakowski & 
Stolzenbach, 1975) and glucocorticoids (Teulings, Treurniet, Alexieva -Figusch, 
Blonk -van der Wijst & van Gilse, 1977), and cell membrane receptors for 
prolactin (Shiu, Kelly & Friesen, 1973; Costlow, Buschow & McGuire, 1974; 
Morgan, Raggatt, de Souza, Salih & Hobbs, 1977) and for insulin (Holdaway & 
Friesen, 1977) have also been identified in specimens of human breast cancer. In 
addition to oestrogen receptors, the MCF -7 cell line also possesses specific 
receptors for progesterone, androgens and glucocorticoids (Horowitz, Costlow & 
McGuire, 1975). The levels of the above -mentioned receptors vary greatly 
between specimens of breast cancer from different patients, with frequently 
negligible or unmeasureable levels being reported. From the follow -up data of 
several centres routinely measuring oestradiol receptor levels it can be con- 
cluded that although the presence of receptors is essential for, it is not 
necessarily proof of, hormone dependency in such cancers (McGuire, Carbone & 
Vollmer, 1975). 
An alternative approach which is more elaborate but may give a better 
indication of functional hormone sensitivity is to study the influence of hormones 
on tumour explants maintained in organ culture or cell lines derived from breast 
cancer tissue. Parameters such as cell proliferation, DNA, RNA and protein 
synthesis and enzyme activity have been used to monitor the responses of these 
preparations. Using this technique, Hobbs and his group have claimed that 
explants of about half the tumours studied appear to be better preserved in the 
presence of prolactin, oestradiol or testosterone, either alone or in combination 
(Flax & Salih, 1973; Flax, Salih, Newton & Hobbs, 1973; Hobbs, de Souza & 
Salih, 1974). The stimulatory effect of prolactin and also that of insulin on 
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tumour explants has been confirmed (Dilley Sc Kister, 1975; Welsch & McManus, 
1977), and stimulatory and inhibitory effects of both oestradiol and testosterone 
have been reported by other groups working on explants (Burstein & Carey, 1974; 
Finkelstein, Geier, Horn, Levij & Ever -Hadani, 1975). Cell lines from breast 
cancer also exhibit hormonal sensitivity, which appears to correlate with the 
presence of specific hormone receptors (Lippman, Bolan & Huff, 1976 a, b, c). 
The reports from a limited number of short follow -up studies claim that the 
tumour responses in vitro relate to clinical responses (Salih, Flax & Hobbs, 1972; 
Flax, Salih, Newton & Hobbs, 1973; Burstein & Carey, 1974). 
In addition to the presence of receptors and hormonal sensitivity of 
explants in vitro, a property of breast cancer tissue which is of importance in 
considerations of hormone dependency or sensitivity is its ability to metabolise 
steroid hormones. Breast cancer preparations have been found capable of the 
synthesis, from relatively inert precursors, of both hormonally active steroids 
and their subsequent metabolic inactivation. The former mechanism, because of 
its close resemblance to those described in the classical endocrine organs, has 
earned breast cancer the description of para- endocrine (Adams & Wong, 1968 a). 
The steroid interconversions known to occur in breast cancer tissue are described 
in greater detail later in the INTRODUCTION as this subject forms the basis of 
the present studies. Of particular interest was the effect of hormonal 
manipulation on tumour growth in relation to tumour metabolism of androgens, a 
group of steroids reported to be capable of inhibiting the growth of breast 
cancer. 
Since it would be unethical to raise the levels of certain hormones in 
patients with breast cancer, an animal model has been chosen for the study of 
the interrelationships between hormone levels, mammary tumour growth and 
androgen metabolism. This approach has the advantages that, in animals with a 
common background living in a controlled environment, one can obtain a large 
number of rapidly growing tumours whose growth can be easily and accurately 
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monitored. In addition treatment regimes can be adopted which increase 
tumour growth rate. The inevitable disadvantage of this approach is that 
extrapolation of results from one species to another has many restrictions, but 
useful basic knowledge can be acquired providing the model is appropriate for 
the parameters under study. 
Unlike the human species breast cancer is relatively rare in other species 
with the exception of the domestic dog (Schneider, 1970), cat (Dorn, Taylor, 
Schneider, Hibbard & Klauber, 1968) and certain laboratory strains of mouse, rat 
and rabbit (Gardner, 1953; Hamilton, 1974; Short & Driffe, 1977). Since breast 
cancer is also rare in the wild counterparts of these species (Hamilton, 1974), it 
appears that the increased rate of breast cancer may be due to the artificial 
restrictions imposed by man possibly associated with breeding restraints (Short & 
Driffe, 1977; Dorn & Schneider, 1976). The incidence of spontaneous mammary 
cancer in cats, dogs and rabbits is too low for use as experimental models, and 
the deliberate induction of tumours in these species for research purposes does 
- not appear to have been investigated. The two species commonly used for large 
scale research purposes are the mouse and rat. 
Although the spontaneous incidence of breast cancer in certain strains of 
mice is almost 100% (Nandi & McGrath, 1973), the tumours take a considerable 
time to appear and the growth of advanced tumours is not usually hormone 
dependent (de Orne, Bern & Elias, 1958; Milhlbock, 1972). Moreover viral 
components are strongly implicated in the aetiology of mammary tumours in 
mice (Bittner, 1936), but their possible involvement in human breast cancer is 
still unclear. 
Alternatively, under favourable conditions in the rat, oestrogenic com- 
pounds, such as oestrone (McEuen, 1938; Geschickter & Byrnes, 1942; Cutts & 
Noble, 1964) and diethylstilbestrol (Nelson, 1944; Dunning, Curtis & Segaloff, 
1947), synthetic chemical carcinogens, such as 2- acetaminofluorene (2AAF) 
(Wilson, de Eds & Cox, 1941; Bielschowsky, 1944), 3- methylcholanthrene (3 -MC) 
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(Dunning, 1940; Shay, Aegerter, Gruenstein & Komarov, 1949) and 7, 
12- dimethylbenz(a)anthracene (DMBA) (Geyer, Bleish, Bryant, Robbins, Saslaw & 
Stare, 1951) and various forms of radiation (Huggins & Fukunishi, 1963) rapidly 
induce tumours of the mammary gland which are largely hormone dependent 
(Dao, 1964). 
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II. The DMBA -induced mammary tumour model 
The mammary tumour model adapted for the present work was that 
induced by DMBA in the female rat. Under optimal conditions, every rat given 
DMBA will develop mammary tumours. These tumours have much in common 
with human breast cancer with regard to the involvement of endocrine factors on 
induction, site of origin, histological appearance and influence of hormones on 
tumour growth. For these reasons this model has been widely studied. It is 
thus pertinent to outline some of the properties of the DMBA- induced tumour, 
drawing comparisons with the human disease where relevant. 
Chemical induction of breast tumours was first observed by Maisin and 
Coolen (1936), following the repeated application of 3 -MC to the skin of mice. 
3 -MC was also found to induce mammary tumours in rats (Shay, Aegerter, 
Gruenstein & Komarov, 1949). The synthesis of DMBA (Bachmann & Chemerda, 
1938; Newman, 1938) provided an alternative carcinogen for the induction of 
mammary tumours (Geyer, Bleish, Bryant, Robbins, Saslaw & Stare, 1951), which 
proved more potent that 3 -MC (Huggins, Grand & Brillantes, 1961). Huggins, 
Grand and Brillantes (1961) reported no fatalaties and the appearance of 
mammary tumours in 100% of a series of female Sprague -Dawley rats given a 
single oral dose of DMBA at 50 days of age. Although DMBA is the more potent 
carcinogen, 3 -MC has been used for several mammary tumour studies. Since 
the properties of tumours induced by the two carcinogens appear to be identical, 
work carried out on not only DMBA - but also 3 -MC- induced mammary tumours 
is cited. 
It has been shown that the induction of mammary tumours is highly 
dependent on the strain of rat, with Sprague - Dawley appearing to be the most 
susceptible (Kim & Furth, 1960 a; Boyland & Sydnor, 1962; Sydnor, Butenandt, 
Brillantes & Huggins, 1962; Engelbart & Gericke, 1964; Gruenstein, Meranze, 
Thatcher & Shimkin, 1966). The age at which the carcinogen, whether 3 -MC or 
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DMBA, is given is also a critical factor in mammary tumour induction, the most 
susceptible period in Sprague - Dawley females being 50 - 60 days of age 
(Huggins, Grand & Brillantes, 1961; Dao, 1969). There is strong evidence that 
DMBA acts directly on the mammary gland to induce tumours (Dao, Tanaka & 
Gawlak, 1964; Brennan, Grau & Singley, 1966; Dao, King & Gawlak, 1968; Dao 
& Sinha, 1972; Sinha & Dao, 1974), and it has been postulated that the stage and 
rate of development of the breast is critical with regard to these variations in 
susceptibility (Huggins, Grand & Brillantes, 1959; Dao, 1965 and 1969; Russo & 
Russo, 1978 a). As the breast develops under hormonal regulation the level of 
DNA, the rate of DNA synthesis, and the binding of DMBA to the DNA of 
epithelial cells correlate well with susceptibility to mammary tumour induction 
(Janss, Moon & Irving, 1972; Nagasawa & Yanai, 1974; Fysh & Okey, 1978; Janss 
& Ben, 1978; Russo & Russo, 1978 b). It is generally accepted that DMBA, like 
most other carcinogens, must be metabolically activated to form covalent bonds 
and exert a carcinogenic effect (Sims & Grover, 1974; Heidelberger, 1975; 
Tamulski, Morreal & Dao, 1973; de Pierre & Ernster, 1978). 
Since the development of the breast and the associated rate of epithelial 
cell DNA synthesis are hormonally controlled (Lyons, 1958; Lyons, Li & Johnson, 
1958; Nagasawa & Yanai, 1974; Stoudemire, Stumpf & Sar, 1975), it is not 
surprising that in common with breast cancer in humans, endocrine factors are 
also involved in the induction of mammary tumours in the rat by carcinogens. 
Thus early pregnancy (Dao, Bock & Greiner, 1960), and prior ovariectomy (Dao, 
1962 and 1968; Welsch, Clemens & Meites, 1968) prevented the occurrence of 
the chemically induced tumours. However if ovariectomy was performed 
slightly before carcinogen treatment, concurrent treatment with prolactin and 
growth hormone increased tumour incidence significantly compared to ovariect- 
omised controls (Talwalker, Meites & Mizuno, 1964). In contrast, when 
ovariectomy was performed 30 days prior to carcinogen treatment elevation of 
prolactin secretion did not increase incidence (Welsch, Clemens & Meites, 1968). 
The inhibitory effect of ovariectomy on tumour induction was overcome by 
concommitant administration of progesterone and low, but not high, doses of 
oestradiol (Huggins, Briziarelli & Sutton, 1959). Early administration of 
oestrogen (Huggins, 1965) and progesterone (Welsch, Clemens & Meites, 1968) 
protected the mammary epithelium against the carcinogenic action of DMBA. 
Whilst the absolute requirement for ovarian hormones at the time of 
induction is unclear, the role of prolactin appears vital. Mammary tumour 
induction by 3 -MC or DMBA fell sharply when plasma prolactin levels were 
reduced by hypophysectomy (Huggins, Grand & Brillantes, 1959), and by ergot 
alkaloids (Clemens & Shaar, 1972; Nagasawa & Yanai, 1976). Tumour incidence 
was also decreased in various conditions associated with hyperprolactinaemia 
prior to carcinogen administration such as pregnancy (Dao, Bock & Greiner, 
1960), pituitary homografts (Welsch, Clemens Sc Meites, 1968), hypothalamic 
lesions (Welsch, Clemens & Meites, 1969; Klaiber, Gruenstein, Meranze & 
Shimkin, 1969), ether stress (Gala & Loginsky, 1973), reserpine (Welsch & Meites, 
1970), oestrogens (Kledzik, Bradley & Meites, 1974) and oral contraceptives 
(Weisburger, Weisburger, Griswold & Casey, 1968; Welsch Sc Meites, 1969). 
The role of prolactin in mammary carcinogenesis is not simple, and it 
appears that the level of prolactin is important in the control of the develop- 
mental stage of the breast at which time the tissue is most susceptible to 
carcinogenic attack (Meites & Clemens, 1972; Meites, Lu, Wuttke, Welsch, 
Nagasawa & Quadri, 1972). If prolactin levels are within the normal range the 
breast is highly susceptible to carcinogens between 50 and 60 days of age 
(Huggins, Grand & Brillantes, 1961; Dao, 1969). By abnormally elevating 
plasma prolactin two or three weeks prior to carcinogen administration the 
development of the breast is accelerated leaving the breast refractory to tumour 
induction by 50 days of age (Nagasawa & Yanai, 1974). Conversely a reduction in 
prolactin levels delays or inhibits normal mammary gland development and thus 
reduces susceptibility (Nagasawa & Yanai, 1976). 
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DMBA- induced tumours appear to arise from the intraductal proliferation 
of the epithelial cells of ducts or terminal end bud elements (Middleton, 1965; 
Moon, 1969; Murad & von Haam, 1972; Russo, Saby & Isenberg, 1976; Russo, 
Saby, Isenberg & Russo, 1977). The high level of terminal end buds different- 
iating at the age when rats are most susceptible to mammary carcinogens 
correlates with tumour incidence and DNA synthesis (Russo & Russo, 1978 
a & b). It has been postulated that the majority of human breast cancers are 
also ductal in origin (Muir, 1941; Wellings, Jensen & Marcum, 1975). Almost all 
tumours appearing early after DMBA treatment are classified as adenocarcin- 
ornas and histologically resemble the adenocarcinomas commonly found in human 
breast cancer (Young, Cowan & Sutherland, 1963; Dao, 1964; Murad & von 
Haam, 1972; Russo, Saby, Isenberg & Russo, 1977). Within this general 
classification, variations in mitotic indices, differentiation and structural ele- 
ments may be observed (Murad & von Haam, 1972; Young & Hallowes, 1973). 
Considerable variations may occur between tumours on the same rat and 
between different areas of a single tumour (Huggins, Briziarelli & Sutton, 1959; 
Young & Hallowes, 1973). Mammary fibroadenomas and nodular adenoses may 
also be induced by DMBA but these, in general, have a longer latent period than 
the adenocarcinomas (Gruenstein, Meranze, Thatcher & Shimkin, 1966). 
Adenocarcinomas induced by DMBA appear very rapidly (two - three 
months) after administration of the carcinogen and grow quickly (Huggins, Grand 
& Brillantes, 1961; Huggins, Moon & Morii, 1962; Huggins & Yang, 1962). 
Multiple primary tumours are very common (Huggins, Grand & Brillantes, 1961), 
but metastases are rare, although local invasion of surrounding tissue such as 
skin and muscle may occur (Huggins, Briziarelli & Sutton, 1959; Young & Cowan, 
1963). Lack of metastases contrasts sharply with human breast cancer, but it 
has been reported that splenectomy or thymectomy or both permit metastases of 
the DMBA- induced tumour (Kim, 1970). 
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Not all adenocarcinomas induced by DMBA continue to grow with age, and 
some will become static or regress (Young, Cowan & Sutherland, 1963; Heise & 
Gorlich, 1966). Reports vary as to the proportions of static and regressing 
tumours, but it appears that the percentage of actively growing tumours reduces 
with age (Bradley, Kledzik & Meites, 1976). Rapid regrowth of some regressing 
and static tumours can occur after a time interval (Heise & Gorlich, 1966). All 
three growth variants can be found in individual rats with multiple tumours and 
have been reported to occur independently of the prevailing hormonal state or 
tumour histology (Young & Cowan, 1963). Other workers have reported a 
correlation between spontaneous growth and the histological appearance of 
tumours (Stevens, Stevens & Currie, 1965). It has been proposed that the 
variations in growth may be due to immunological factors possibly associated 
with the adrenal necrosis induced by DMBA (Huggins & Morii, 1961; Young & 
Cowan, 1963; Heise & Gorlich, 1966). 
Just as hormones play an important role in the initiation of mammary 
carcinogenesis by DMBA, the hormonal status of the animal plays a profound role 
in the development and growth of these mammary cancers. Hypophysectomy or 
ovariectomy performed after DMBA administration will cause a decrease in the 
number of palpable tumours per rat and will cause regression in the majority of 
growing tumours (Dao, 1959; Huggins, Briziarelli & Sutton, 1959; Daniel & 
Prichard, 1963; Young, Cowan & Sutherland, 1963). Marked tumour regression 
also occurs after combined ovariectomy and adrenalectomy (Sterental, 
Dominguez, Weissman & Pearson, 1963; Nagasawa & Yanai, 1970), but adrenal - 
ectomy alone has a stimulatory effect on tumour growth (Chen, Bradley & 
Meites, 1976). As with human breast cancer the responses of individual 
DMBA- induced tumours to hormonal manipulation showed marked variation 
(Segaloff, 1968; Nagasawa, Chen & Meites, 1973; Bradley, Kledzik & Meites, 
1976), but a far greater proportion of the carcinogen- induced tumours are 
hormone dependent than their human counterparts (Young, Cowan & Sutherland, 
I -14 
1963; Daniel & Prichard, 1963; Dao, 1964). It has been reported that the 
hormonal dependency of DMBA- induced tumour decreases with age (Griswold & 
Green, 1970; Bradley, Kledzik & Meites, 1976). 
From a wide range of experimental evidence it is accepted that the key 
pituitary hormone controlling the development and growth of DMBA- induced 
mammary tumours is prolactin. Thus a reduction in plasma prolactin levels 
whether by hypophysectomy (Daniel & Prichard, 1963; Sterental, Dominguez, 
Weissman & Pearson, 1963; Pearson, Llerena, Llerena, Molina & Butler, 1969), 
anti -rat prolactin serum (Butler & Pearson, 1971) or specific drug treatment 
(Muckter, Frankus & More, 1970; Nagasawa & Meites, 1970; Heuson, 
Waelbroeck -van Gaver & Legros, 1970; Cassell, Meites & Welsch, 1971; 
Stahelin, Burckhardt -Vischer & Fluckiger, 1971; Meites, Lu, Wuttke, Welsch, 
Nagasawa & Quadri, 1972; Quadri, Clark & Meites, 1973; Quadri, Kledzik & 
Meites, 1973; Welsch, de Iturri & Meites, 1973; Chan & Cohen, 1974; Sweeney, 
Poore, Kornfeld, Bach, Owen & Clemens, 1975) reduced the number of palpable 
tumours and caused regression of growing tumours. Conversely an increase in 
the number of palpable tumours and an increase in the growth rate of established 
tumours were observed when plasma prolactin levels were elevated by a variety 
of procedures including adrenalectomy (Chen, Bradley & Meites, 1976), preg- 
nancy (Dao & Sunderland, 1959; McCormick & Moon, 1965), implantation of 
pituitary homografts and pituitary tumours (Kim & Furth, 1960 a; Welsch, 
Clemens & Meites, 1968; Takizawa, 1973; Harada, 1976), hypothalamic lesions 
(Clemens, Welsch & Meites, 1968; Klaiber, Gruenstein, Meranze & Shimkin, 
1969; Welsch, Clemens & Meites, 1969; Sinha, Cooper & Dao, 1973), hypothal- 
amic implants of steroids (Nagasawa, Chen & Meites, 1969; Nagasawa & Meites, 
1970), and specific drug treatment (Pearson, Llerena, Llerena, Molina & Butler, 
1969; Meites, 1970; Meites, Lu, Wuttke, Welsch, Nagasawa & Quadri, 1972; 
Quadri, Kledzik & Meites, 1973). However there appears to be no correlation 
between serum prolactin levels that lie in the "normal range" and rats bearing 
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either fast -or slow -growing DMBA- induced tumours (Nagasawa, Chen & Meites, 
1973). 
Although the secretion of other hormones apart from prolactin may be 
changed by these procedures there is sufficient evidence to suggest that 
prolactin is important. The circulating levels of growth hormone may also be 
altered by some of the treatments listed above. However the median eminence 
lesions, which stimulate tumour growth, raise prolactin output but depress 
growth hormone secretion (Klaiber, Gruenstein, Meranze & Shimkin, 1969; 
Welsch, Clemens & Meites, 1969; Sinha, Cooper & Dao, 1973). Anti -rat 
prolactin which causes tumour regression is specific for prolactin and has little 
crossover reaction with growth hormone (Butler & Pearson, 1971). Furthermore 
the administration of prolactin free of growth hormone caused a stimulation of 
tumour growth (Meites, 1972), and reversed the regression imposed by hypo - 
physectomy (Pearson, Llerena, Llerena, Molina & Butler, 1969). Administration 
of growth hormone itself has been reported to have no effect (Pearson, Llerena, 
Llerena, Molina & Butler, 1969; Nagasawa & Yanai, 1970), or a slightly 
stimulatory effect (Li & Yang, 1974) on the growth of DMBA- induced tumours. 
Immediate regression has been reported to occur in 75 - 90% of DMBA- 
induced tumours in rats following ovariectomy (Young, Cowan & Sutherland, 
1963; Teller, Kaufman, Bowie & Stock, 1969; Bradley, Kledzik & Meites, 1976). 
Tumours often regrow when the ovariectomised rats are given progesterone plus 
low doses of oestradiol (Young & Cowan, 1963), or low doses of oestradiol alone 
(Sterental, Dominguez, Weissman & Pearson, 1963; Talwalker, Meites & Mizuno, 
1964). Huggins, Briziarelli and Sutton (1959) observed a stimulation of 
mammary tumour growth in rats ovariectomised prior to DMBA and given only 
progesterone, but progesterone alone was insufficient to reverse the inhibitory 
effects of ovariectomy performed on tumour -bearing rats (Kelly, Asselin, Labrie 
& Raynaud, 1977). However it has also been reported that in untreated 
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ovariectomised rats certain tumours will regrow after a lengthy latent period 
(Boylan, Fowler & Wittliff, 1977). 
Growth of DMBA- induced mammary tumours is also inhibited by high doses 
of oestradiol (Huggins & Yang, 1962; Dorfman, 1965), and anti -oestrogenic 
compounds, such as tamoxifen (ICI 46,474) (Nicholson & Golder, 1975), nafoxidine 
(U 11100 A) (Terenius, 1971; Heuson, Waelbroeck -van Gaver, Legros, Gallez, 
Robyn & L'Hermite, 1972), Parke -Davis CI 628 (de Sombre & Arbogast, 1974), 
and RU 16117 (Kelly, Asselin, Caron, Raynaud & Labrie, 1977). Large doses of 
prolactin overcome the inhibitory effect of oestradiol (Meites, Cassell & Clark, 
1971), but the high doses of oestradiol do not inhibit prolactin secretion and 
appear to exert their effect by direct action at tumour level (Meites, Lu, 
Wuttke, Welsch, Nagasawa & Quadri, 1972). 
The administration of progesterone (Huggins, Moon & Morii, 1962; 3abara & 
Harcourt, 1970; Kelly, Asselin, Labrie & Raynaud, 1977), low doses of 
oestrogens (Huggins, Grand & Brillantes, 1961), or the contraceptive pill combin- 
ation, Enovid (Welsch & Meites, 1969), have all been reported to stimulate 
tumour growth in intact rats. 
Since a decrease or increase in circulating oestrogen causes a correspond- 
ing change in prolactin levels (Nicoll & Meites, 1962 & 1964; Meites & Nicoll, 
1966), there has been debate as to whether the effects of oestrogen are mediated 
through prolactin secretion as proposed by Furth (Furth, 1967 & 1972), or 
whether the tumour has a basic requirement for ovarian hormones (Dao, 1971). 
In an attempt to resolve this problem, tumour growth has been monitored in 
ovariectomised and ovariectomised -plus -adrenalectomised rats in which the 
levels of lactogenic hormone have been artificially maintained or raised 
(Pearson, Llerena, Llerena, Molina & Butler, 1969; Welsch, Clemens & Meites, 
1969; Nagasawa & Yanai, 1970 & 1973; Sinha, Cooper & Dao, 1973; Leung, 
Sasaki & Leung, 1975). Under these conditions tumour growth continues or is in 
some cases stimulated for several days but these effects do not usually persist, 
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and most tumours eventually regress. Rapid regrowth could be obtained by 
grafting ovaries into such rats (Clemens, Welsch & Meites, 1968; Sinha, Cooper 
& Dao, 1973). However Pearson, Llerena, Llerena, Molina and Butler (1969) 
found that the administration of ovine prolactin to rats whose tumours had 
regressed completely following ovariectomy and adrenalectomy caused complete 
regrowth of tumours. In addition, prolonged growth of 3 -MC- induced tumours 
in ovariectomised rats whose prolactin levels were grossly elevated by pituitary 
tumour grafts has been reported (Kim & Furth, 1960 b). Hormone profiles were 
not thoroughly studied and the role of the adrenal glands, or additional properties 
of the grafts, were not assessed. Whereas it appears that elevated prolactin 
levels delay the inhibitory effect of ovariectomy on tumour growth the admin- 
istration of steroids to hypophysectomised rats did not prevent tumour regression 
(Sterental, Dominguez, Weissman & Pearson, 1963; Pearson, Llerena, Llerena, 
Molina & Butler, 1969). From these data it seems likely that the continued 
growth of most DMBA tumours has an absolute requirement for both pituitary 
and ovarian hormones acting in synergism (Sterental, Dominguez, Weissman & 
Pearson, 1963; Leung, Sasaki & Leung, 1975), but that growth rate is partic- 
ularly sensitive to changes in prolactin levels (Bradley, Kledzik & Meites, 1976). 
This concept has received support from the demonstration in DMBA- 
induced mammary tumours of not only specific cytoplasmic and nuclear receptor 
proteins for oestradiol (King, Cowan & Inman, 1965; Mobbs, 1966; Sander & 
Attramadal, 1968; Terenius, 1968; Kyser, 1970), and progesterone (Terenius, 
1973; Asselin, Labrie, Kelly, Philibert & Raynaud, 1976; Koenders, 
Geurts - Moespot, Zolingen (Sc Benraad, 1977), but also specific prolactin receptors 
in the cell membrane (Turkington, 1974; Kelly, Bradley, Shiu, Meites & Friesen, 
1974; de Sombre, Kledzik, Marshall & Meites, 1976). Prolactin may influence 
the concentration of oestrogen receptors (Vignon & Rochefort, 1974 & 1976; 
Leung & Sasaki, 1975; Sasaki & Leung, 1975), and oestradiol the number of 
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receptor sites for prolactin binding (Kledzik, Bradley, Marshall, Campbell & 
Meites, 1976). 
In addition to high doses of oestrogen and anti -oestrogens, the admin- 
istration of naturally- occurring and synthetic androgens inhibit the growth of 
DMBA - induced mammary tumours (Huggins, Briziarelli & Sutton, 1959; Harada, 
Rooks & Dorfman, 1965; Griswold, Skipper, Laster, Wilcox & Schabel, 1966; 
Teller, Stock, Stohr, Merker, Kaufman, Escher & Bowie, 1966; Heise & Gorlich, 
1966; Griswold & Green, 1970), and of a hormone -sensitive transplanted 
mammary fibroadenoma (Huggins & Mainzer, 1957). It is interesting that raising 
the dose of testosterone abolished the inhibitory effect of lower doses on tumour 
growth (Heise & Gorlich, 1966). 
The mechanism by which androgens cause tumour regression is still unclear 
but the effect can be reversed by prolactin (Quadri, Kledzik & Meites, 1974). 
Although it has been demonstrated that prolactin receptors were reduced in 
tumours which regressed after testosterone treatment it was concluded that the 
extent of the receptor reduction was probably insufficient to account for 
androgen- induced mammary tumour regression (Costlow, Buschow & McGuire, 
1976). It is also possible that androgens may interfere with oestrogen action at 
its receptor- binding level (Nicholson, Davies & Griffiths, 1978; Rochefort, 
Capony & Garcia, 1979). Specific cytoplasmic receptors for 5d- dihydro- 
testosterone have been identified in the DMBA- induced mammary tumour and 
may indicate a more direct action of androgens on tumour growth (Ip, Milholland, 
Kim & Rosen, 1978). 
In addition to prolactin and oestradiol, insulin appears to be a hormone 
essential for the maintenance and growth of D MBA-induced tumours (Hilf, Hissin 
& Shafie, 1978). DMBA- induced tumours regress in animals rendered diabetic 
experimentally (Heuson & Legros, 1970 & 1972; Cohen & Hilf, 1974 & 1975), and 
will regrow upon the administration of insulin (Heuson, Legros & Heimann, 1972). 
Insulin receptors have been identified in the plasma membrane of DMBA tumour 
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cells (Hilf, Hissin & Shafie, 1978; Shafie & Hilf, 1978). The presence of insulin 
is also essential in cultured tumour system for maximal effects of pituitary and 
ovarian hormones to be demonstrated (Pasteels, Heuson, Heuson -Stiennon & 
Legros, 1976). 
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III. Steroid metabolism 
Steroid metabolism can be considered in three parts. 
(1) Synthesis is classically associated with the endocrine organs of the adrenal 
cortex, testis, ovary and placenta. In these organs cholesterol is formed 
from non -steroidal components and serves as precursor for the synthesis of 
steroid hormones. The pathway from cholesterol to form C -21, C -19 and 
C -18 steroids is common to all these tissues. Apart from adrenal cortex 
which is exclusive in its synthesis of corticosteroids these tissues differ 
from each other in their quantitative production of specific hormones. The 
steroids so produced are secreted into the circulation for transportation to 
target tissues where they can initiate biological responses by attachment 
to specific intracellular receptors. 
(2) Target tissues have distinctive patterns of steroid metabolism. This can 
play a role in modulating responses of target tissues to steroid hormones by 
regulating the local levels of active steroid. The metabolism of steroids 
by target cells is not obligatory, however, and certain hormonal steroids 
are recovered unaltered after incubation with their target tissues (King & 
Mainwaring, 1974). 
(3) The third area of steroid metabolism can be considered as deactivation and 
preparation for excretion by transformations such as hydroxylation and 
conjugation. The liver has a large capacity for such activity (Baird, 
Horton, Longcope & Tait, 1969). 
In contrast to most other major classes of steroid which are secreted from 
endocrine organs in their ultimately active form, the C -19 steroids in the 
circulation, DHA, DHASO4, 4- androstenedione and 5- androstenediol, which are 
precursors for the major androgen, testosterone, and testosterone itself, appear 
to require further conversion to 5oc- dihydrotestosterone in situ for the expression 
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of most androgenic effects (Baulieu, Lasnitzki & Robel, 1968; Gloyna & Wilson, 
1970). 
Evidence that 50c- dihydrotestosterone functions as a proximal androgen has 
come from several sources. When tested in systems which assess androgenic 
potency, 50c- dihydrotestosterone was found to be highly active and usually the 
most potent of the naturally occurring steroids (Dorfman & Shipley, 1956; 
Lasnitzki, Whitaker & Withycombe, 1975). It has been demonstrated that 
5o -dihydrotestosterone is formed from testosterone by male accessory organs 
(Pearlman & Pearlman, 1961; Farnsworth & Brown, 1963), and that it is bound by 
the nuclei of these organs (Anderson & Liao, 1968; Brucho vsky & Wilson, 1968; 
Tveter & Attramadal, 1968). The binding of 50c- dihydrotestosterone to 
cytoplasmic androgen receptors has been widely demonstrated and occurs more 
readily than that of testosterone (Liao, Liang, Fang, Castenada & Shao, 1973; 
King Sc Mainwaring, 1974). It has also been shown that 5oc- dihydrotestosterone 
receptor complexes can stimulate DNA - dependent RNA polymerase activity in 
rat prostatic tissue (Davies & Griffiths, 1974). 
The critical conversion of testosterone to 5o - dihydrotestosterone is irrev- 
ersibly catalysed by the enzyme 50(- reductase (4- ene -3- ketosteroid, 
5o.- oxidoreductase). This enzyme has been found in both microsomal and nuclear 
fractions of the male accessory glands and appears to have an absolute 
requirement for NADPH (Brucho vsky & Wilson, 1968; Morfin, Alipoulios, 
Chamberlain & Ofner, 1970; Moore & Wilson, 1972). 
In general the quantities of active steroid available for receptor binding 
are controlled by the modulatory action of hypophyseal trophic hormones on the 
metabolism and secretion of these steroids by endocrine glands. That the final 
step in the production of 5o(- dihydrotestosterone occurs in the target tissues 
rather than in the endocrine glands provides another level for the control of 
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androgenic stimulation by modification of 5 dC- reductase activity in the target 
tissues. 
Of particular relevance to the present work are reports of prolactin 
exerting an effect on 5a- reductase activity in adrenal cortex (Witorsch & Kitay, 
1970 and 1972; Witorsch & Edwards, 1976), prostate (Helmerich & Altwein, 
1976; Kurth, Jacobi, Sinterhauf & Altwein, 1977) and liver (Schriefers, Keck, 
Klein & Schroder, 1975; Skett, Eneroth & Gustafsson, 1978). Oestradiol has 
also been reported to modulate 5o4- reductase in adrenal cortex (Kitay, Coyne & 
Swygert, 1970; Maynard & Cameron, 1973), prostate (Farnsworth, 1970; 
Griffiths, Harper, Groom, Pike, Fahmy & Pierrepoint, 1970; Belham & Neal, 
1971; Leav, Morfin, Ofner, Cavazos & Leeds, 1971; Danutra, Harper & Griffiths, 
1973; Fencl & Villee, 1973; Jenkins & McCaffery, 1974) and liver (Schriefers, 
1967; Szamatowicz, 1974; Dieringer, Lamartiniere & Lucier, 1979). Although 
differences in protocol make comparisons between these reports difficult it 
appears that the hormones can induce either stimulatory or inhibitory effects on 
5c- reductase dependent on the tissue under study. Most of these studies were 
based on the measurement of 5oc- reductase activity after manipulations to raise 
or lower prolactin and oestradiol levels in plasma. Because of the complex 
hormonal interrelationships in both male and female endocrine systems it is 
possible that some of the observed changes in 50- reductase activity could have 
resulted not only from direct actions of prolactin or oestradiol but from 
secondary changes in the plasma levels of other hormones. 
Since breast cancer, in common with normal mammary gland, is a target 
for steroid hormones and possesses specific receptors for most categories of 
steroid it is not unexpected that it should metabolise steroids. Preliminary 
indications that breast cancer might be capable of steroid interconversion have 
been provided by observations of unusual patterns of steroid metabolites in the 
urine of breast cancer patients who had received ablative endodrine therapy 
(West, Damast, Sarro & Pearson, 1956; Bulbrook & Greenwood, 1957; Bulbrook, 
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Greenwood & Williams, 1960; Chang & Dao, 1961; Adams & Wong, 1968 b; 
Adams Sc Brown, 1971). 
Early attempts to study the conversion of steroids by human breast cancer 
in vitro using non - labelled precursors revealed that human mammary gland, 
mammary fibroadenoma and adenocarcinoma all converted oestradiol to oestrone 
and that mammary cancer rapidly metabolised testosterone with 4- androstene- 
dione as a major product (Ryan & Engel, 1953; Breuer, 1958; Wotiz, Lemon & 
Voulgaropoulos, 1954). In later studies the introduction of radioactive steroids 
as precursors permitted more accurate detection and identification of the 
metabolites formed during in vitro incubations. 
Fig. 1 diagrammatically interprets the results of these studies with 
particular emphasis being given to the interconversions of C -19 steroids. The 
pathways boldly shown have been identified but may not have been invariably 
observed. The inability to confirm a conversion which others have shown to 
exist can result from the use of inappropriate incubation conditions, insensitive 
detection techniques, or the chance that some, but not all, tumours possess the 
necessary enzyme activity. The latter possibility has become apparent from the 
qualitative differences in metabolism observed in tumours of larger series 
incubated under identical conditions (de Thibault de Boesinghe & Lacroix, 1974; 
Miller & Forrest, 1976, Abul -Hajj, 1979). 
Although cleavage of the side chain of cholesterol as an initial step in the 
synthesis of steroid hormones is usually considered an exclusive property of the 
classical endocrine organs, extensive metabolism of cholesterol by breast cancer 
has been demonstrated. It yields amongst its metabolites the C -21 steroids, 
progesterone and pregnenolone (Adams & Wong, 1969), and the C -19 steroids, 
testosterone, androsterone, 4- androstenedione, 50t- androstanedione and 
5ot- androstane -30,17ß -diol (Dao, Varela & Norreal,1972). Pregnenolone is 
converted to progesterone (Adams & Wong, 1968 a; Deshpande, Carson, Martino 
& Tarquini, 1976), and to 1704- hydroxyprogesterone, DHA and 4- androstenedione 
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(Abul -Hajj, Iverson & Kiang, 1979 c). Both o(- and ß -hydroxylation at the 
20- position of 17K- hydroxyprogesterone and its conversion to 4- androstenedione 
have been demonstrated in human breast cancer (Adams & Wong, 1969). 
The metabolism of DHA and DHASO4, secreted in large quantities by the 
adrenal (Wieland, Levy, Katz & Hirschmann, 1963; Baulieu, Corpéchot, Dray, 
Emilozzi, Lebean, Mauvais- Jarvis & Robel, 1965) is of particular importance 
because of the high concentrations of DHASO4 found in plasma (Yamaji & 
Ibayashi, 1969; Doouss, Skinner & Couch, 1975), and because of the possible 
implication of DHASO4 in the aetiology of breast cancer in postmenopausal 
women (Adams, 1977). The presence of a sulphotransferase which controls the 
interconversion of DHA and its sulphate was demonstrated first in breast cancer 
by Adams in 1964 and has been subsequently confirmed by other workers (Dao & 
Libby, 1968; Jones, Cameron, Griffiths, Gleave & Forrest, 1970; Leung, Jack & 
Wood, 1972; Couch, Skinner, Tobler & Doouss, 1975). Incubation of DHA or 
DHASO4 with normal or cancerous breast yields the oxidation product 
4- androstenedione and the reduction product 5- androstenediol (Adams & Wong, 
1968 a; Jones, Cameron, Griffiths, Gleave & Forrest, 1970; Couch, Skinner, 
Tobler & Doouss, 1975; Deshpande, Carson, Martino & Tarquini, 1976; Li, Foo & 
Adams, 1978). Both of these products could act as intermediates for the 
conversion of DHA to testosterone (Miller, McDonald, Forrest & Shivas, 1973; 
Miller, Forrest & Hamilton, 1974; Abul -Hajj, 1975). DHA is also converted to 
5o(- dihydrotestosterone, 50c- androstane -3a,174 -diol and 5oc- androstanedione 
(Miller, Forrest & Hamilton, 1974; Abul -Hajj, 1975), presumably by the 
5K-reduction of 4 -ene products. 16c- Hydroxylase activity has also been noted 
in breast cancer tissue with the formation of 16K- hydroxyDHA, 5- androstene- 
3/3,16K,17ß -triol and 16K- hydroxytestosterone from DHA (Adams & Wong, 
1968 a; Jones, Cameron, Griffiths, Gleave & Forrest, 1970; Miller, Forrest & 
Hamilton, 1974). Two recent reports describe extensive oxygenation of DHA at 
the 7- position by breast cancer and normal breast (Couch, Skinner, Tobler & 
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Doouss, 1975; Li, Foo & Adams, 1978). 7 -Keto, 7othydroxy- and 7ß- hydroxy- 
DHA are all formed from DHA and in fact the lot- hydroxylated product appears 
to be the major metabolite of DHA in human breast cancer incubations. The 
physiological significance of the addition of ketone or hydroxyl groups to the 
7- position of DHA is not yet clear. 5- Androstenediol also undergoes 
7ot- hydroxylation to form 5- androstene -3,1ß,7a,17 - triol, a conversion which 
reduces the affinity of 5- androstenediol for oestrogen receptors (Li, Foo & 
Adams, 1978). 
The main products formed during the incubation of normal and cancerous 
human breast preparations with testosterone are 4- androstenedione (Breuer, 
19.58; Jenkins (Sc Ash, 1972), and the 5a- reduced products, 5oi- dihydro- 
testosterone and 5o(- androstanediol (Jones, Cameron, Griffiths, Gleave & 
Forrest, 1970; Miller, McDonald, Forrest & Shivas, 1973; Geier, Horn & 
Lichtshtein, 1974; Lippman, Bolan & Huff, 1976). 50k- Androstane -30,17ß -diol 
appears to be the major 5a- androstanediol formed (Li, Chandra, Foo, Adams & 
McDonald, 1976; Lloyd, 1979), although 5a- androstane -3ß,170 -diol has also 
been identified as a metabolite (Griffiths, Jones, Cameron, Gleave & Forrest, 
1972). In general the production of 4- androstenedione is slightly greater than 
that of the 5a- reduced products (Miller & Forrest, 1974 (Sc 1976; Abul -Hajj, 
Iverson & Kiang, 1979 a). In addition to 5a- reductase, the presence of 
5ß -reductase has also been demonstrated in some but not all breast cancers 
(Abul -Hajj, 1979). The other C -19 metabolites which have been identified after 
the incubation of radioactively labelled testosterone with human breast cancer 
are 16d- hydroxytestosterone (Adams & Wong, 1968 a; Miller, Forrest & 
Hamilton, 1974), DHA (Miller, Forrest & Hamilton, 1974), 5a- androstanedione 
(Geier, Horn & Lichtshtein, 1974; Adams & Li, 1975), epitestosterone (Griffiths, 
Jones, Cameron, Gleave & Forrest, 1972) and androsterone (Geier, Horn & 
Lichtshtein, 1974). 
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Varela and Dao (1978) reported that 5a- androstanes form the main 
products of the metabolism of 4- androstenedione by human breast cancer. These 
products may be formed directly from 4- androstenedione or via its initial 
conversion to testosterone (Jones, Cameron, Griffiths, Gleave & Forrest, 1970; 
Varela & Dao, 1978). The oestrogen responsive MCF -7 cell line was capable of 
transforming 4- androstenedione to aetiocholanolone, whereas the oestrogen 
non -responsive cell line BT -20 was not (Levitz, Raju, Sklarew & Post, 1978). 
Since the early tentative evidence for the formation of oestrogens by 
human breast cancers (Adams & Wong, 1968 a; Jones, Cameron, Griffiths, 
Gleave & Forrest, 1970; Dao, Varela & Morreal,1972), the conversion of both 
DHA and testosterone to oestradiol has been unequivocally demonstrated in 
homogenates of at least half of all breast cancers studied (Miller & Forrest, 1974 
& 1976; de _ Thibault de Boesinghe, Lacroix, Eechaute & Leusen, 1974; 
Abul -Hajj, 1975; Adams & Li, 1975; Li, Chandra, Foo, Adams & McDonald, 
1976; Abul -Hajj, Iverson & Kiang, 1979a) More recently Varela and Dao (1978) 
have shown that 4- androstenedione can also be aromatised by human breast 
cancer. 
Their inability to demonstrate the production of oestrogens by breast 
cancer cells in long term tissue culture has led d'Agata and co- workers to 
conclude that the presence of fat or normal breast tissue may be responsible for 
the formation of oestrogens from C -19 steroids by breast cancer slices (d'Agata, 
Monaco, Lippman & Loriaux, 1978). However Abul -Hajj, Iverson and Kiang 
(1979 a) have recently shown that although human breast fat cells can aromatise 
C -19 steroids, oestradiol synthesis in fat occurs at a lower rate than in 
cancerous tumour. In agreement with Miller, Shivas and Forrest (1978), they 
were unable to demonstrate aromatisation by normal breast. The problem of the 
apparent lack of aromatisation by cultured human breast cancer cells has 
recently been resolved by Maclndoe (1979), who was able to demonstrate the 
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conversion of testosterone to oestradiol if serum was present in the incubation 
medium. 
The recently demonstrated production of oestrone along with oestradiol 
from 4- androstenedione (Varela Sc Dao, 1978), and from DHA and testosterone 
(Abul -Hajj, Iverson & Kiang, 1979 a) agrees with earlier reports of a tumour 
17i -hydroxysteroiddehydrogenase capable of converting oestradiol to oestrone 
(Ryan Sc Engel, 1953; Breuer, 1958; Melville, 1973; Geier, Horn, Levij, 
Lichtshtein & Finkelstein, 1975). In common with DHA, oestradiol is also 
sulphated by a sulphotransferase system and may also be converted to oestrone 
sulphate, 2- methoxyoestrone and possibly 2- methoxyoestrone sulphate in certain 
breast cancers (Melville, 1973). However, oestriol has not been found as a 
product of oestrogen metabolism in human breast cancer (Geier, Horn, Levij, 
Lichtshtein & Finkelstein, 1975; Abul -Hajj, Iverson & Kiang, 1979 b). 
Steroid metabolism in the DMBA- induced rat mammary tumour has been 
less extensively investigated than human breast cancer. The possibility of the 
side chain cleavage of cholesterol or C -21 steroids does not appear to have been 
investigated in the DMBA- induced tumour although the formation of other C -21 
steroids from progesterone has been recently reported (Mori, Tominaga & 
Tamaoki, 1978). Steroid metabolism studies using the DMBA- induced tumour 
model have been focussed on interconversions of C -19 steroids. The results of 
these studies are diagrammatically presented in Fig. 2. 
The metabolism of DHA in DMBA- induced rat mammary carcinomas 
appears similar to that in human breast cancer. DHA is rapidly converted to 
5- androstenediol (King, Panattoni, Gordon & Baker, 1965) and 70(- hydroxy -, 
70 -hydroxy- and 7- ketoDHA (Li, Adams & Chandra, 1976) by DMBA- induced 
tumours and normal breast tissue. Testosterone, 54- dihydrotestosterone and 
5°(- androstanediol have also been identified as metabolites of DHA in DMBA- 
induced tumours (Miller, Forrest & Hamilton, 1974). A sulphotransferase for 
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--- confirmed conversions 
confirmed conversions, but intermediates not shown 
- - - possible conversions 
1. 7 -keto DHA 11. epitestosterone 
2. DHA sulphate 12. aetiocholanolone 
3. 16a- hydroxy DHA 13. 4- androstenedione 
4. 16a- hydroxy 5- androstenediol 14. testosterone 
5. Toc- hydroxy DHA 15. 16o(- hydroxytestosterone 
6. DHA 16. 50(- androstanedione 
7. 5- androstenediol 17. 5o(- dihydrotestosterone 
8. lot- hydroxy 5- androstenediol 18. oestriol 
9. 7j3- hydroxy DHA 19. androsterone 
10. oestradiol 20. 50(- androstanediol(3o) 
21. 5o(-androstanediol (3,8) 
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1975). The importance of DHA metabolism in the rat may be less than in the 
human, as 4 -ene- rather than 5- ene -C -19 steroids predominate in rat plasma 
(Dupon & Kim, 1973; Cutler, Glenn, Bush,Hodgen, Graham & Loriaux, 1978). In 
this respect the metabolism of testosterone and 4- androstenedione may be of 
more relevance. 
In 1964 King, Gordon and Helfenstein reported the conversion of testo- 
sterone to 5a- dihydrotestosterone, 501.- androstane -3x,17$ -diol, 5o(- androstane- 
dione and 4- androstenedione by hormone - dependent and hormone -independent 
DMBA- induced mammary tumours, fibroadenoma and normal breast tissue. 
5o4- Dihydrotestosterone was the major product followed by 5o.- androstanediol, 
the level of formation being greater in the tumours than in normal breast. High 
5o&- reductase activity in DMBA- induced carcinomas has been subsequently 
confirmed (Miller, Forrest & Hamilton, 1974; Mori, Tominaga & Tamaoki, 1978; 
Abul -Hajj, 1979). However, in contrast to the earlier work of King, Gordon and 
Helfenstein (1964), Mori's group found androst- 4- ene -3° ,17ß -diol to be the only 
product of testosterone metabolism by normal breast of the rat. This steroid 
was not formed when testosterone was incubated with DMBA- induced mammary 
tumours (Mori, Tominaga & Tamaoki, 1978). Testosterone is also converted in 
small amounts to DHA and 16 -OH testosterone (Miller, Forrest & Hamilton, 
1974), but no evidence has been found for the 50-reduction of testosterone 
(King, Gordon & Helfenstein, 1964; Abul -Hajj, 1979). 
In contrast to human breast cancer, the presence of an aromatase system 
in DMBA- induced mammary cancer has not been conclusively demonstrated. 
Oestradiol in very low amounts was tentatively identified as a metabolite of both 
DHA and testosterone in two DMBA- induced tumours from the same rat (Miller, 
Forrest & Hamilton, 1974). However this result has not yet been confirmed and 
other tumours have provided negative results (King, Gordon & Helfenstein, 1964; 
King, Panattoni, Gordon & Baker, 1965; Miller, Forrest & Hamilton, 1974). 
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The DMBA- induced carcinoma of the rat also differs from human breast 
cancer in that the 5o(- reduced products of testosterone account for a far greater 
percentage of the metabolism in the rat model than does 4- androstenedione. 
From the limited work on oestrogen metabolism in the rat tumour model it 
appears that oestrone is converted to oestradiol (King, Panattoni, Gordon & 
Baker, 1965), and oestradiol is converted to water soluble products (Jellinck, 
Smith & Cleveland, 1975). 
In addition to the human and rat, steroid metabolism also appears to be a 
feature of canine mammary cancer (Evans, Harvey, John & Pierrepoint, 1977), 
and of mammary cancer in mice whether arising spontaneously (Smith & King, 
1966), or maintained as specialised androgen- dependent and androgen - 
independent tumour lines (Bruchovsky & Meakin, 1973; Gordon, Smith & King, 
1974; Yamaguchi, Kasai, Minesita, Kotoh & Matsumoto, 1974). 
Since steroid metabolism would appear to be a common feature of all 
breast cancers it is important to understand its role in the disease. The high 
capacity of the DMBA- induced rat mammary tumour to form the active 
androgen, 5oc- dihydrotestosterone, and the ability of human breast cancer to 
form both 5ac- dihydrotestosterone and oestradiol from precursor steroids avail- 
able from the circulation may be relevant to tumour growth. However, the 
physiological significance of these conversions in breast cancer is not known. 
With regard to the relationships between steroid metabolism and other 
parameters, King, Panattoni, Gordon & Baker (1965) reported that the conversion 
of oestrone to oestradiol correlated positively with the growth rate of hormone - 
dependent DMBA- induced tumours but that there was no relationship between 
5oc- reductase and tumour growth in the same tumours. Hormone dependency 
was assumed if tumours regressed after ovariectomy and regrew after the 
administration of oestradiol plus progesterone but it was not stated whether 
tumour growth and steroid metabolism were measured before or after endocrine 
manipulation. Although Mori, Tominaga and Tamaoki (1978) noted that the most 
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poorly differentiated tumour of a small series of DMBA- induced rat mammary 
tumours showed the highest 5 °- reductase activity, a relationship between 
tumour histology and 5ok- reductase activity has not been established. Using 
testosterone as a precursor Abul -Hajj (1979) found that, although 50l- reductase 
activity correlated well with oestrogen receptor content in human breast 
cancers, there was no such relationship in DMBA- induced rat mammary tumours. 
However the range of values obtained for both parameters in the rat tumours 
was much narrower than in the human tumours. 
The relationships outlined above have been derived almost exclusively from 
the spontaneously arising variations between tumours with respect to steroid 
metabolism and the other parameters selected for study. No attempt has been 
made to alter these parameters, including that of steroid metabolism. In fact, 
very little is known about the control of the activity of enzymes which 
metabolise steroids in breast cancer.. 
Recent evidence has indicated, however, that androgen metabolism in 
DMBA- induced rat mammary tumours might be influenced by hormones. 
Tumours induced in rats rendered hyperprolactinaemic by chronic perphenazine 
administration from 30 days of age had a greater capacity to form both 5,x- 
dihydrotestosterone and 50c- androstanediol from testosterone than had tumours 
from normoprolactinaemic rats (Miller, Buchan & Forrest, 1974; Miller, 1974 & 
1976 a). Since perphenazine was administered both prior to and after tumour 
induction (50 days of age), it is not possible to determine whether the changes 
occurred as a result of the induction of tumours with a different potential for 
testosterone metabolism or whether alterations occurred during tumour growth. 
It has also been reported that oestradiol is capable of lowering 5os- reduction of 
testosterone by DMBA- induced mammary tumours both in vitro and in vivo 
(Miller, 1976 b & c). 
The intention of the present study was to deliberately alter the hormonal 
status of rats bearing DMBA- induced mammary adenocarcinomas in a manner 
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known to affect the growth of these tumours. Any resultant changes in steroid 
metabolism of the tumours would not only provide the opportunity to study 
possible relationships between steroid metabolism and other tumour parameters, 
but also provide an insight into the control of the activity of steroid metabolising 
enzymes in this tumour. 
Since, as discussed earlier, prolactin and oestradiol can profoundly influ- 
ence the growth of DMBA- induced mammary tumours plasma levels of these two 
hormones were specifically altered and closely monitored. Attention was 
focussed on the ability of the tumour to metabolise testosterone, in particular by 
5a-reduction, for the following reasons:- DMBA- induced tumours regress on 
androgen therapy; 5a- reductase is associated in many tissues with the express- 
ion of androgenic effects; 50t- reductase activity is high in DMBA- induced 
tumours and appears to constitute the main route of metabolism of testosterone. 
Some of the results obtained in the course of this study have been 




I. Chemicals and reagents 
With the exception of those listed below, all chemicals were obtained from 
BDH Chemicals Ltd, Poole, or Fisons Scientific Apparatus, Loughborough. These 
were of analar grade and stored according to the suppliers' specifications. 
Ethanol, also of analar grade, was redistilled twice before use. Tap water was 
deionised and distilled before use. 
Reagent 
Calf thymus DNA, type I : sodium salt 
7, 12- Dimethylbenz [a] anthracene 
Glucose -6- phosphate 
Glucose -6- phosphate dehydrogenase 
from torula yeast, type XI, 
(EC No 1.1.1.49) 
Nicotinamide adenine dinucleotide 
phosphate 
Norit A charcoal 
Anti -oestradiol -17ß serum 
(rabbit 348 /bleed 6) 
CB 154 
Corn oil (commercial sample) 
Cotton seed oil (commercial sample) 
Dextran T -70 
Sephadex LH -20 












Dr W Hunter, MRC Reproductive 
Biology Unit, Edinburgh 
Sandoz, Basle, Switzerland 
Boots, Nottingham 
Valvona & Crolla, Edinburgh 
Pharmacia, Uppsala, Sweden 
Pharmacia, Uppsala, Sweden 
Burroughs Wellcome, Beckenham 
Burroughs Wellcome, Beckenham 
Koch -Light, Colnbrook 
R A Lamb, London 
Fentazin injection (1m1 ampoules) Allen & Hanburys, London 
Perphenazine BP Allen & Hanburys, London 
Heparin Weddel Pharmaceuticals, London 
Kieselgel HF254 
+ 366 (Typ 60) Merck, Darmstadt, W Germany 
Liquifluor NEN Chemicals, Dreieich, W Germany 
3% OV -1 on gas chrom Q Applied Science Labs, Philadelphia, USA 
Rat prolactin RIA kit NIAMDD, Bethesda, USA 
Non -radioactive steroids were supplied by Steraloids, Croydon; Sigma, 
London; or Koch -Light, Colnbrook. 7oç hydroxytestosterone was supplied by 
Searle, Chicago, USA, and androst- 4- ene -3o., 17/3 -diol was a gift from Schering, 
Berlin, W Germany. All steroids were stored at 4 °C. 
[ 7 KC- 3H ] Testosterone, [ 4 - 3H ] toluene, and Na125I were obtained 
from the Radiochemical Centre, Amersham. [ 2, 4, 6, 7 - 3H ] Oestradiol was 
obtained from NEN Chemicals, Dreieich, W Germany. 
II. Purification of steroids 
[ 3H ] Testosterone was found to be chromatographically homogeneous in 
the major solvent systems used and had the same chromatographic mobility as 
authentic unlabelled testosterone. Nevertheless the precursor was purified 
immediately before use by t.l.c. in solvent system III. 
[ 3H ] Oestradiol was purified by a method based on that of Mikhail, Wu, 
Ferin and Van de Wiele (1970). 20 -40 pCi [ 3H ] oestradiol in benzene : 
methanol (85:15 v /v) was applied to a column of Sephadex LH -20 (175mm x 
10mm) and eluted with the same solvent. Radioactivity was measured in 20}11 
portions of 1ml fractions of eluate and only the 2 -3 peak fractions were pooled 
to yield purified [3H] oestradiol. 
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III. Animal procedures 
1. Animals 
Female albino rats of the Sprague -Dawley strain were used throughout. 
These animals came from a random -bred colony, maintained in the Department 
of Clinical Surgery, whose original breeding stock were obtained from Oxford 
Laboratory Animal Colonies (Bicester, Oxfordshire) in 1973. After weaning at 
21 - 26 days of age, females were isolated from males and kept virgin. Caged in 
groups of 2 - 5 these animals were housed at 21 ±2 °C with daily lighting from 
0700 - 1900 hours. Diet consisted of standard rat cake (MacGregor & Co (Leith) 
Ltd, Quayside Mills, Leith, Scotland) and tap water was provided ad libitum. 
2. Tumour induction 
At 47 - 55 days of age, a sample of blood was taken from a tail vein of each 
rat for assay of plasma prolactin and the stage of oestrous cycle assessed by 
vaginal smear. A single dose of 30mg DMBA dissolved in 2ml cotton -seed oil 
was then administered by intragastric instillation. These procedures were 
carried out between 1400 and 1600 hours under light ether anaesthesia. 
The animals, individually identified by ear markings made at DMBA admin- 
istration, were palpated weekly for mammary tumours. Once palpable, two 
perpendicular diameters of the tumours were measured two or three times 
weekly by caliper in the conscious animal. Tumour size was defined as the 
product of the two diameters and expressed in cm2. Animals bearing no 
actively growing tumours at 120 days after receiving DMBA were not used for 
tumour studies. 
3. Vaginal smears 
Daily vaginal smears were taken from rats with actively growing tumours 
above about 1.5cm2 in size and from rats used for plasma hormone studies to 
monitor the stage of the oestrous cycle. Smears were obtained by vaginal 
lavage and after microscopic examination classified according to the description 
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Figure 3. Cytology of vaginal smears in the cycling rat 
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of Long & Evans (1922). Photographs of the cell types seen in vaginal smears 
taken at different stages of the oestrous cycle are shown in Fig. 3. Cells were 
stained by the May- Grunwald -Geimsa technique (Baker, Silverton & Luckcock, 
1966) and are magnified 250 -fold. 
4. Anaesthesia 
All operative procedures and the removal of blood samples were conducted 
under ether anaesthesia. Anaesthesia was induced by placing the animal in a 
large airtight jar containing an atmosphere saturated with ether. For longer 
operative procedures anaesthesia was maintained by inhalation of ether from a 
swab in a small nose -cone. 
5. Blood collection 
Two methods were employed for the collection of blood for assaying 
plasma hormone levels. The method which could be used repeatedly in 
individual animals was to drain a volume of approximately 1 ml into a heparinised 
glass tube from a small incision of a tail vein. Since these samples were taken 
mainly for the estimation of plasma prolactin, a hormone whose levels can alter 
dramatically with stress (Nicoll, Talwalker & Meites, 1960; Stern & Voogt, 
1973), every attempt was made to obtain the sample as soon as possible after the 
animal was removed from its normal environment (usually within two minutes of 
removal from animal house). The second method of blood collection was 
performed at sacrifice and involved exsanguination via the abdominal aorta into . 
a heparinised syringe. Blood was immediately transferred to a heparin- coated 
plastic tube for plasma separation. 
Both tail vein and aorta blood samples were put on ice and then centrifuged 
at 2,500 r.p.m. for 10 minutes at 4 °C using a Mistral 6L centrifuge (MSE Ltd, 
London). The resultant plasmas were stored at -20 °C either in 100p1 aliquots in 
polythene tubes for prolactin assay or in bulk in acid -washed glass vials for 
oestradiol assay. 
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6. Surgical procedures 
Rats were bilaterally ovariectomised through two dorsal skin incisions. 
The ovary and a distal piece of the uterus were ligated, severed and removed, 
and the incisions sutured. 
7. Drugs and steroid treatment 
All drugs and steroids were dissolved or finely suspended in corn oil and 
administered daily by subcutaneous injection into the inguinal region. The 
dilution in corn oil was such that the required daily dose was always achieved by 
injecting 1 ml of the solution /kg body weight: for example, if the required dose 
was 5mg /kg a 200g rat would receive 0.2ml of a 5mg /m1 solution. When 
appropriate, control animals received the relevant volume of corn oil. 
8. Treatment protocol 
The central part of the work involved assessing the effects of five 
different hormonal manipulations on certain tumour parameters. The five 
hormonal manipulations which were each applied to groups of rats were (a) intact 
control, (b) intact + perphenazine, (c) intact + CB 154, (d) ovariectomised 
control, (e) ovariectomised + perphenazine. The animals selected for these 
groups were required to have at least one actively growing tumour greater than 
2.0cm2 in size and to be displaying regular 4 -day cycles. Treatment was 
initiated on the day of dioestrus and normally lasted 12 days so that animals 
which continued to cycle were sacrificed on the day of dioestrus. In these 
groups of animals plasma was collected from the tail vein immediately prior to 
the start of treatment and on the day of sacrifice for plasma prolactin assay. 
Also at sacrifice blood was collected from the aorta for oestradiol assay. 
9. Tumours 
At sacrifice tumours were immediately excised and processed on ice. 
Portions were taken for histology, steroid metabolism studies and, when suff- 
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icient material was available, DNA estimation and measurement of oestradiol 
receptor activity. Necrotic tumours were discarded. 
The background to other animals which were not in treatment groups listed 
above, but whose tumours were used for steroid metabolism studies, are 
described in the relevant parts of the RESULTS section. 
IV. Tumour histology 
Representative portions of tumour were fixed in 10% formal saline for 24 
hours, automatically processed, sectioned and stained in Mayer's haematoxylin 
and eosin (Baker, Silverton & Luckcock, 1966). 
V. DNA extraction and estimation 
The method was a modification of that of Burton (1956). Weighed 
duplicate portions of tumour (25 - 40mg) were finely cut and homogenised by 
hand with a ground glass mortar and pestle in 5m1 distilled water. This was 
transferred to a centrifuge tube washing the homogeniser with 2 x 2.5ml 10% 
(w /v) trichloroacetic acid which was bulked with the homogenate. The 
precipitate was then allowed to settle for at least 15 minutes at room 
temperature before centrifugation at approximately 2,000 r.p.m. on a bench 
centrifuge (MSE Ltd, London) for 3 minutes. The supernatant was discarded and 
the pellet twice resuspended in 5m1 of 5% (w /v) trichloroacetic acid, centrifuged 
and the supernatants discarded. The precipitate was then suspended in 0.5M 
perchloric acid (4.0m1), heated at 70 °C for 15 minutes, with occasional mixing, 
and centrifuged. The supernatant was carefully decanted off and the precip- 
itate resuspended in a further 2.0m1 of 0.5M perchloric acid and heated and 
centrifuged as before. The supernatant was bulked with the previous extract 
and mixed. Duplicate aliquots (2ml) were then estimated colourimetrically 
(600nm) after incubating overnight at 30 °C with diphenylamine /acetaldehyde 
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reagent (Burton, 1956). The results were read off a linear calibration curve 
constructed with calf thymus DNA standards. 
VI. Oestrogen receptor assay 
The method used was based on saturation analysis as described by Hawkins, 
Hill and Freedman (1975), with slight modifications (Hawkins, Hill, Freedman, 
Killen, Buchan, Miller & Forrest, 1977). In brief, tumours were left in tris 
buffer solution (0.25M sucrose, 10mM tris (hydroxymethyl) aminomethane and 
1mM ethylene diamine tetra -acetate pH 8.0), containing 0.5mM dithiothreitol, 
for one hour prior to homogenisation (15 seconds disruption + 45 seconds rest x 3 
using the Silverson mixer emulsifier) in tris buffer (300mg /m1). The homogenate 
was centrifuged at 105,000g for 50 minutes and the resultant supernatant used 
for assay of the cytoplasmic receptors. Duplicate tubes containing 10pg 
[3H]- oestradiol (100}ß1 tris), 0, 10, 30, 50, 70, 90 or 20,000pg non - radioactive 
oestradiol (1m1 tris) and 100p1 tumour supernatant were allowed to equilibriate 
overnight. Unbound steroid was separated by adding 0.5ml of a dextran- 
coated- charcoal solution (1.5g charcoal, 0.015g dextran /1 tris buffer) to the 
tubes which then stood for 15 minutes before centrifuging for 10 minutes at 
2,500 r.p.m. The supernatant (bound) fraction was decanted directly into a 
counting vial containing 5m1 organic scintillator solution (21m1 Liquifluor, 10m1 
ethanol and 49ml toluene). All procedures were conducted at 4 °C. Two 100}t1 
aliquots of the [3H]- oestradiol solution plus an appropriate amount of buffer 
were added directly to the scintillant to determine total counts added. "No 
protein" and "no charcoal" blanks were also included to determine the efficiency 
of the charcoal suspension and the decanting step respectively. After 
correcting for non -specific binding by subtraction of the mean value for 
20,000pg the ratio of radioactivity bound over radioactivity free on the 
ordinates is plotted against the mass of total oestradiol bound (pg) on the 
abscissa according to Scatchard (1949). The concentration of oestrogen receptor 
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binding sites (in f mol /g tissue) and dissociation constant were then calculated 
from intercept on the ordinate and gradient of the line respectively. 
VII. Incubation of tumour homogenates for steroid metabolism 
All chemicals and solutions were stored at 4 °C and all procedures prior to 
the start of the incubation were carried out on ice. A portion of tumour (wet 
weight = 0.500g) was finely sliced and sonicated twice using an Ultrasonic A180G 
sonicator (Shipley, Yorkshire), adjusted to maximum noise at power position 8 for 
1 minute with a 1 minute interval in 5m1 Krebs -Ringer solution buffered with 
phosphate (Krebs & Henseleit, 1932). The final concentrations of the compon- 
ents in this medium were NaC1, 118mM; KC1, 4.7mM; CaC12, 2.5mM; K2H PO4, 
1.18mM; MgSO4, 7H20, 1.18mM; phosphate buffer, 16mM. The stock solution 
of phosphate buffer consisted of 17.8g Na2HPO4 .2H20 plus 20m1 HCI, 1M, made 
up to a volume of 1 litre with distilled water. The pH of the final solution was 
adjusted to 7.4 at room temperature by the addition of NaOH. The homogenate 
was transferred to a conical flask containing an NADPH -generating system of 100 
umol glucose -6- phosphate, 15 }mol NADP+ and 25 units glucose -6- phosphate 
dehydrogenase (EC 1.1.1.49). A small volume of Krebs buffer was added to the 
solution of glucose -6- phosphate dehydrogenase supplied by Sigma to permit the 
accurate addition of 25 units in a convenient volume (25 or 100µl). 
To the final volume of 7.5ml was added 50 x 106 d.p.m. (= 750ng) of 
freshly purified [70( -3H] testosterone in 50111 of a solution of propylene 
glycol : ethanol (1:1, v /v). Incubation systems were aerated with a mixture of 
95% 02/5% CO2, stoppered and incubated by shaking at 37 °C for one hour in a 
water bath (Gallenkamp, London). 
The reaction was stopped by the addition of approximately 30m1 methanol 
to the flask which was stored at -20 °C until the extraction and identification of 
steroids. 
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VIII. Extraction of steroids 
Before extraction of steroids from the incubation mixture 500ug of non- 
radioactive carrier steroid in 0.5ml ethanol were added for the precursor and for 
each metabolite to be investigated. The carrier steroid served to monitor 
recovery losses during subsequent procedures and to identify the steroid on t.l.c. 
plates on examination under u.v. light. Aliquots of carrier were also used to 
prepare u.v. spectrophotometric and g.l.c. standards. 
The mixture was then centrifuged at approximately 2,500 r.p.m. on a bench 
centrifuge (MSE Ltd, London) for two minutes and the supernatant decanted off. 
The pellet was homogenised twice in 20m1 acetone washings of the incubation 
flask using a Silverson mixer emulsifier (Silverson Machines Ltd, London), (one 
minute at maximum r.p.m.) and the acetone supernatants bulked with the 
aqueous methanol supernatant. Aliquots were taken for estimation of total 
initial radioactivity. The supernatants were evaporated to dryness under a 
partial vacuum at 50 °C using a rotary evaporator (Buchi, Switzerland). The 
residue was dissolved in 20m1 ethyl acetate and partitioned with 20m1 distilled 
water. The ethyl acetate phase was separated off and the aqueous fraction 
extracted with a further 20m1 ethyl acetate. The pooled ethyl acetate fractions 
were evaporated to dryness and redissolved in 0.2ml ethanol for initial separation 
of steroids by t.l.c. The aqueous fraction was retained until t.l.c. of the organic 
fraction. 
IX. Thin layer chromatography 
1. Preparation of plates 
A slurry of Kieselgel HF254 
+ 366 (30g 
in 72ml distilled water) was spread 
over glass plates (20cm x 20cm) using a t.l.c. spreader (Shandon Scientific 
Company Ltd, London), set for a depth of 0.25mm. Plates were then dried at 
100 °C for two hours and kept desiccated until used. 
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2. Solvent systems 
The solvent systems used are listed in Table 1. The choice of solvent 
system used for particular steroids is indicated in Table 2. The Roman numerals 
following the reactions listed in this table refer to the solvent system used to 
separate the products of those particular reactions. 
3. Detection of steroids 
The unlabelled carrier steroids and their derivatives were visualised under 
a Camag TL -900 /U Universal u.v. lamp (Camlab, Cambridge) with two wave- 
length settings. At the 254nm wavelength emission 4 -ene, 3- ketosteroids 
appeared as a deep purple colour on a neutral background, whereas at 350nm 
3- hydroxylated and 5o(- reduced steroids and their derivatives appeared as a pale 
white or yellow area against a blue background. For comparison authentic 
standards were run in channels of the t.l.c. plate adjacent to those carrying the 
samples. In addition the distribution of radioactivity on the plates was located 
using a Panax RTLS -1A scanner with SREC -2 chart recorder (Panax Equipment 
Ltd, Surrey). 
4. Elution of steroids 
After detection the area of silica gel containing the steroid was scraped 
from the plate and eluted by one of two methods. In the first method, employed 
in the preliminary stages of separation, silica gel was scraped into a micro - 
column stoppered with a glass wool filter. The silica gel was deactivated with a 
few drops of water and steroids eluted from the gel into a test tube with 10m1 of 
ethanol. Prior to determination of specific activities, a second method of 
elution was adopted in which the silica gel was scraped into a test tube, a few 
drops of water and 5m1 of ethanol added and the contents mixed. After centrif- 
ugation for two minutes at approximately 2,000 r.p.m. the eluate was decanted 
off. The silica was resuspended in two further rinses of ethanol (2.5ml each) and 
after centrifugation these eluates were bulked with the previous eluate. Eluates 
from both procedures were dried in a stream of air at 60 °C. 
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Table 1 
Solvent systems for thin layer chromatography 
TIME 
SYSTE M SOLVENTS (RATIO OF VOLUMES) (Hours) CONDITIONS 
la Chloroform : acetone (98:2) 2 i continuous 
elution tank 
Ib Chloroform : acetone (185:15) 2 continuous 
elution tank 
II Chloroform : acetone (98.2) 1 Sealed tank 
III Chloroform : acetone (185:15) 1 
IV Cyclohexane : ethyl acetate (70:30) 1 
V Diethylether : ethyl acetate (95:5) 1 
VI Benzene : ethanol (90:10) 1 
VII Cyclohexane : chloroform : (140:10:50:1) 4x1 
ether : acetone 
Silica gel HF254 
+ 366 plates were used in all systems. The solvent 
in the 
sealed Shandon Chromatank was run to the top of the plate (running time = 
approximately one hour). In system VII plates were dried between 
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Roman numerals refer to the solvent systems listed in Table 1. 
a Dione = 4- androstenedione; A4Diol(3a) = 4- androstene -3a, 170 -diol; 
Testo = testosterone; 50LAdiol(304) = 5a- androstane -3a, 17a -diol; 
5aAdione = 5d.- androstanedione; 5oiAdiol(3/3) = 5a- androstane -30, 17(4-diol; 
5a-DHT = 50t- dihydrotestosterone; 50(Adiols = 5 -tAdiol (3a) + 5 Adiol(3(3); 
Ac = acetate; acetn = acetylation; oxidn = oxidation; redn = reduction; 
SA = specific activity determined. 
(b) indicates the use of alternative methods of oxidation or reduction (M -14) 
= steps omitted in determination of total 50(Adiols. 
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X. Formation of steroid derivatives 
1. Acetylation 
Acetates were prepared by the method of Zaffaroni and Burton (1951). The 
dried steroid was mixed with six drops acetic anhydride and three drops pyridine 
and incubated for one hour at 60 °C or overnight at room temperature. lml of 
methanol was added at the end of the incubation to facilitate the drying of the 
reaction products at 60 °C under a gentle air flow. 
2. Hydrolysis of acetates 
Steroid acetates were hydrolysed by overnight incubation at 37 °C in lml 
methanol + 0.25m1 2% K2CO3 in distilled water. 
3. Reduction 
(a) Apart from 4- androstenedione, reduction was performed by adding 
10mg solid NaBH4 to the steroid dissolved in lml methanol and 
leaving the mixture for 15 minutes at room temperature. 
(b) 4- androstenedione was reduced to testosterone by incubation for 35 
minutes at 0 °C with 0.1m1 of freshly prepared 0.1% NaBH4 in 
methanol. 
4. Oxidation 
(a) Apart from 4- androstenediol (300 oxidation of steroids was performed 
by the method of Griffiths, Grant and Whyte (1963). Steroids were 
incubated at room temperature for 20 minutes in 0.5ml of a freshly 
prepared solution of 5m1 acetone + 50}il of a stock oxidising solution 
(1.61g sodium dichromate /litre 5.2N H2SO4). 
(b) 4- androstenediol (30) was oxidised to testosterone by adding 100mg 
of manganese dioxide to the steroid in 0.5ml chloroform and the 
mixture shaken overnight at 37 °C. This preparation was adapted 
from the method of Attenburrow, Cameron, Chapman, Evans, Hems, 
Jansen and Walker (1952). 
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Apart from the acetates all steroids were recovered by extracting with 2 x 
5m1 ethyl acetate after the addition of 3ml distilled water. 
XI. Determination of non -radioactive steroids 
1. Spectrophotometry 
Testosterone, testosterone acetate and 4- androstenedione were dissolved in 
ethanol and absorption peak height measured at 240nm against ethanol in the 
reference cell using an SP800 spectrophotometer (Pye Unicam, Cambridge). The 
steroid content was calculated by comparison with standard solutions after 
correction against a silica gel blank taken through the same procedure as the 
steroid. 
2. Gas -liquid chromatography 
All other steroids were measured by g.l.c. analysis over a 5 ft glass column 
(diameter = 4mm) containing pretested 3% OV -1 coating on Gas Chrom Q (100 - 
120 mesh). The column was silanised by overnight steeping in a solution of 5% 
hexamethyldisilazane in toluene (5 w /v). The column was packed under reduced 
pressure and conditioned overnight (16 hours) at 230 °C with a carrier gas flow 
rate of 60m1 /minute. Chromatography was conducted at 220 °C with a carrier 
gas (argon) flow rate of 60m1 /minute in a Pye 104 Chromatograph with Flame 
Ionisation Detector, model 2a, (Pye Unicam, Cambridge). 
Internal standards, testosterone for free steroids and testosterone acetate 
for acetylated steroids, were added in the same quantity to all samples and 
standards. In each batch there were included a minimum of three standards to 
span the range of quantities in the samples. From the ratio of sample peak 
height to internal standard peak height and the mean of comparative values for 
consistent standards (less than 10% variation) the quantity of steroid in the 
sample was determined. 
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XII. Measurement of radioactivity 
Aliquots from steroid solutions were dried in glass scintillation vials (FGB- 
Trident, Avon) and dissolved in 10m1 of a mixture of 42 parts "liquifluor ", 1,000 
parts toluene. Radioactivity was measured with a Packard Tricarb Liquid 
Scintillation Counter (Packard Instrument Company Inc, Illinois, USA). Counting 
efficiency was routinely checked using a tritiated toluene standard of specified 
radioactivity and decay rate supplied by the Radiochemical Centre, Amersham. 
The radioactivity of each sample was determined by correcting the measured 
count rate for background and counting efficiency. 
XIII. Expression of steroid metabolism results 
Following purification by derivative formation and chromatography the 
specific activities (d.p.m. /nmol) were calculated for steroids and their deriv- 
atives. Once the specific activities between the parent steroid and its 
derivatives were constant (all within 5% of the mean) the mean value was used 
to calculate the formation of each characterised steroid as a percentage of the 
total radioactivity using the recovery of cold steroid to correct for losses. 
XIV. Plasma prolactin assay 
The plasma prolactin concentration was determined by radioimmunoassay 
using a kit provided by NIAMD (Hawkins, Freedman, Marshall & Killen, 1975). 
Each plasma sample was assayed in duplicate (2 x 100ul) along with standard 
solutions of rat prolactin (NIAMD RP -1, 32 to 400ng /m1 in doubling dilutions). 
Horse serum (100µ1), which contains negligible rat prolactin -like activity, was 
added to standard curve tubes so that their protein content was approximately 
similar to that of the plasma samples. Radioligand solution (100}1) containing 
20,000 c.p.m. 125I- prolactin prepared from purified rat prolactin (NIAMD- RP -I -2) 
and Na 125I by oxidation by chloramine -T (Greenwood, Hunter & Glover, 
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1963) was mixed with the non -radioactive prolactin samples before the 
addition of 200µl rabbit anti -prolactin antibody (NIAMD anti -RP -serum 2) at a 
dilution of 1:25,000. After a three -day equilibration period at 4 °C separation of 
free and bound ligand was achieved by a further incubation for one day at 4 °C 
with donkey anti -rabbit serum (Burroughs Wellcome RD -17, diluted 1:6; 200p1 
per tube) followed by centrifugation at 3,000 r.p.m. for 30 minutes at 4 °C in a 
Mistral 6L centrifuge (MSE Ltd, London). The radioactivity in the precipitate 
was determined at approximately 60% efficiency in a Wallac gamma sample 
counter GTL 300 -500 (Wallac, Turku, Finland). A value for the concentration of 
prolactin in an unknown sample was read from a plot of c.p.m. bound vs logl0 
prolactin concentration for the standard tubes. Because the reproducibility of 
the assay varied due to the inevitable deterioration on storing certain reagents, a 
correction was made in each assay with data from quality controls of rat plasma 
stored under the same conditions as unknown samples. (see A p P c"x `A 1 
XV. Plasma oestradiol assay 
Plasma oestradiol -17ß concentration was determined by radioimmunoassay 
using modification of the method of de Jong, Hey and van der Molen (1973) as 
described by Hawkins, Freedman, Marshall and Killen (1975). To each plasma 
sample (2.5 - 5m1) was added[ 3H1 oestradiol tracer (~2pg), 50µl 1M sodium 
hydroxide and the volume made up to 5m1 with water. Samples were extracted 
with 2 x 10m1 diethylether and evaporated to dryness. The dried extracts were 
redissolved in 100}t1 toluene /methanol (9:1, v /v) and chromatographed on 
Sephadex LH -20. Quality controls from male rats and man, appropriate blanks 
and accuracy checks were routinely included. The oestradiol -17ß fractions after 
chromatography were 
oestradiol standards. 
subjected to radioim munoassay with non -radioactive 
Eluting solvent and appropriate tracer were added to 
standard curve tubes so as to resemble the sample tubes. After thorough 
evaporation of solvent the steroid was dissolved in 120µl of ethylene glycol/ 
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0.05M phosphate buffer solution (1:5, v /v), pH 7.0 containing gelatin (2g /1). An 
aliquot of 20µl was removed for tracer measurement, and 100µl of radioligand 
solution containing approximately 5,000 c.p.m. (= 13pg) added, followed by l00µ1 
antiserum (raised against oestradiol -17(3, 6- carboxymethyloxime conjugated to 
bovine serum albumin) at a dilution of 1:16,400 with mixing after each addition. 
Following overnight equilibration at 4 °C, free and bound ligand were separated 
by the addition of dextran -charcoal suspension (0.5g dextran T -70 and 5g Norit A 
charcoal /litre 0.05M phosphate buffer, pH 7.0). The bound fraction was decanted 
and its radioactivity measured as in the oestrogen receptor assay. The plasma 
oestradiol concentration was read from a plot of % Bound vs mass of oestradiol- 




L Testosterone metabolism by D MBA- induced rat mammary tumours 
1. Identification and characterisation of steroids 
The metabolism of testosterone by DMBA- induced rat mammary tumours 
was studied by incubating homogenates of tumour with[ 7a -3H] testosterone in 
vitro as described in the METHODS section. After termination of the 
incubation by the addition of excess methanol, solid material was removed by 
low -speed centrifugation, and acetone washings of the pellet were bulked with 
the initial supernatant. The total radioactivity present in the supernatant 
mixture of incubation medium, methanol and acetone always corresponded 
closely to the quantity of tritiated precursor originally added to the incubation. 
This mixture was evaporated to dryness and the residue redissolved in an 
ethyl acetate -water partition system. Only the products entering the ethyl 
acetate phase were routinely investigated, but the quantities of radioactivity 
present in the aqueous phase of the ethyl acetate -water partition system were 
also assessed in a limited number of cases. 
The evidence for the identification of a radioactive steroid metabolite 
present in the ethyl acetate fraction was based on the following criteria: - 
(1) When subjected to thin layer chromatography the metabolite dis- 
played the same mobility as a sample of the authentic steroid. 
(2) The metabolite formed the same derivatives chemically as the 
authentic steroid under similar reaction conditions. This was 
checked by observing the change in the mobility of the metabolite 
and the authentic steroid to that of the expected authentic deriv- 
atives in appropriate solvent systems. 
(3) When unlabelled authentic steroid (carrier steroid) was added to the 
products of incubation, the putative metabolite and its different 
chemical derivatives maintained a constant specific activity on all 
solvent systems tested. 
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These criteria were applied in the following manner. The dried residue of 
the ethyl acetate phase was run in solvent system Ia and the resultant 
distribution of radioactivity initially examined on the thin layer scanner. 
Tracings such as those in Fig. 4 revealed that the majority of radioactivity was 
present in 3 zones, A, B and C. Additional radioactivity was observed 
sometimes, but not always, in zones D, E, F and G (compare a and b of Fig. 4). 
From the examination of the t.l.c. plate under ultra- violet light the 
positions of the carrier steroids were identified by comparing their mobilities 
with those of authentic standards run in adjacent channels. The mobilities of 
the radioactive zones were found to correspond with those of the carrier steroids 
as follows:- zone A with 5g- androstane -3,17(3 -diol and 50c- androstane -3/, 
17-diol which were not separated in this system, RT (= relative mobility to 
testosterone) = 0.67; zone B with testosterone, RT = 1.00 by definition; zone C 
with 5a- dihydrotestosterone, RT = 1.29; zone D with 4- androstenedione, RT = 
1.60 and zone E with 5c -androstanedione, RT = 2.10. Zone F, which was located 
close to or at the origin, probably contained more polar steroids, but usually 
represented a very small part of the total radioactivity and was not further 
investigated. Zone G, RT = 0.53, was only detected as a separate entity from 
the adjacent and more radioactive zone A at a late stage in the work. The 
possible nature of this material is considered at the end of this section. 
When zone A was eluted from the initial plate, rerun in solvent system V or 
VI and scanned, 2 zones of radioactivity were identified (Fig. 5a). The zone with 
the slightly greater mobility, A1, ran with authentic 5a- androstane -3a,17(á -diol 
and the other zone, A2, had the same mobility as 5a- androstane -3 f3,17(á -diol. 
Both areas were eluted and rerun separately in the same solvent system for 
further purification. Elution and oxidation of both zones yielded derivatives 
which ran with the same mobility as 50( -androstanedione in solvent sytem II. 
(The oxidation of zone A2 sometimes yielded an extra product which had the 
same mobility as 4- androstenedione. This area of radioactivity was thought to 
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Figure 5. Scans of radioactivity in t.Lc. plates - 
a. separation of 5o'.- androstanediols b. reduction of 4- androstenedione 
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be due to the oxidation product of contaminant material from zone G of the 
initial plate.) Subsequent reduction of the oxidised derivatives which had the 
same mobility as 5A- androstanedione yielded products with the same chromato- 
graphic characteristics as 5a- androstane- 30,17g-diol in solvent system III. The 
products of acetylation of the material from either zones Al or A2 behaved 
similarly to 5ot- androstane -30,17(- diacetate and 5oÁ- androstane -3ß, 
17 j -diacetate, both of which had the same mobility in solvent system IV. 
Hydrolysis of the acetylated derivatives yielded products with the same mobility 
as 5oÁ- androstane -3°c,17(á -diol and 5o(- androstane -3(3,1713 -diol in solvent sys- 
tem V. The chromatographic characteristics of the materials in zones Al and 
A2 were unchanged by reduction. 
When authentic unlabelled 5oc- androstane -3x,17/3 -diol and 5oc- 
androstane -3ß,l7(3 -diol were added as carriers to the incubate the specific 
activities of the oxidised and reduced derivatives of either isomer were 
identical. Although the specific activity of the diacetate derivative was 
sometimes similar to that of the oxidised and reduced derivatives, in general it 
was noticeably higher. The specific activities of the diol from which the 
acetate was formed and the diol which was produced on hydrolysis of the 
diacetate were alike and were both lower than that of the diacetate. Other 
than checking the purity of the standards used for measuring the quantity of 
unlabelled diacetate chromatographically, the discrepancy was not further 
investigated. From all other observations it was concluded that the radio- 
activity in zone A of the initial plate was due to the presence of the 3o(- and 
3(á- isomers of 5a.- androstanediol which could be separated in solvent systems V 
or VI. Since the specific activities of the 5a- androstane -3 (3,17(3 -diol and 
5oc- androstanedione derivatives always showed close agreement, these 2 alone, 
without the more problematic diacetate derivative, were used for the determin- 
ation of 5a- androstanediol production. 
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When the material in zone B of the initial plate was eluted and acetylated 
the radioactive area had the same mobility as testosterone acetate in solvent 
system IV. Hydrolysis of the acetylated derivative yielded a product which was 
chromatographically identical to testosterone in solvent system III. The 
oxidation of the material in zone B or of the hydrolysate yielded a derivative 
with the same chromatographic properties as 4- androstenedione in solvent 
system III. When unlabelled testosterone was added to the incubate as a carrier 
steroid, constant specific activities were obtained from free testosterone and 
the oxidised and acetylated derivatives. It was concluded that zone B 
represented the radioactivity due to unmetabolised testosterone precursor. 
Elution and acetylation of the material in zone C of the initial plate 
yielded a product which was chromatographically identical to 5oc- dihydro- 
testosterone acetate in solvent system VII. Subsequent hydrolysis of this 
acetate produced a compound with the same mobility as free 5ot- dihydro- 
testosterone in solvent system III. Reduction of the material eluted from zone 
C or reduction of the hydrolysate yielded products with a chromatographic 
behaviour identical to that of 5a- androstane- 3 ?,l7(3 -diol in solvent system III, 
whereas oxidation of the parent steroid or of the hydrolysate yielded products 
which had the same mobility as 50t- androstanedione in solvent system II. When 
unlabelled 5a- dihydrotestosterone was added as a carrier steroid the specific 
activities of free 56t- dihydrotestosterone and the acetylated, oxidised and 
reduced derivative remained constant. It was concluded that the steroid in zone 
C was 5a- dihydrotestosterone. 
The mobility of the steroid eluted from zone D did not alter upon 
acetylation, but remained identical to that of 4- androstenedione in solvent 
system IV. Likewise the mobility was unaffected by subsequent hydrolysis. 
Reduction of this steroid under mild conditions (see METHODS) yielded a 
mixture of 2 main products, one with the mobility of testosterone, the other with 
R-(, 
the mobility of 4- androstene -3(3,17 -diol in solvent system III (Fig. 5b). 
Acetylation of the product with the same mobility of testosterone altered its 
mobility to that of testosterone acetate. Inclusion of unlabelled 4- androstene- 
dione as a carrier steroid resulted in constant specific activities in free steroid, 
its reduced product testosterone and testosterone acetate. It was concluded 
that the steroid running in zone D was 4- androstenedione. 
Zone E ran close to the solvent front and when reduced ran in solvent 
system III with the same mobility as 5%- androstane- 3(3,17(3 -diol. Oxidation of 
the reduced product yielded a material with the same mobility as 50(- androstane- 
dione in solvent system II. The chromatographic properties of the original 
material from the initial plate were unaltered by oxidation or acetylation. When 
cold 5o(- androstanedione was added to the incubate, the specific activities of the 
free steroid and the reduced derivative remained constant. It was assumed that 
the radioactivity in zone E was (probably) due to the presence of 5oc- androstane- 
dione. 
The radioactivity in zone G was first observed as a polar shoulder on the 
radioactive peak of the 5o(- androstanediol band in solvent system Ia. The peak 
of zone G was more clearly seen when steroids ran further from the origin and it 
appeared that this peak was greater when those of 5o.- dihydrotestosterone were 
relatively low. 
The mobility of zone G (RT = 0.53) was greater than that of 704 -hydroxy- 
testosterone (RT = 0.2) and 16%- hydroxytestosterone (RT = 0.4), and was less 
than that of 5- androstenediol (RT = 0.65) and androst- 4 -ene- 30,l7ß -diol (RT = 
0.70). 
In order to obtain enough material for an analysis of the chemical 
reactivity of the material in zone G, the areas between the origin and the 
50 -androstanediol band from the initial plates of several different incubations 
were pooled and eluted. When this eluate was rerun in solvent system Ia, 2 
peaks were observed, one with the mobility of the 5u- androstanediols and the 
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other with the mobility of the original zone G. The material in zone G was 
recovered and run twice in solvent system Ib to remove contaminant 5oc- 
androstanediol. 
When reduction of the material in zone G was attempted there was no 
alteration in its chromatographic characteristics (Fig. 6a). Acetylation of the 
material in zone G yielded a major product which had a mobility characteristic 
of diacetates (e.g. 5oß- androstane(3 of or 3(3)diacetate and 5- androstene- 
diacetates) in solvent system IV (Fig. 6b). On hydrolysis the mobility of the 
major acetylated region returned to that of zone G. Oxidation of the material 
in zone G with chromic acid resulted in a product with the same mobility as 
4- androstenedione in solvent system III (Fig. 7a). Reduction of this oxidised 
product under strong reaction conditions (method a) resulted in a major band of 
radioactivity, which had the same mobility as androst- 4- ene -3ß, l7ß -diol, and 2 
minor bands, one with the same mobility as testosterone and the other with the 
same mobility as the original zone G in solvent system III. These 3 bands were 
also seen when weak reduction conditions (method b) were applied to the oxidised 
product but the radioactivity in the band running with the same mobility as 
testosterone had increased greatly relative to the other 2. Since authentic 
4- androstenedione behaved in the same manner it was concluded that the 
oxidised product of the material in zone G was probably 4- androstenedione. 
The interpretation of these results was that the material in zone G was an 
unsaturated steroid with 2 hydroxyl groups and no ketone groups. As androst- 
4- ene -3(3, 173 -diol and 5- androstenediol had shown a greater mobility than zone 
G in the initial solvent system, the possibility of the material in zone G being 
androst- 4- ene -3of, 170 -diol was considered. This steroid was not available 
commercially, but was later obtained as a gift from Schering. In the meantime 
the material in zone G was subjected to oxidation by manganese dioxide, a 
reaction which was reported to show specificity for allylic alcohols 
(Attenburrow, Cameron, Chapman, Evans, Hems, Jansen and Walker, 1952). 
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Figure 6. Scans of radioactivity in t.Lc. plates - 
a. reduction of zone G b. acetylation of zone G 
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Figure 7. Scans of radioactivity in t.l.c. plates - oxidation of zone G 




I I I 





- -- untreated zone G 
0 
Testo 
4 Diol (3a) 
Origin 
Three bands of radioactivity were identified when the products of the reaction 
were run in solvent system III. The major product ran with the same mobility as 
testosterone (and displayed further properties identical to those of testosterone), 
and 2 minor bands which ran with the same mobility as 4- androstenedione and 
the original zone G (Fig. 7b). 
When authentic androst- 4- ene -3a, 17f3 -diol was received it was dissolved 
in ethanol (just soluble at 1mg /ml), and found to be chromatographically pure in 
all solvent systems tested. Furthermore the chromatographic and chemical 
behaviour of the authentic steroid was found to be identical to that of the 
material in zone G. When authentic androst- 4- ene -3u, 173 -diol was added as a 
carrier steroid to a series of incubates (section V), constant specific activities 
were maintained in 4- androstenedione, testosterone and testosterone acetate 
derivates. Because of its instability when subjected to g.l.c. the free steroid 
was not considered as a derivative for the determination of specific activity. 
The aqueous phase remaining after the extraction of hydrophobic steroids 
into the ethyl acetate phase was partitioned twice more with ethyl acetate. The 
aqueous extract was made up to a volume of 40m1 and an aliquot of 0.5ml added 
to a counting vial containing 10m1 of Aquafluor. After an incubation of 2 hours 
at 37 °C, counts were measured until a constant value was obtained. This 
procedure was performed with the extracts from 12 incubations and, assuming 
the maximum counting efficiency of 50%, the radioactivity in these aqueous 
phases accounted for 0.33 - 1.69% of the total radioactivity with a mean of 
0.79%. The nature of the radioactivity component(s) of the aqueous phase were 
not further investigated. 
2. Quantification of metabolism 
The percentage metabolism of testosterone and its conversion to individual 
metabolites was determined by measuring the percentage of the total radio- 
activity which was incorporated into the appropriate steroids. Before extract- 
ion, 500K of non -radioactive carrier steroids were added to monitor recovery 
R- I I 
losses and aliquots of the incubates were taken for measurement of the total 
radioactivity present. Following purification and characterisation of the 
steroids as described in Table 2 the average specific activity of derivatives was 
used to estimate the percentage conversion from an equation derived as follows: 
metabolite formed 




total d.p.m. incubate 
x 100 
d.p.m. derivative x loss correction 
total d.p.m. incubate 
d.p.m. derivative x 
x 100 
nmol carrier added 
nmol derivative 
- x100 
total d.p.m. incubate 
S.A. (ave.) x nmol carrier added 
= x 100 
total d.p.m. incubate 
An example illustrating the recoveries of radioactive and non -radioactive 
steroids and the use of these values to calculate percentage conversion is given 
in Table 3. Although 5pl- androstane- 30/,17A-diol was added as a carrier steroid 
it was the total production of all 4 isomers which was measured since the 
isomers removed from the initial plate as a 5c(- androstanediol band were 
subsequently oxidised to yield a common product, 5a- androstanedione. This 
method was routinely employed for determining the steroid conversion described 
in sections III and IV. When the 3 o(,17í3 - and 3(3,173 -isomers were added and 
separated in solvent system V or VI before oxidation, the 3ß- isomer was always 
the minor product, and contributed less than 11% of the total 5ol- androstane- 














































































































































































































































































































































































































The radioactive peaks corresponding to 4- androstenedione and 5oc- andro- 
stanedione on the initial plate were invariably small or absent. These 
metabolites were not routinely studied but in the incubations in which their 
production was measured, that of 4- androstenedione never exceeded 0.68 %, n = 
13, and that of 5a- androstanedione never exceeded 1.03 %, n = 3. 
3. Control conditions 
In order to determine the non -enzymatic conversion of testosterone to 
5 <- dihydrotestosterone and 5a- androstanediol a 0.5g portion of tumour was 
sliced and sonicated, boiled for 15 minutes and then incubated with [ 3H 
testosterone under standard conditions for one hour. The results of this 
incubation along with those from the incubation of a second portion of the same 
tumour which was treated normally are shown in Table 4. 
The conversion of testosterone to 5a- dihydrotestosterone and 5k- andro- 
stanediol was high in the portion of tumour handled normally. In contrast the 
specific activities associated with 5«- dihydrotestosterone and 5a- androstane- 
diol decreased with sequential derivative formation indicating that the con- 
version to both steroids under such conditions was less than 0.1%. In accord, 
unmetabolised testosterone in this incubate accounted for almost all of the 
radioactivity present. 
It can therefore be assumed that the tissue component responsible for the 
conversion of testosterone to 5o(- dihydrotestosterone and 5t -androstanediol is 
inactivated by heat. 
4. Time course of steroid formation 
The metabolism of testosterone was studied over a 2 hour period using 3 
tumours from different rats, 255L, 269L and 14M. Rat 255L had shown an 
oestrus -type smear for 3 days and rat 269L had shown a constant oestrus -type 
vaginal smear for at least 12 days. Rat 14M had been cycling regularly and was 
in dioestrus. At the time of tumour excision plasma levels of prolactin were 25, 
R-14 
Table 4 
Effect of boiling on the ability of a DMBA - induced tumour 












Testosterone testo free III 4,547 
testo acetate IV 4,297 15.76 
o4 -Dione III 4,302 
5a -DHT 50L-DHT free III 6,370 
5a- Adione II 6,480 22.95 
5a- Adiol(313) III 6,425 
50k-Adiol(3c0 5ot -Adiol(3/3) III 15,372 53.95 
5a- Adione II 15,041 
Boiled tissue 
Testosterone testo free III 28,481 
testo acetate IV 27,405 97.97 
A 4 -Dione III 27,793 
Sa-DHT 50L-DHT free III 206 
5d- Adione II 139 4 0.12 
5d- Adiol(3f3) III 35 
5a-Adiol(30-) 5ol- Adiol(3j3) III 140 0.12 
5d- Adione II 36 
R-I5 
45 and 21 ng /ml respectively and plasma levels of oestradiol were 0.46, 2.42 and 
0.96ng/100m1 respectively. All tumours were increasing in size. 
From each tumour a portion of 1.5g was finely sliced and sonicated in 
22.5m1 Krebs -Ringer phosphate buffer, pH 7.4, to which an NADPH - generating 
system of 300 »mol glucose -6- phosphate, 45 }Imo' NADP+ and 75 units glucose - 
6- phosphate dehydrogenase were added. After a 10 minute preincubation period 
at 37 °C, [3H] testosterone (150 x 106 d.p.m.) was added and aliquots of 3.5ml 
removed into 20m1 of ice -cooled methanol at recorded times close to 0, 10, 20, 
30, 60 and 120 minutes after testosterone addition. Unlabelled carrier steroids 
were added to each aliquot and percentage conversions to individual steroids 
calculated from measurements of the specific activities. In the incubates of 
255L RCh and 269L RGr specific activities were determined in only one 
derivative of each steroid following purification by chemical transformation and 
t.l.c. The results and details of derivative formation are given with Table 5. 
The tumour from rat 14M was also used to study the effect of omitting the 
NADPH -generating system. 
The methods of steroid determination in incubates from 14M LAx, which 
differed from those mentioned above, are given in the next section along with 
the results obtained from that tumour (Table 6). The metabolism of testo- 
sterone by the 3 tumours is illustrated in Figs. 8 - 10. 
It can be seen that in all 3 incubations the metabolism of testosterone was 
extensive, being accounted for largely by the formation of 5a- reduced products. 
5a- Reduction proceeded rapidly for the first hour, but decreased as the level of 
precursor fell. 
Initially the levels of 5o4- dihydrotestosterone present in the medium 
increased more rapidly than those of the 5o(- androstanediols, but at 20, 30 and 60 
minutes the levels of 5 o!- androstanediols had exceeded those of 5(- dihydro- 
testosterone in the incubations of 255L RCh and 14M LAx. Although over the 
same period the levels of 5d- androstanediols rose more quickly than that of 
R-16 
Figures 8 and 9. Time course of testosterone metabolism by DMBA -induced 








0 30 60 90 
time ( minutes ) 
5 d Reduction 
5dDHT 
--Testosterone 
Vd 4 Ad ione 


















-5dAdione -- 4Adione 
90 120 
Legend for Table 5 
Preparation of derivatives 
Carrier steroid 
Reactions for 
derivative formation Solvent systems 
Testosterone acetylation Ia, IV 
5oc -DHT acetylation, hydrolysis Ia, IV, III 
5ot- Adiol(3a) oxidation, reduction Ia, V x 2, II, III 
5D -Adiol(3f3) oxidation, reduction Ia, V x 2, II, III 
p -Dione "acetylation ", "hydrolysis" Ia, IV, III 
5v- Adione reduction, oxidation Ia, III, II 
Table 5 
Time course for the metabolism of testosterone 
by DMBA -induced rat mammary tumours 











3 testosterone 9,356 95.22 
(17,057,697) 5ds- DHT 135 1.36 
5d.- Adiol(3d) 54.7 0.55 
50k- Adiol(3/3) 5.63 0.056 
A4 -Dione 50.8 0.52 
10.5 testosterone 10,316 86.24 
(20,764,544) 5d -DHT 492 4.08 
5o(- Adiol(3d) 433 3.57 
5ot- Adiol(3j) 23.6 0.19 
4,4 -Dione 57.8 0.48 
20 testosterone 7,758 77.31 
(17,421,081) 5d -DHT 457 4.52 
50t- Adiol(30k) 982 9.65 
5oc- Adiol(31ß) 52.3 0.51 
A4 -Dione 49.2 0.49 
30.5 testosterone 6,730 69.41 
(16,831,107) 50(-DHT 721 7.39 
5ot- Adiol(30() 1,453 14.78 
5c(- Adiol(3ß) 66.3 0.67 
A 4 -Dione 48.7 0.51 
R -.9 
Table 5 (continued) 










62 testosterone 4,737 50.36 
(16,331,056) 5ok-DHT 1,247 13.16 
5oC- Adiol(3t) 2,361 24.75 
5oc- Adiol(3)3) 83.2 0.86 
A4 -Dione 52.7 0.56 
120 testosterone 3,448 32.42 
(18,463,534) 5o( -DHT 3,617 33.77 
5oc- Adiol(30) 1,888 17.51 
5o -Adiol(3A ) 223.2 2.07 
11 4 -Dione 77.1 0.73 
Rat 269L 
0.5 testosterone 12,764 98.02 
(22,468,853) 5á -DHT 77.4 0.59 
5(4- Adiol(30k) 5.91 0.045 
5o1- Adiol(3ß ) 1.84 0.014 
A 4 -Dione 87.0 0.68 
50k- Adione 4.42 0.034 
10.5 testosterone 9,638 85.67 
(19,530,094) 5o( -DHT 879 7.76 
5o(.- Adiol(3K ) 316 2.77 
50(,- Adiol(3j ) 27.1 0.24 
R- Zo 
Table 5 (continued) 










22 testosterone 7,581 70.71 
(18,612,585) 5v4-DHT 1,447 13.40 
5ot- Adiol(3 x ) 1,118 10.28 
5 0c Adiol(3p ) 132 1.21 
31 testosterone 6,732 57.59 
(20,292,365) 5a-DHT 2,081 17.68 
5dL- Adiol(3c&) 1,907 16.09 
50(- Adiol(3)3 ) 161 1.35 
60.5 testosterone 3,721 30.64 
(31,081,479) 5o< -DHT 3,505 28.66 
5 -Adiol(3oc ) 3,355 27.25 
5oL- Adiol(3p ) 384 3.12 
,64 -Dione 126 1.04 
5 «-Adione 125 1.03 
120 testosterone 1,352 11.10 
(21,142,397) 50(.-DHT 6,394 52.14 
5 a- Adiol(30t) 2,232 18.07 
50k- Adiol(33) 715 5.79 
4-Dione 232 1.92 
5dldione 419 3.14 
R- Z1 
Figures 10 and 11. Time course of testosterone metabolism by DMBA- induced 
rat mammary tumour (14M LAx) in the presence of (upper), 
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Table 6 
Time course of testosterone metabolism by a DMBA- induced mammary tumour 
(14M LAx), with and without the addition of an NADPH -generating system 
Time in minutes % of 
(d.p.m. in S.A. total 
aliquot) Steroids (d.p.m. /nmol) d.p.m. 
With NADPH -generating system 
0.5 testosterone 12,676 97.81 
(22,497,408) 5a -DHT 127 0.97 
5ot Adiols 80.4 0.34 
10.5 testosterone 9,552 83.44 
(19,810,400) 50C-DHT 880 7.66 
5 o(- Adiols 613 5.30 
20.5 testosterone 8,459 74.37 
(19,744,766) 5o( -DHT 1,114 9.72 
5o4- Adiols 1,408 12.21 
30 testosterone 8,112 65.29 
(21,594,948) 514-DHT 1,386 11.06 
5 ot- Adiols 2,622 20.78 
60 testosterone 4,837 43.81 
(19,166,122) 5o( -DHT 1,552 13.96 
5 o&- Adiols 4,348 38.84 
as 50k- Adiol(30() 4,157 37.14 
122 testosterone 4,561 33.54 
(23,604,646) 5o -DHT 4,102 29.96 
5G- Adiols 4,291 31.12 
as 5.(- Adiol(3a ) 4,022 29.17 
R- 2.3 
Table 6 (continued) 
Time in minutes % of 
(d.p.m. in S.A. total 
aliquot) Steroids (d.p.m. /nmol) d.p.m. 
Without NADPH -generating system 
0.5 testosterone 9,788 99.33 
(17,106,056) 5a -DHT 15.5 0.16 
5 c- Adiols 28.9 0.29 
10 testosterone 8,006 97.91 
(14,195,325) 5oc -DHT 94.7 1.15 
5 °- Adiols 28.2 0.34 
20.5 testosterone 7,735 93.97 
(14,289,491) 5oc -DHT 302 3.64 
5oß- Adiols 39.3 0.47 
30 testosterone 8,311 88.42 
(16,022,250) 5 ek-DHT 725 7.66 
5d.- Adiols 110 1.15 
60 testosterone 7,345 66.06 
(19,300,708) 5oc -DHT 2,908 25.98 
5L- Adiols 473 4.20 
as 5a- Adiol(30) 378 3.26 
122 testosterone 3,349 33.28 
(17,469,234) 5a -DHT 5,071 50.04 
50(- Adiols 1,119 10.97 
as 5a- Adiol(30() 982 9.62 
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50(- dihydrotestosterone in the incubation of 269L RGr, only at 60 minutes did the 
combined level of the 3o(- and 3g-isomers of 5a- androstanediol exceed that of 
5 a -dihydrotestosterone. 
Between 60 and 120 minutes the levels of 5%- androstane -3a,17(3-diol, but 
not those of the 3(3- isomer, fell, and the levels of .5%-dihydrotestosterone 
increased in all 3 incubations. Since the increases in 5x- dihydrotestosterone 
levels between 60 and 120 minutes were greater than the corresponding 
decreases in the levels of testosterone, one must conclude that during this 
period, conversion of 5a- androstane- 30,17(3 -diol back to 5«- dihydrotesto- 
sterone had occurred. There was no evidence for the conversion of 5a- andro- 
stane -3 3,17(3 -diol to 5c- dihydrotestosterone. 
It was noticed that the levels of 4- androstenedione recovered initially were 
relatively high in the incubations of 255L RCh (0.55 %) and 269L RGr (0.68 %), but 
increased very slowly. The batch of precursor which was used for both these 
incubations had been purified 2 weeks prior to use and was stored at 4 °C. When 
these results were finally calculated, about 8 weeks after incubation, the original 
batch of precursor was still available since it had not been required for further 
incubations and therefore not repurified. An aliquot of the precursor solution, 
which had now been purified 10 weeks previously, was mixed with 100 »g of 
unlabelled testosterone and 100}íg unlabelled 4- androstenedione. These steroids 
were separated in solvent system III. After correcting for losses from the 
amount of unlabelled steroid recovered the distribution of radioactivity was as 
follows:- testosterone - 98.72 %, 4- androstenedione - 0.82% and the remainder 
of the plate 0.46 %. It therefore seems likely the[ 3H] 4- androstenedione found in 
the early stages of incubation did not arise by enzymatic conversion of 
testosterone but was probably present in the aliquot of precursor added. 
5. Effect of an NADPH- generating system on testosterone metabolism 
The 5w- reduction of testosterone to 5a- dihydrotestosterone and 5a- andro- 
stanediol required a supply of hydrogen ions. NADPH provides a suitable source 
R-.25 
of hydrogen ions (Moore (3c Wilson, 1975), and therefore a system which generates 
NADPH was routinely included in the incubations performed for this thesis. The 
results in this section show the effect of omitting the NADPH -generating sytem 
on the metabolism of testosterone over a 2 hour incubation period. 
Tumour 14M LAx was divided into 2 portions of 1.5g. The first portion 
was incubated with an NADPH -generating system containing NADP +, glucose - 
6- phosphate and glucose- 6- phosphate dehydrogenase as described in the pre- 
vious section. All 3 components were omitted from a parallel incubation of the 
second portion of tumour. The standard methods of steroid determination were 
modified to the following procedure. Unlabelled testosterone, 5oc- dihydrotesto- 
sterone and 5oe- androstane -3o,176'-diol (500}ßg of each) were added to all 
aliquots removed from the 2 incubations. The steroids extracted in the organic 
phase were run in solvent system Ib, scraped off, eluted and rerun separately in 
solvent system III. The specific activities were determined in the bands of 
steroid removed from this plate. Since the 3a- and 3f3- isomers of 5«- andro- 
stanediol run identically in these systems the specific activity of the band with 
the 5a- androstane -3«,170-diol carrier steroid reflected the radioactivity 
associated with total 5c -androstanediol levels. The isomers of 50- androstane- 
diol were then separated in solvent sytem V and the specific activity of the 
3 a- isomer determined. The specific activities and corresponding percentage 
convenons are given in Table 6 and the latter shown diagrammatically in Figs. 10 
and 11. 
The pattern of steroid metabolism by the portion incubated with the 
NADPH -generating system resembled those of the 2 tumours described in the 
previous section and is discussed along with them. 
When the NADPH -generating system was omitted the pattern of testo- 
sterone metabolism was considerably altered, showing a slow initial rate of 
metabolism which increased up to 60 minutes and stayed high for the remainder 
of the incubation period. This meant that at 60 minutes almost twice as much 
testosterone had been metabolised in the incubation to which an NADPH- 
R-ZG 
generating system had been added, but after 120 minutes similar amounts of 
testosterone had been metabolised in both incubations. 
Although in the absence of an NADPH -generating system testosterone 
metabolism was still largely accounted for by 5oc- reduction, the composition of 
the 5 oc- reduced metabolites was the reverse of that normally found. At all times 
the levels of 5a- dihydrotestosterone greatly exceeded those of the 5a- andro- 
stanediols. Moreover, there was no decrease in the levels of 5ot- androstane -3(, 
17-diol between 60 and 120 minutes. 
The different method used to measure 5oc- androstane diol production in 
these incubates gave results in close agreement with the conventional methods 
used in the previous section, namely, that in both series of incubates, the 
contribution of the 3$- isomer to the total 5v- androstanediol was small and that 
in the incubation containing the NADPH -generating system the level of 
3d- isomer, but not that attributed to the 3(3- isomer (total 5a- androstanediol 
minus the 3 ct- isomer), declined between 60 and 120 minutes. 
6. Source of variation in the measurement of testosterone metabolism 
To ascertain the precision of method used to measure testosterone 
metabolism duplicate portions of certain larger tumours were separately incub- 
ated under the same standard conditions. In a few cases incubations were 
performed on 2 tumours taken from one rat. The data from these incubations 
have been used to compare variations within tumours, between tumours within 
rats and between rats. The parameter of 5oc- reduction which accounts for the 
majority of testosterone metabolised has been considered. 
The tumours used for duplicate incubations came from 6 untreated and 3 
perphenazine- treated rats. For the assessment of variation between 2 tumours 
from the same rat, results from untreated rats only have been used. The 
averages of the duplicate portions from the 6 untreated rats and the values of 
the "a" tumours from rats with pairs of tumours were used to assess the variation 
between rats (Table 7). 
R-17 
Figure 12. Variation in the 5a- reduction of testosterone 









within within between 
tumours rats rats 
Source of variation 
The points in the first two columns represent the difference between pairs of 
values minus the mean of the differences. The points in the third column 
represent individual values minus the mean. Horizontal bars indicate means 
(all zero after the above transformation) and s.d.'s (see text). 
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Table 7 
Variations in the 5o4- reduction of testosterone 
by DMBA- induced mammary tumours 
Source of 
variation a 
50(- reduction % 
b a - b 
a + b 
2 
32.17 30.59 + 1.58 31.38* 
49.58 49.10 + 0.48 49.34* 
36.99 30.43 + 6.56 33.71* 
portions 47.42 39.51 + 7.91 43.46* (a - b) = +2.94 
of same 5.87 3.11 + 2.76 4.49* R = 4.74 
tumour 64.77 70.06 - 5.29 67.42* s.d. (est) = 4.1 
81.93 71.46 +10.47 from 
41.66 36.84 + 4.82 perphenazine- 
30.56 33.40 - 2.84 treated rats 
37.80* 41.72 - 3.92 
45.48* 35.84 + 9.04 
tumours 43.00* 22.17 +20.83 (a - b) = -4.31 
of same 27.62* 44.92 -17.30 R = 17.42 
rat 21.11* 67.42 -46.31 s.d. (est) = 14.9 
26.16* 30.13 - 3.97 
75.57* 53.62 +21.95 
63.83* 79.24 -15.41 
tumours of values marked mean = 40.74 
different * above used s.d. = 19.21 
rats 
mean of range, R = a -b i, s.d. est = d (see text) 
2 
The 5o(- reduction from the arbitrarily designated "b" incubates were 
subtracted from those of the corresponding "a" incubates. For diagrammatic 
comparison of the variation, these values were transformed by subtracting the 
mean of each set from each individual value within the set. By this 
transformation the absolute spread of the values remained the same, but the new 
means were both equal to zero (Fig. 12). The variation between rats was 
illustrated subtracting the mean 5(4-reduction from individual values. The 
variation which occurred between pairs of values is expressed in Table 7 by R, 
the mean of the range of differences, irrespective of sign. The standard 
deviation was estimated from the expression d where d is a factor dependent on 
2 
the degrees of freedom. 
The mean of the range of differences between portions of the same tumour 
was 4.74% with an estimated standard deviation of 4.1 whereas the mean of the 
range of variation between tumours of the same rat was 17.42 with an estimated 
standard deviation of 14.9. The standard deviation of 5« - reduction values 
obtained from tumours from different rats was 19.2,.. 
This analysis indicates that although certain variations occur between 2 
portions of the same tumour, whether due to tumour heterogeneity or limits in 
methodological precision, the results obtained are largely reproducible. In 
contrast, the variation between tumours, either within the same rat or in 
different rats, is far greater. The variation in 5oC- reduction between tumours 
from the same rats, although a little less than that of tumours from different 
rats, was considered great enough to include 2 tumours from the same rats as 
separate entities for intergroup comparison in sections III and IV. 
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II. Effects of treatment regimes on plasma hormone levels 
The main part of this work involved the alteration of the circulating levels 
of hormones known to be involved in the growth of DMBA- induced mammary 
tumours so that relationships between tumour steroid metabolism, tumour 
growth and hormone levels could be studied. The effects of altering plasma 
prolactin levels in the presence and absence of ovarian influences were partic- 
ularly investigated. However, since repeated induction of anaesthesia for 
removal of blood for plasma prolactin assay presented a risk of untimely death 
and might have altered the levels of hormones which respond to stress, it was 
proposed to measure plasma prolactin only before and at the end of treatment in 
rats bearing tumours under study. In addition, since a minimum of 2.5ml of 
plasma was required for reliable estimation of oestradiol levels in the rat by 
radioimmunoassay, a single sample of blood for this purpose could only be 
routinely obtained at sacrifice. Because of these restrictions it was necessary 
to establish that the chosen treatment regimes were having the desired effect 
and moreover that hormone levels at sacrifice might appropriately reflect 
changes due to treatment. Animals which had received DMBA but which had 
not developed continuously growing tumours were kept under identical conditions 
to those used in tumour studies. Thus at the same age as their tumour -bearing 
counterparts these animals provided a suitable stock in which the effect of the 
various treatment regimes on plasma prolactin and oestradiol could be more 
elaborately studied. The animals in this category were required to have regular 
oestrous cycles (4 days), as assessed by vaginal smears, prior to allocation to 
starting treatment on the day of dioestrus. 
1. Perphenazine and plasma prolactin 
Initially attempts were made to elevate plasma prolactin by daily s.c. 
administration of an aqueous preparation of perphenazine supplied in ampoules 
R-3 
(5mg /mi) by Allen & Hanburys Ltd. Rats were given 0.2ml daily for 14 days. 
Plasma prolactin values measured 24 hours after the 4th and 14th injection are 
shown in Fig. 13. Most, but not all, animals showed an increase in plasma 
prolactin at 4 days but by 14 days plasma prolactin had fallen in all animals, in 
some cases to levels below pre- treatment values. A comparison of the prolactin 
values in this group by the paired t -test (Table 8) revealed that while levels were 
significantly elevated on day 4 of treatment there was no significant difference 
between pretreatment levels and those on day 14. 
In view of the inability of the commercial preparation to sustain elevated 
plasma prolactin levels it was decided to change the vehicle. Perphenazine 
powder (Allen & Hanburys Ltd) was dissolved in corn oil (5mg /mi) and daily s.c. 
injections (1m1 /kg body weight) given to 7 rats. Blood was again taken before 
and 4 and 14 days after treatment. Plasma prolactin levels, also shown in Fig. 
13, were elevated in 6 out of 7 animals at 4 days and in all 6 surviving animals at 
14 days. Group analysis shows that prolactin levels were significantly higher at 
4 and 14 days compared to pretreatment levels (Table 8). 
This regime was therefore studied in more detail and Fig. 14 shows mean 
prolactin values for the intermediate days in 6 rats so treated. An increase in 
plasma prolactin was evident 24 hours after the first injection and had reached 
maximal levels by day 2. Although the mean value from day 2 onwards 
remained relatively constant there were individual variations in the plasma 
levels. Prolactin levels in a group of animals given only corn oil vehicle are 
shown in Fig. 18. The mean prolactin values in this group are approximately 
half those of the perphenazine treated group and show fluctuation which 
probably represents variation due to the oestrous cycle. From the vaginal smear 
pattern it appeared that perphenazine treatment arrested the normal oestrous 
cycle presenting most commonly with many leukocytes as in a dioestrus -type 
smear after 1 - 4 days of perphenazine treatment. 
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Rats in group A received a daily s.c. injection of 0.2ml Allen & Hanburys' 
aqueous fentazin preparation (5mg /m1). Rats in group B received a daily s.c. 
injection of lml /kg body weight of perphenazine B.P. dissolved in corn oil. 
Plasma samples were obtained 24 hours after perphenazine administration. 
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Table 8 
Effects of two perphenazine preparations on plasma prolactin levels 
Perphenazine 
preparation Number 
Plasma prolactin (ng /ml) 
Pretreatment Days of treatment 
(daily dose) of rats 0 4 14 
Fentazin in 11 28.4 ± 6.2a 57.9 ± 11.1 21.6 IF 8.3 
aqueous solution (p < 0.025)b N.S. 
(1 mg /rat) 
Perphenazine in 7 26.1 ± 6.1 58.6 ± 13.3 84.5 ± 7.63 
corn oil (p< 0.01) (p < 0.0025) 
(5 mg /kg body weight) 
The aqueous solution of Fentazin (perphenazine) was obtained from ampoules for 
injection prepared commercially by Allen & Hanburys Ltd. 
a 
b 
= mean - s.e. mean 
= obtained by comparison with pretreatment values by t -test for paired 
samples. 
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Each point represents the mean of the plasma prolactin levels in 6 rats which 
received a daily s.c. injection of perphenazine (5mg /kg body weight) in corn 
oil solution. Plasma samples were obtained 24 hours after injection. 
Vertical lines indicate s.e. means. 
R -35 
The effect of a single injection of perphenazine in corn oil at 1200 hours on 
the day of dioestrus in 8 rats is shown in Fig. 15. Administration of the drug 
produced a rapid rise in plasma prolactin, elevated levels being detected within 
30 minutes in certain individuals, and all animals showed maximally raised levels 
by 4 hours. Plasma prolactin levels remained significantly elevated even 24 
hours after the administration of perphenazine. Control animals given corn oil 
vehicle failed to show such a marked rise in plasma prolactin although there was 
a slight trend of increased prolactin levels up to 24 hours, possibly due to rats 
moving into the proestrus stage of the cycle or due to stress. 
It was also of interest to know the effect of a single injection of 
perphenazine when prolactin levels were already elevated by previous injections 
of perphenazine. Blood samples were therefore collected from 6 rats during the 
24 hour period after the 12th and final daily injection of perphenazine. The 
plasma prolactin levels in these samples are shown in Fig. 16. The mean plasma 
prolactin level just prior to the final injection (i.e. 24 hours after the 11th 
injection) was significantly higher than the pretreatment value. Although there 
was a trend towards increased prolactin levels 2 hours after the final injection 
the large scatter in values renders the difference insignificant. It is apparent 
from these results that the measurement of plasma prolactin 24 hours after the 
final injection of perphenazine should provide a reasonable indication of the 
mean prolactin levels over the period prior to sacrifice. The measurement of 
plasma prolactin in single sacrifice blood samples was used to assess the efficacy 
of perphenazine in the experimental protocols for tumour -bearing rats. 
2. Ovariectomy and plasma prolactin 
In order to determine the effects of ovariectomy on plasma prolactin 
levels, blood was taken from 4 animals immediately before and at 2 and 4 hours 
and 1, 2, 4, 8 and 16 days after ovariectomy. As controls 4 animals were 
sham - operated and blood taken at the same time. The results are shown in Fig. 
17. Since the operations were performed on the day of dioestrus in animals with 
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At noon of dioestrus (time = 0) rats received a single s.c. injection of 
(a) perphenazine, 5mg /kg body weight, n = 8; or (b) corn oil vehicle, lml /kg 
body weight, n = 6. Vertical lines indicate s.e. means. 
R-3.1 







I I I 
0 0 1/2 1 2 4 24 
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The 12th daily s.c. injection of perphenazine (5mg /kg body weight) was given 
to a group of rats (n = 6) at noon on day 11 of treatment. Vertical lines 
indicate s.e. means. 
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Rats were ovariectomised (n = 4) or sham -operated (n = 4) between 1100 and 




a 4 -day oestrous cycle, operated rats were usually in dioestrus on days 4, 8 and 
16. Ovariectomised rats displayed cónstant dioestrus -type vaginal smears. 24 
hours after the operation the mean plasma prolactin levels in both groups were 
significantly higher than the preoperative values. In the ovariectomised group 
prolactin levels fell in comparison to those of the sham -operated group and on 
days 8 and 16 the mean plasma prolactin levels in the ovariectomised group were 
significantly lower than those in the sham -operated group (p C 0.01 and p <0.05 
by the Student t- test). 
3. CB 154 and plasma prolactin 
The ergot alkaloid CB 154 was chosen to suppress the release of pituitary 
prolactin. The effect of daily administration of this drug is compared with that 
of the corn oil vehicle in Fig. 18. Daily tail vein blood samples were taken 
between 1400 and 1500 hours immediately prior to the next injection of drug or 
vehicle. Plasma prolactin levels were similar in samples taken from both groups 
during the oestrous cycle immediately prior to starting treatment. In the 
control animals plasma prolactin levels remained within the same range as 
pretreatment values and although there was considerable variation between 
individual levels there appears to be a cyclic variation in plasma prolactin. In 
contrast plasma prolactin levels were greatly suppressed by CB 154 treatment 
with no indication of cyclic variation. From day 1 of treatment onwards 
prolactin levels were always significantly lower in the CB 154 treated animals 
(p 40.05 by the Student t- test). During treatment the s.e. means of prolactin 
levels in the CB 154- treated rats were all less than IF 3 and are not shown in the 
diagram. A cyclic pattern of vaginal smears was displayed by all individuals in 
both groups before and during treatment. Due to the occasional 5- instead of 
4 -day cycle the oestrous cycles of certain individuals were out of phase towards 
the end of treatment and this may account for the less pronounced cyclic 
variations in plasma prolactin in the control group. 
R 
Figure 18. Effect of daily administration of CB 154 on plasma prolactín levels 
plasma 
prolactin 
( ng /ml ) 
100- 
50- 
-corn oil vehicle 
-----CB 154 
4 3 2 1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
time ( days ) 
At dioestrus (day 0) rats were allocated to groups (n = 6 in each) to receive 
daily s.c. injections of either CB 154 (5mg /kg body weight) or corn oil (1m1 /kg 
body weight). Vertical lines indicate s.e. means. The s.e. means during 
CB 154 treatment were all less than 3ng /ml and are not shown. 
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When these results are compared with those in Fig. 17 it would appear that 
under the experimental conditions described lower plasma prolactin levels were 
obtained in CB 154 -treated rats than in ovariectomised rats. 
The plasma prolactin levels in 3 rats given a single dose of CB 154 are 
compared with those of 6 control animals given only corn oil vehicle during the 
24 hour period immediately following injection in Fig. 19. There was no 
difference between the prolactin levels of the 2 groups up to 2 hours after the 
injection. However, after 4 and 24 hours the mean plasma prolactin levels in 
CB 154- treated rats were significantly lower than those of control rats (p <0.05 
and p< 0.025 respectively by Student t- test). 
4. Perphenazine and CB 154 on plasma oestradiol levels 
The minimum volume of plasma on which oestradiol levels in the female 
rat could be reliably determined by radioimmunoassay was 2.5ml. This was only 
routinely available at sacrifice when blood was collected by aortic exsanguin- 
ation. However, oestradiol levels vary considerably throughout the oestrous 
cycle in the rat (Yoshinaga, Hawkins & Stocker, 1969; Butcher, Collins & Fugo, 
1974) and a single estimation of oestradiol at sacrifice may therefore be 
unrepresentative in animals which continue to cycle during the treatment period. 
In order to determine the overall effect of treatment on oestradiol levels 
in rats from the intact treatment groups it was decided to take a series of daily 
tail vein samples and bulk the plasma of individual animals for measurement of 
oestradiol. This would give an indication of the average oestradiol level over a 
given period which could then be compared with the level in plasma from the 
same animal at sacrifice. A further comparison could also be made with both 
sets of values between the different treatment groups. 
The effects of perphenazine and CB 154 administration (5mg drug /kg body 
weight daily) on plasma oestradiol levels were therefore studied using the 
following protocol. Rats with regular oestrous cycles received 12 daily 
injections of drug or corn oil vehicle commencing on the day of dioestrus (day 0). 
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At noon of dioestrus (time = 0) rats received a single s.c. injection of either 
(a) CB 154, 5 mg /kg body weight (n = 3), or (b) corn oil vehicle, lml /kg body 
weight (n = 6). Vertical lines indicate s.e. means. 
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On each of the last 8 days of treatment (days 5 - 12) lml of blood was taken 
from the tail vein between 1430 and 1500 hours, immediately prior to the daily 
injection, or, on day 12, immediately prior to sacrifice. All animals were 
sacrificed 24 hours after the 12th injection, irrespective of the stage of cycle. 
Aliquots of plasma (400}ßl) from the 8 daily blood samples for each animal were 
pooled to give a final volume of 3.2ml (cumulative sample). 3m1 of this sample 
was assayed for oestradiol along with a similar volume of plasma collected by 
aortic exsanguination at sacrifice. Plasma oestradiol levels in individual 
cumulative and sacrifice samples are listed in Table 9 and diagrammatically 
shown in Fig. 20. 
All animals in the corn oil- and CB 154 -treated groups continued to cycle 
regularly except for one of the CB 154 -treated rats, 288L (cumulative value 
indicated by ( )b in Table 9 and Fig. 20) which displayed a continuous dioestrus- 
type smear throughout the sampling period. Amongst the cycling rats a strict 
4 -day cycle was not always adhered to so that not all rats were in dioestrus at 
sacrifice on day 12. However, all cycling animals appeared to pass through 
proestrus twice during the 8 day sampling period. In the perphenazine- treated 
group all animals displayed a constant dioestrus -type smear pattern throughout 
the sampling period, apart from one individual, 125L (cumulative value indicated 
by ( )a in Table 9 and Fig. 20) which appeared to undergo one cycle in the first 
half of the 8 -day sampling period. 
The range of oestradiol levels in the cumulative samples of both the 
cycling control and CB 154- treated rats was relatively small and the mean values 
from both these groups were very similar. The oestradiol level in the 
cumulative sample of the CB 154 -treated animal ( )b which did not appear to 
cycle was much lower than those of the other members of the group. 
The most striking observation was that of the extremely low levels of 
oestradiol measured in the cumulative samples of the perphenazine -treated rats 
whose cycle appeared to be arrested in dioestrus. The values in this group 
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corn oil perphenazine CB 154 corn oil perphenazine CB154 
cumulative samples sacrifice samples 
Rats received daily s.c. injections of drug (5mg /kg body weight) or corn oil 
vehicle (1m1/kg body weight) for 12 days. A cumulative plasma sample of 
3.2ml was obtained for each rat by pooling 40011 aliquots of plasma obtained 
from blood samples removed daily from the tail vein on days 5 - 12 of 
treatment. 
( )a and ( )b were not included in the determination of means and s.e. means 
(horizontal bars) - see text. 
X and XX = significantly lower than, the control group by the Student's t -test, 
p <0.0005 and < 0.05 respectively. 
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Table 9 
Effect of perphenazine and CB 154 on plasma oestradiol in intact rats 
Plasma oestradiol (ng /100 ml) 
Treatment Rat no. Cumulative sample Sacrifice sample 
Corn oil 153L 1.78 0.01 
158L 2.00 1.75 
176L 2.45 0.74 
178L 2.12 
184L 1.57 1.25 
186L 2.41 0.1 
306L 2.24 0.18 
311L 1.87 0.16 
316L 2.48 4.14 
329L 3.14 2.49 
mean 2.21 1.21 
s.e. mean 0.14 0.45 
Perphenazine 125L (1.02)a 0.08 
129L 0.20 0.04 
149L 0.24 0.04 
165L 0.12 0.00 
171L 0.12 0.13 
181L 0.15 0.28 
mean 0.17 0.09 
s.e. mean 0.02 0.04 
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Table 9 (continued) 
Plasma oestradiol (ng /100 ml) 
Treatment Rat no. Cumulative sample Sacrifice sample 
CB 154 284L 1.73 2.84 
285L 2.16 1.33 
288L (0.42)b 0.10 
312L 2.22 1.10 
315L 2.48 1.04 
327L 2.71 0.26 
mean 2.26 1.11 
s.e. mean 0.17 0.40 
)a +b - figures not included in statistical analysis because rats showed 
atypical vaginal smear patterns 
- full details are given in text 
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showed no overlap with those of the control group and were therefore signif- 
icantly different (p ¿0.0005 by the Student t- test). Even allowing for the 
dilution effect of pooling aliquots of plasma, these extremely low levels imply 
that no single aliquot taken throughout the sampling period contained substantial 
quantities of oestradiol. Only the rat ( )a which appeared to undergo one 
oestrous cycle had an exceptional level of oestradiol compared to those of the 
others in the group. 
In comparison to oestradiol levels in cumulative samples, sacrifice values 
for plasma oestradiol in the control and CB 154- treated groups have a wide 
range, presumably due to the different stages of cycle at which the animals were 
killed. The mean sacrifice levels of plasma oestradiol were lower than the 
cumulative means and again there was no significant difference between values 
from control and CB 154 -treated groups. As would be expected from the values 
of cumulative samples, oestradiol levels at sacrifice in the perphenazine- treated 
rats were very low and significantly different from those of the control group 
(p <0.05 by the Student t -test) although some values from control rats were also 
very low. 
When the sacrifice values are compared with the cumulative values (Table 
9), it can be seen that there is little correlation between the levels of oestradiol 
in the cumulative and sacrifice samples of individuals. Thus certain individuals 
in the control group with very low levels of oestradiol at sacrifice had relatively 
high values of oestradiol in their cumulative samples. However, since all animals 
with continuously low oestradiol levels throughout treatment have low sacrifice 
values (e.g. in perphenazine- treated group) and a higher mean level of oestradiol 
at sacrifice occurred in the groups of cycling rats with substantial oestradiol 
levels in the cumulative samples, inter -group comparisons of plasma oestradiol 
content at sacrifice are still valid. 
Although this method of cumulative sampling consists of pooling aliquots 
taken only once every 24 hours, the oestradiol values in these samples correlate 
remarkably well with the individual's cyclicity as measured by the vaginal smear 
pattern. This is evident not only from the lower oestradiol values obtained in 
the non -cycling perphenazine- treated rats, but also from the intermediate 
oestradiol level of the perphenazine- treated individual ( )a which appeared to 
cycle once and from the low oestradiol level of the CB 154 -treated individual 
( )b which remained in constant dioestrus. 
5. Summary 
Using the method of blood sampling from the tail vein under ether 
anaesthesia it has been possible to show that s.c. administration in corn oil at a 
daily dose of 5mg /kg body weight perphenazine elevated, and CB 154 depressed, 
plasma prolactin levels in intact rats. Whereas CB 154 does not appear to 
inhibit the ovulatory cycle in the rat, intact perphenazine- treated rats exhibit 
constant dioestrus -type smears and from the oestradiol levels obtained in 
cumulative samples it seems likely that oestradiol output is greatly inhibited by 
this drug. Plasma prolactin levels were also decreased in ovariectomised animals 
as compared to intact controls. 
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III. Effect of hormonal manipulation on tumour growth 
and testosterone metabolism by DMBA -induced mammary tumours 
In order to study the relationships between plasma hormones, tumour 
growth and tumour steroid metabolism, rats bearing DMBA- induced mammary 
tumours were allocated to 5 treatment regimes designed to alter the levels of 
plasma hormones important in controlling the growth of these tumours. Incub- 
ation of the tumours with[3H] testosterone after treatment provided a measure- 
ment of the capacity of tumour to convert testosterone to its major metabolites 
in vitro which could then be related to tumour growth and plasma levels of 
prolactin and oestradiol. 
1. Experimental design 
Only tumours which were actively growing and borne by rats showing 
regular oestrous cycles of 4 days were considered for this study. At the 
dioestrus stage of the cycle the rats were allocated to one of the 5 treatment 
regimes shown in Table 10. All animals were sacrificed when exhibiting a 
dioestrus -type vaginal smear, so that the vaginal smear appearance was uniform 
in all treatment groups at the start and completion of treatment (perphenazine- 
treated and ovariectomised animals displayed a constant dioestrus -type vaginal 
smear pattern). Occasionally the treatment period was extended beyond the 
intended 12 days to accommodate rats whose cycle had varied during treatment 
such that a dioestrus -type vaginal smear was not seen on day 12. It was also 
sometimes necessary to sacrifice animals with rapidly regressing tumours before 
the twelfth day of treatment so that sufficient tumour tissue was available for 
incubation. 
At sacrifice tumours were excised and divided into portions for testo- 
sterone metabolism studies, histology and, when sufficient, determination of 
DNA content. Necrotic tumours and tumours which were not classified as 
adenocarcinomas were not used for the study. 
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Legend for Tables 10 - 15 
The values obtained from groups 2, 3, 4 and 5 were compared to those of 
group 1 by variance analysis plus Dunnett's test and those of group 4 with those 
of group 5 by the F -test (- = not significant; > and >? = greater than, and < 
and « = less than, the control values at p< 0.05 and p 40.01 levels respect- 
ively). The first symbol after group 5 values refers to the comparison with 
group 1 values and the lower symbol refers to the comparison with group 4 
values. When the variances within groups were deemed incomparable by 
Hartley's test (p<0.01), all data were transformed to natural logarithms (In) 
before the variance analysis. Where this was done the In means and 
corresponding standard deviations (s.d.) are given in the tables with the geo- 
metric means (= antilogarithms of the In means) in brackets. The arithmetic 
means are given in the complete tables of results. Where additional analyses 

















1. IC intact corn oil 11 89.5 13.3 
2. I + P intact perphenazine 9 118.1> 14.9- 
3. I + B intact CB 154 7 97.9- 12.6- 
4. Ovx C ovariectomised corn oil 10 107.3- 9.6< 
5. Ovx + P ovariectomised perphenazine 7 93.3- 14.0- 
_ > 
within 1. pooled s.d. 21.8 1.9 
group d.f. 39 39 
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The complete results from the individual rats in each treatment group are 
given at the end of this section in Tables 18 - 22. Data pooled for the statistical 
analyses of intergroup variations are given in Tables 10 - 13 and 15, and are 
illustrated diagrammatically in Figs. 21 - 29. The interrelationships between 
certain parameters have also been considered on an individual basis by investig- 
ating correlations within groups and over all groups taken together. 
Although allocation to a treatment group usually occurred as soon as a rat 
had a sufficiently large, growing tumour and was cycling regularly, there was a 
considerable range in times between carcinogen administration and allocation to 
a treatment group. Only when all data were compiled at the end of the study 
was it realised that average time between the administration of carcinogen and 
the allocation to treatment groups was significantly greater in the intact, 
perphenazine- treated group than in the intact control group (Table 10). The 
relevance of this situation is considered further in the section on individual 
inter correlations. 
2. Vaginal smear pattern 
All intact rats given corn oil vehicle or CB 154 continued to cycle regularly 
throughout the treatment period. Ovariectomised animals, whether given corn 
oil or perphenazine, displayed a constant dioestrus -type vaginal smear pattern. 
Perphenazine administration to intact rats also produced a generalised pattern of 
persistent dioestrus smears but this effect was not always immediate, with some 
rats apparently undergoing one further cycle before arresting in dioestrus. 
3. Plasma prolactin levels 
Blood samples for the assay of plasma prolactin were removed from the 
tail vein between 1030 and 1200 hours immediately prior to starting treatment 
and at the same time of day at sacrifice, 24 hours after the final administration 
of drug or vehicle. The mean plasma prolactin values for the groups are shown 
in Table 11. 
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Table 11 
Plasma prolactin levels in rats bearing tumours 







(In ng /ml + geom. mean) 
initial final 
1. I C 11 3.06 (21.4) 2.92 (18.5) 
2. I + P 9 3.23 (25.3)- 4.23 (68.4)» 
3. I + B 7 3.26 (26.0)- 1.64 (5.2)E< 
4. Ovx C 10 3.15 (23.3)- 1.78 (5.9)« 
5. OVX + P 7 3.32 (27.7)- 4.42 (83.1)» » 
within pooled s.d. 0.95 0.61 
group d.f. 39 39 
Legend on page R.-51. 
Blood samples for plasma prolactin assay were taken immediately prior to the 
start of treatment (initial), and at sacrifice - 24 hours after the last injection 
(final). 
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Pretreatment values were similar in all 5 groups. In intact animals the 
final prolactin levels showed no difference from pretreatment values after corn 
oil treatment, but were significantly raised by perphenazine and depressed by CB 
154. In ovariectomised rats given corn oil the final plasma prolactin levels were 
lower than pretreatment values whereas an elevation from pretreatment to final 
levels was observed in ovariectomised rats given perphenazine. These differ- 
ences were all significant by the paired t -test (p <0.05). As pretreatment 
values were similar in all groups this meant that in perphenazine- treated rats 
(intact and ovariectomised), sacrifice levels were significantly higher and in 
ovariectomised rats given corn oil and in CB 154- treated rats sacrifice levels 
were significantly lower than the plasma prolactin levels in the control group at 
sacrifice. 
The prolactin values obtained at sacrifice are similar to those reported in 
the previous section where more detailed studies were carried out on non- tumour- 
bearing rats. Since the single sacrifice samples tend to reflect the plasma 
prolactin levels throughout the treatment period the various treatments applied 
to the tumour -bearing rats in this study appear to have had the desired effect on 
plasma prolactin. 
4. Plasma oestradiol levels 
Plasma oestradiol concentration was measured in a large volume of blood 
(8- 12m1), withdrawn from the abdominal aorta at sacrifice. The mean values 
obtained from each group are shown in Table 12. Mean plasma oestradiol levels 
in both groups of ovariectomised animals were obviously lower than those of the 
intact control group and since they were around the limits of detection of the 
assay for the volume of plasma available, were not statistically analysed. 
The mean oestradiol level in the perphenazine- treated intact group was 
almost half that of the control group, and although the difference was not 
significant by variance analysis by the Wilcoxon rank test the difference was 
significant at the 5% level. Plasma oestradiol levels were however significantly 
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Table 12 
Plasma oestradiol levels in rats bearing tumours 







1. I C 11 0.68 
2. I + P 9 0.37- * 
3. I + B 7 1.17> 
within pooled s.d. 0.43 
group d.f. 24 
4. Ovx C 10 0.12 
5. Ovx + P 7 0.21 
Legend on page R- 5I. 
Blood samples for plasma oestradiol assay were taken at sacrifice - 24 hours 
after the final injection. Limit of detection of the oestradiol assay - 0.16ng /ml. 
* The difference between the intact + perphenazine and the intact control 
group is significant when tested by the Wilcoxon rank test (p <0.05). 
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higher in the CB 154 -treated group than in the control group by variance 
analysis. 
These results from the intact groups are not in complete accord with the 
data presented for non -tumour -bearing intact rats in the previous section. In 
that study plasma oestradiol levels at sacrifice were clearly significantly lower 
in the perphenazine- treated group compared to the control group whereas there 
was no difference between the values of the CB 154 -treated animals compared 
to those of the control group. The apparent dissimilarity between the 2 sets of 
results can be accounted for by the difference in oestradiol sacrifice values in 
the control groups of the 2 studies. The control group in the previous section 
had a mean sacrifice value of 1.21ng/100m1 compared with 0.68ng/100m1 for the 
control group in this study. This difference may be due to the fact that all 
animals in the present study were sacrificed in dioestrus whereas in the earlier 
study the date of sacrifice was determined by a fixed number of days of 
treatment and not by stage of the cycle. An alternative explanation may be 
that the time of sampling was earlier in the present study. 
Whilst it was demonstrated in the cumulative sampling study that treat- 
ment with perphenazine clearly suppressed plasma oestradiol levels in intact 
rats, and that CB 154 had no apparent effect on oestradiol levels over the 
treatment period, it would appear from the results of the present study that the 
plasma oestradiol levels at dioestrus may be higher in CB 154 -treated rats than 
in control rats at the same stage of the cycle. 
5. Tumour growth 
Tumour size, expressed as a multiple of major and minor diameters, was 
measured every 2 or 3 days before and during treatment. The individual tumour 
sizes and growth rates at the start and end of treatment are given in Tables 18 - 
22. The growth rates were derived from the change in tumour size over the 
week preceding the start of treatment and over the last week of treatment. 
Since the tumour growth rate in certain rats varied throughout the treatment 
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period, only the measurements taken over the last week were used to assess 
tumour growth so that as nearly as possible the actual growth rates at the time 
of sacrifice were expressed. Therefore, the final growth rate does not 
necessarily correspond to the difference in tumour size at the start and at the 
end of the treatment period. 
The mean values of tumour size and growth rate are compared in Table 13, 
and the mean tumour growth rates are shown in Figs. 21 and 22. For direct 
comparison of growth rates in the figures individual tumour size was first 
expressed as a percentage of that on the day treatment commenced before 
calculating the mean at each time point. Individual examples are given in Figs. 
23 and 24. 
It can be seen from Table 13 that both the initial size and initial growth 
rate of tumours in CB 154- treated and ovariectomised- plus -perphenazine- 
treated groups are significantly higher than those of the control group. The 
difference in initial tumour size resulted from the deliberate allocation of rats 
with larger tumours to the 2 groups where tumour regression was expected so 
that at sacrifice sufficient tumour mass was available for steroid metabolism 
studies. Conversely , if rats with large tumours were allocated to the intact - 
plus- perphenazine treatment group in which rapid tumour growth was expected, 
there was an increased risk of complications such as tumour necrosis before the 
end of treatment. The higher tumour growth rate observed in the groups with 
the greater initial tumour size may reflect a general relationship between 
tumour growth rate and tumour size due to the way in which these parameters 
were expressed. When tumour size was expressed as a percentage of the size at 
the start of treatment (Figs. 21 and 22), there was no apparent initial difference 
in growth rate. In general, tumours in the intact control group given corn oil 
grew at a similar rate before and during treatment. One of the tumours did 
cease to grow during treatment. 
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Table 13 
Size and growth rate of tumours 







(In cm2 + geom. mean) 
initial final 
Tumour growth rate 
(cm2 /week) 
initial final 
1. I C 14 0.92 (2.52) 1.30 (3.67) 0.89 0.68 
2. I+ P 10 0.68 (1.98)- 1.57 (4.81)- 0.70- 1.39-* 
3. I + B 11 1.64 (5.13)» 1.46 (4.30)- 1.70> -0.29 < 
4. Ovx C 10 1.89 (6.92)» 1.31 (3.69)- 1.59> -2.41 c< 
5. Ovx + P 10 1.00 (2.71)- 1.15 (3.16)- 1.01- -0.16 < 
- - » 
within pooled s.d. 0.39 0.47 0.68 0.87 
group d.f. 50 50 50 50 
Legend on page R -51 
* Significantly higher than the control value when compared by the Wilcoxon 
rank test (p <0.05). 
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Figure 21. Effect of perphenazine and CB 154 on the growth of 
DMBA -induced tumours in intact rats 
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Rats received daily s.c. injections of perphenazine or CB 154 (both at 5mg /kg 
body weight) or corn oil vehicle (1m1 /kg body weight) starting on day O. 
Tumour sizes were calculated individually as percentages of that on day 0 and 
the means of these percentages at given times were used to construct the 
graph. Vertical lines indicate s.e. means. 
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Figure 22. Effect of perphenazine on the growth of DMBA- induced 
mammary tumours after ovariectomy 
150 - 
tumour size 
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+6 12 
The experimental design and expression of results were the same as described 
in Figure 21, except that all rats were bilaterally ovariectomised on day O. 
Vertical lines indicate s.e. means. 
Mean tumour growth rate in intact animals was accelerated by the 
administration of perphenazine. All tumours in this group continued to grow 
throughout the treatment period, and in all but 2 of the 10 tumours the growth 
rate was increased. The percentage increase in tumour size and the final 
tumour growth rate of the intact perphenazine -treated rats were significantly 
higher than corresponding values for the intact control group by the Wilcoxon 
rank test (p< 0.05). 
The mean tumour growth pattern of intact rats treated with CB 154 
became static after the start of treatment. The result was that by the end of 
treatment the percentage change in tumour size and final tumour growth rate 
was significantly less in the CB 154 -treated animals than in the control group. 
Expressing the results as means does however obscure the responses of individual 
tumours. Typical examples of the 3 main types of tumour growth with the 
number of tumours classified into each type are shown in Fig. 23. Of the 11 
tumours in this group, 7 regressed, 2 continued to grow and in the remaining 2 
growth was checked, but resumed by the end of treatment. 
The mean tumour growth rates of animals in the 2 ovariectomised groups 
are shown in Fig. 22. In the animals which were ovariectomised and received 
corn oil all tumours showed immediate regression which continued throughout 
the treatment period. The administration of perphenazine from the time of 
ovariectomy prevented immediate tumour regression and the mean change in 
tumour size over the treatment period and the final growth rate were signif- 
icantly different between the 2 ovariectomised groups. There was however a 
large variation in the growth pattern of tumours in ovariectomised rats given 
perphenazine. Individual examples of 3 broad categories of tumour growth with 
the number of tumours which fit into these categories are given in Fig. 24. Of 
the 10 tumours in this group, 5 regressed after an initial growth period lasting 
5 -10 days, one showed little net change in size and 4 grew throughout the 
treatment period. 
Figure 23. Growth patterns of individual DMBA- induced mammary tumours 
in intact rats given CB 154 
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The differing growth patterns of 3 tumours in CB 154- treated rats are 
displayed. From the 11 tumours incubated for steroid metabolism studies in 
this group, the number typified by a particular growth pattern is given in 
brackets. 
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Figure 24. Growth patterns of individual DMBA- induced mammary tumours 
in ovariectomised rats given perphenazine 
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The differing growth patterns of 3 tumours in rats receiving perphenazine 
after ovariectomy are displayed. From the 10 tumours incubated for steroid 
metabolism studies in this group, the number typified by a particular growth 
pattern is given in brackets. 
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The variation in tumour growth seen in certain groups could have been due 
to the variations in the extent of hormonal changes caused by the various 
treatment regimes. However, it seems unlikely that this is the full explanation 
since variations in tumour growth were often seen within one rat bearing 2 or 
more tumours (Table 22). Thus to a certain degree variations of the tumour 
growth in response to particular treatment would seem to depend on the 
properties of the individual tumours. 
6. Metabolism of testosterone by tumours 
At sacrifice tumours were excised and an accurately weighed portion of 
0.5g was homogenised and then incubated with 50 x 106 d.p.m. of [70. -3H] 
testosterone in 7.5ml Krebs -Ringer phosphate buffer, pH 7.4, for one hour at 
37 °C in the presence of an NADPH generating system as described in full in the 
METHODS section. Total testosterone metabolism and the net formation of 
5o(- dihydrotestosterone and 5D(- androstanediol were determined by measuring 
the percentage incorporation of radioactive label into the individual steroids 
following their purification and characterisation. Table 14 gives representative 
examples of the characterisation of precursor and metabolites following the 
incubation of a tumour from each of the 5 groups. Data for testosterone 
metabolism by the individual tumours are given in Tables 18 - 22 and are pooled 
for inter -group statistical analysis in Table 15. Total 5ot - reduction has been 
expressed as the sum of the percentages of 5o(- dihydrotestosterone and 
51X- androstanediol production. The ratio of 5b(- androstanediol over 
5a- reduction has also been calculated to give an indication of the relative 
amount of 5X-reduced steroid which has further undergone hydroxylation at the 
3- position. 
All tumours investigated under the conditions described metabolised testo- 
sterone to 5o(- dihydrotestosterone and 5 o(- androstanediol and in every case the 
quantity of 5e(- androstanediol recovered was greater than that of 5a- dihydro- 
testosterone, in a ratio of 4:1 on average. In all but 4 of the 55 tumours 
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Table 14 
Characterisation of steroids in representative tumour incubates 














332E RIn (I C) 
testo free III 13,605 
testosterone testo acetate IV 13,256 47.75 
0 4 -dione III 13,506 
50L-DHT free III 2,942 
50t -DHT 5oc-DHT acetate IV 3,130 10.56 
5a- Adiol(3/3) III 2,916 
Sa-Adiol (3°) 5o(-Adione II 7,368 26.39 
5 4-Adio1(3p ) III 7,710 
65H LNk (I +P) 
testo free III 9,791 
testosterone testo acetate IV 9,772 33.79 
A4 -dione III 9,531 
50t -DHT free III 5,849 
50(-DHT 504.-DHT acetate IV 5,881 20.29 
5ot- Adiol(3ß) III 5,863 
5o1-Adiol(3o0 5a-Adione II 12,786 43.79 















354L RIn (I + B) 
testo free III 10,897 
testosterone testo acetate IV 10,574 39.53 
A 4 -dione III 10,736 
50t-DHT free III 1,231 
5o -DHT 5o4-Adiol (313) III 1,255 4.59 
5 o(- Adione II 1,278 
5d -Adiol (30) 5d- Adione II 11,694 42.79 
5o4-Adiol (V) III 11,874 
48L LIn (Ovx C) 
testo free III 21, 499 
testosterone testo acetate IV 21,855 77.00 
A 4 -dione III 21,211 
5ö -DHT free III 1,135 
.50-DHT 5 of -Adiol (3ß) III 1,136 4.01 
5 ot- Adione II 1,113 
5o( -Adiol (3(1) 5i- Adione II 3,982 13.68 
5ot -Adio1 (3ß) III 3,775 
R- C,7 














297K RAx (Ovx + P) 
testo free III 8,903 
testosterone testo acetate IV 8,969 37.51 
4 4 -dione III 8,988 
5d -DHT free III 1,367 
5d -DHT 5d -Adiol (3ß) III 1,338 5.54 
5 -Adione II 1,287 
5o( -Adiol (3d) 50(- Adione II 7,753 32.76 
5 á -Adiol (3ß) III 8,104 
R -G8 
conversion to the 50-reduced products, 5 oC- dihydrotestosterone and 5 oC- andro- 
stanediol accounted for the majority of the testosterone metabolism. Although 
these generalisations apply to all groups certain quantitative differences were 
seen between the groups when the results were subjected to statistical analysis 
(Table 1.5). 
Total testosterone metabolism (Fig. 25) by tumours from intact rats given 
corn oil ranged from 35.60 - 66.88% with a mean of 53.74%. Tumours from 
intact rats given perphenazine metabolised testosterone to a significantly 
greater extent with only one tumour metabolising less than 50% of the precursor. 
The mean level of testosterone metabolism by tumours from intact rats given 
CB 154 was similar to that of the control group but the range of values was 
remarkably small (47.91 - 63.15 %). In contrast a large variation in the ability to 
metabolise testosterone was observed in both groups of ovariectomised animals. 
Although mean level of testosterone metabolism by tumours from ovariect- 
omised rats given perphenazine was significantly higher than that of the 
ovariectomised control group, it was not significantly different from that of the 
control and numerically less than that of intact rats given perphenazine. The 
metabolism of testosterone by tumours from the ovariectomised control group 
was significantly lower than that found in all other groups. 
The quantities of 5o(- dihydrotestosterone recovered at the end of tumour 
incubation are shown in Fig. 26. Since 5o(- dihydrotestosterone can be further 
converted to So(- androstanediol during incubation, the quantity of 5o4,- dihydro- 
testosterone recovered reflects its total formation minus its further metabolism. 
This net formation of 5ot- dihydrotestosterone by tumours from intact rats given 
perphenazine was significantly higher than by those of the intact control group. 
None of the other treatment regimes appeared to significantly change the net 
formation of 5a- dihydrotestosterone. 
The production of 50(- androstanediol by the same groups of tumours is 
shown in Fig. 27. The formation of this metabolite was significantly higher by 
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Table 15 
Metabolism of testosterone by tumours 








Testosterone metabolism ( %) 
5d -DHT* 5 L Adiol 5o -red'n 
5 .Adiol 
5 . -red'n 
1. I C 14 53.74 1.77 (5.88) 32.09 38.46 0.83 
2. I + P 10 67.65 > 2.59 (13.32)> 44.66> 61.94>> 0.74- 
3. I+ B 11 56.07- 1.90 (6.68)- 37.29- 45.14- 0.83- 
4. Ovx C 10 40.114 1.41 (4.10)- 22.96- 27.49- 0.82- 
5. Ovx + P 10 57.64- 1.81 (6.76)- 33 . 22- 42.17- 0.81- » - > > 
within pooled s.d. 12.17 0.63 10.09 13.43 0.09 
group d.f. 50 50 50 50 50 
Additional comparisons by the Student -Newman -Keuls test 
Group 2 vs 5 
Group 3 vs 4 
> » 
Legend on page R.-51 
* data for the conversion of testosterone to 5c -DHT were transformed to 
natural logarithms. 
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Figure 25. Testosterone metabolism by DMBA- induced mammary tumours in rats 




( °/U ) 
5 0 - 
2 5 - 
2. 
intact intact + intact ovx. ovx. 
control perphenazine +CB 154 control perphenazine 
Treatment regimes are described in Table 10 and details of incubation 
procedures are given in the METHODS section. Each point represents the 
value from an individual tumour. Horizontal bars indicate the means and s.e. 
means for each group. Statistical analyses are given in Table 15. 
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Figure 26. Testosterone metabolism by DMBA- induced mammary tumours in rats 
of different hormonal status, (b) Conversion to 5K dihydrotestosterone 
conversion 








intact intact 4- intact + ovx. ovx + 
control perphenazine CB 154 control perphenazine 
See legend of Figure 2.5 
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Figure 27. Testosterone metabolism by DMBA- induced mammary tumours in rats 








intact intact 4- intact + ovx. ovx + 
control perphenazine CB 154 control perphenazine 
See legend of Figure 25 
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Figure 28. Testosterone metabolism by DMBA- induced mammary tumours in rats 
of different hormonal status, (d) 5.(-reduction of testosterone 
75- 






intact intact -I- intact + ovx. ovx + 
control perphenazine CB 154 control perphenazine 
See legend of Figure 25 
R - 74 
tumours from both intact and ovariectomised rats given perphenazine than by 
those of their respective control groups. However, the formation of _V- andro- 
stanediol by tumours from the ovariectomised group given perphenazine was 
similar to that of the intact control group and significantly less than that of the 
intact group given perphenazine. The formation of 5c -androstanediol by 
tumours from intact rats given CB 154 did not differ significantly from that of 
the intact control group, but was significantly greater than that of the 
ovariectomised control group. 
Tumour 5o(- reduction of testosterone is shown in Fig. 28. The pattern of 
differences is similar to that described above for the production of the major 
component, .W- androstanediol. In both intact and ovariectomised rats perphen- 
azine treatment significantly stimulated the 5a- reduction of testosterone by 
DMBA- induced tumours. The effect was highly significant in the intact animals 
(p .0.01), reflecting the individually significant elevations in the formation of 
both 5o.- reduced metabolites. This increase in 5a- reduction is alone sufficient 
to account for the increased levels of testosterone metabolism observed in 
tumours from perphenazine- treated rats. The extent of the 5a- reduction of 
testosterone by tumours from the ovariectomised animals given perphenazine 
was similar to that found in the control group and significantly lower than that 
of the intact animals given perphenazine. 5a- reduction by tumours from intact 
rats given CB 154 did not differ significantly from that of the control group, but 
was significantly higher than that of the ovariectomised group given corn oil. 
The mean ratio of 5a- androstanediol formation over Soc.-reduction lay 
between 0.81 and 0.83 for all groups except the intact, perphenazine- treated 
group which gave a ratio of 0.74. The lower values in this group resulted from 
the greater contribution of 5o.- dihydrotestosterone levels to 5a-reduction by 
some tumours in the group. However, the difference was not significant. 
In summary, the administration of perphenazine to intact rats increased 
the total metabolism of testosterone and its conversion to both 5a-dihydro- 
R-75 
testosterone and 5o4- androstanediol by DMBA- induced mammary tumours incub- 
ated in vitro. Perphenazine also stimulated tumour metabolism of testosterone 
and its conversion to 5oc- reduced products in ovariectomised rats. However, the 
levels of total metabolism of testosterone and its conversion to 5 ò- dihydro- 
testosterone and 50<- androstanediol by the tumours of ovariectomised rats given 
perphenazine were similar to those of the intact control group and were not as 
high as those of the intact rats which received perphenazine. This set of 
circumstances appears to have been made possible by the lowered metabolism of 
testosterone found in ovariectomised -control compared to the intact -control 
group. 
Treatment with CB 154 appeared to have no noticeable effects on the 
metabolism of testosterone by DMBA- induced tumours in that the values 
obtained for all parameters measured were similar to those of the intact control. 
When the effects of the 2 treatment regimes which lower plasma prolactin 
were compared it was found that the metabolism of testosterone and its 
5th- reduction was significantly higher in the tumours from intact rats given 
CB 154 compared to those from ovariectomised rats given corn oil. 
7. DNA content of tumours 
The DNA content of tumours from the animal groups studied is shown in 
Fig. 29. The mean tumour DNA content of the control group does not differ 
significantly from the mean of other groups. The similarity between the DNA 
content of tumours from the groups receiving corn oil or perphenazine render it 
unlikely . that the increased tumour metabolism of testosterone induced by 
perphenazine treatment is due to increased tumour cellularity. 
8. Correlations between parameters determined on an individual basis 
Since intergroup comparisons revealed that treatment regimes which 
elevated plasma prolactin and stimulated tumour growth also stimulated the 
capacity of tumours to metabolise testosterone to 5o'- reduced products it was of 
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Figure 29. DNA levels in tumours used for steroid metabolism 







intact intact + intact + ovx. ovx.+ 
control perphenazine CB l54 control perphenazine 
See legend of Figure 25 
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interest to see if there were any correlations between these parameters within 
individual groups. It was also important to investigate possible relationships 
between testosterone metabolism and parameters such as the time from DMBA 
administration to the start of treatment and initial tumour size and growth since 
the latter were significantly greater in certain treatment groups than in the 
intact control group. 
Interrelationships between the 16 parameters listed in Tables 18 - 22 have 
been examined by calculating the simple coefficient of correlation (r) for all 
paired combinations of interest (Table 16). When at least one of the pair of 
parameters was measured after treatment, the correlations were investigated on 
a within -group basis. When both of the parameters to be studied were measured 
prior to the start of treatment the correlations were investigated with data 
pooled from all five groups. The relationships between pretreatment para- 
meters and tumour DNA content were also investigated in this manner as the 
levels of the latter appeared to be unaffected by the various treatment regimes. 
The test for the simple coefficient of correlation, without excluding 
outlying values, was applied in preference to more sophisticated tests because it 
was desired to provide a general picture from a large volume of data. However, 
the number of observations for each parameter within a group was relatively 
small, and one or two extreme values in the presence of otherwise close 
groupings could greatly influence the determination of the coefficient of 
correlation. For this reason and the fact that the test was repetitively applied 
it is possible that some apparently significant correlations, especially at the 5% 
level, have been obtained purely by chance. Therefore, consideration should be 
given to trends throughout the groups or highly significant observations which 
may be supported by related findings rather than to odd individual values. 
Certain relevant observations deserve further comment. 
The time between the administration of DMBA and the allocation to 
treatment groups varied considerably within each group, and was by chance 
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Legend for Table 16 
The values presented in the table are the simple coefficients of correl- 
ation (r) for the corresponding parameters listed vertically and horizontally. 
Dependent on the appropriate degrees of freedom (d.f.), the further the value is 
displaced from zero towards +1 or -1 the greater the likelihood of a positive or 
negative correlation respectively. (- = p < 0.05, ** = p < 0.01) 
1 = days since DMBA 
2 = days of treatment 
3 = initial prolactin 
4 = final prolactin 
5 = oestradiol (at sacrifice) 
6 = initial tumour size 
7 = final tumour size 
8 = initial tumour growth rate 
Parameters 
9 = final tumour growth rate 
10 = tumour DNA content 
11 = testosterone metabolism 
12 = 5o( -DHT production 
13 = 5o -Adiol production 
14 = 5ct- reduction 
15 - 5ot -Adiol production 
5ot- reduction 
16 = unaccounted -for metabolism 
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Table 16 
Correlations between parameters measured in the five treatment groups 
Parameter 9 10 11 12 13 14 15 16 
1 .14 .12 .13 -.03 .47 .43 .30 -.49 
4 -.30 -.08 .52 .51 .17 .29 -.23 .29 
5 -.12 -.13 -.29 -.50 -.27 -.38 .32 .17 
6 .14 .63* -.17 -.08 -.02 .00 -.04 -.24 
7 .68* .76 ** .09 -.05 .03 .02 -.12 .10 
8 .22 .40 .27 .36 .05 .14 -.09 .17 
9 .41 .27 -.22 -.03 -.08 .20 .52 
10 .13 -.37 .19 .08 .49 .06 
11 .27 .76 ** .78 ** .38 .21 
12 Group 1. I C .12 .36 -.69 ** -.19 
13 Comparison d.f. .97 ** .58 -.43 
14 10vsl -16 9 .37 -.45 
15 all others 12 -.04 
1 .02 -.03 .26 .42 .15 .36 -.45 -.42 
4 -.22 .06 .01 .28 .13 .12 -.29 -.27 
5 .42 .34 -.36 -.41 -.05 -.31 .37 .11 
6 -.25 .40 .17 .33 -.06 .19 -.32 -.16 
7 .44 -.01 .14 .14 -.16 .00 -.08 .25 
8 -.17 .00 .53 .49 .20 .49 -.41 -.13 
9 -.14 -.49 -.50 -.52 -.63* .50 .67* 
10 -.43 -.02 -.47 -.25 -.11 -.18 
11 .75* .78 ** .93 ** -.64* -.50 
12 Group 2. I + P .32 .85 ** -.98 *" -.74* 
13 Comparison d.f. .77 ** -.18 -.51 
14 10 vs 1 - 16 7 -.76 ** -.78 ** 
15 all others 8 .72* 
520 
Table 16 (continued) 
Parameter 9 10 11 12 13 14 15 16 
1 .01 -.05 -.02 -.12 .05 -.05 .09 .05 
4 .06 -.37 .03 .46 .11 .41 -.39 -.53 
5 .34 .42 -.12 -.25 -.40 -.49 .15 .57 
6 .48 -.51 .42 .42 .33 .55 -.34 -.38 
7 .79 ** -.68* .48 .48 .28 .55 -.40 -.33 
8 .72* -.58 .53 .48 .35 .61* -.38 -.36 
9 -.65 .30 .40 .16 .40 -.35 -.28 
10 -.29 -.82 ** -.30 -.77* .76* .80 ** 
11 .06 .80 ** .68* .08 -.04 
12 Group 3. I + B -.10 .61* -.98 ** -.78 ** 
13 Comparison d.f. .73 ** .27 -.28 
14 10 vs 1 - 16 7 -.46 -.76 ** 
15 all others 9 .70* 
1 -.29 .29 -.23 .13 .01 .04 -.18 -.55 
2 .57 .33 .45 -.09 .18 .15 .30 .76 ** 
4 -.33 .12 -.02 -.09 .19 .16 .01 -.28 
6 -.77 ** -.38 -.41 .14 -.40 -.34 -.64* -.37 
7 -.54 -.40 -.16 .30 -.23 -.15 -.53 -.11 
8 -.51 -.22 -.19 .06 -.25 -.22 -.41 -.08 
9 .21 .75* .11 .56 .53 .64* .83 ** 
10 .14 -.38 .16 .08 .47 .18 
11 .43 .92 ** .91 ** .55 .80 ** 
12 Group 4. Ovx C .46 .59 -.46 .05 
13 Comparison d.f. ** 5 .52 
14 all 8 .38 .49 
15 .62 
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Table 16 (continued) 
Parameter 9 10 11 12 13 14 15 16 
1 .13 .36 .20 .29 .33 .34 -.08 -.41 
4 .30 -.20 -.09 .34 .02 .14 -.45 -.47 
6 -.28 .13 -.14 -.08 .07 .02 .06 -.28 
7 .66* -.31 -.21 .15 -.32 -.17 -.28 .02 
8 -.28 -.03 -.18 -.21 -.16 -.20 -.01 .13 
9 -.28 -.35 -.07 -.45 -.35 -.09 .17 
10 -.11 .06 .16 .14 .13 -.50 
11 .72* .87 ** .90 ** -.44 -.25 
12 Group 5. Ovx + P .61 .82 ** -.90 ** -.57 
13 Comparison d.f. .95 ** -.28 -.60 
14 10 vs 1 - 16 7 -.54 -.65* 
15 all others 8 .42 
Parameter 3 8 10 all data 
1 -.25 -.19 .07 Comparison d.f. 
3 .07 .17 1 vs 3 42 
6 .81 ** .14 10 vs 1 - 8 46 
8 .11 all others 53 
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significantly higher in the intact perphenazine- treated group than in the intact 
control group. However, within each group this parameter showed no significant 
correlation with any of the other parameters. Initial tumour size and initial 
tumour growth, which were greater in rats being allocated to the intact -plus -CB 
154 group and the ovariectomised control group, did not show significant 
correlations with any of the testosterone metabolism parameters in any of the 
five groups. From these results there is no evidence that the pretreatment 
differences between groups had any influence on subsequent measurements of 
testosterone metabolism. In the only group in which a noteworthy variation in 
the length of treatment period occurred, the ovariectomised control group, this 
parameter appeared to be unrelated to the metabolism of testosterone or to the 
formation of 5ol- reduced products. 
In each group the level of prolactin found in the plasma at sacrifice showed 
no significant correlation with final tumour growth rate, tumour DNA content or 
any of the testosterone metabolism parameters. However, the range of 
prolactin values within certain groups was very small due to the treatment 
regimes. The plasma oestradiol levels in each of the three intact groups also 
showed no significant correlation with any of the other parameters although it 
was observed that when plasma oestradiol levels were related to testosterone 
metabolism or the formation of 5o(- reduced products, negative coefficients of 
correlation were always obtained. When final tumour size and final tumour 
growth rate or tumour DNA content were related to the parameters of 
testosterone metabolism no consistent correlations were observed throughout the 
groups. 
As was suspected from the observation that in the two groups with higher 
initial tumour size initial tumour growth was also greater, there was a highly 
significant positive correlation between initial tumour growth and size, when all 
data were considered together. 
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When the relationships between testosterone metabolism parameters were 
investigated certain obvious correlations were observed. In each group the total 
level of testosterone metabolism showed a highly significant correlation with its 
major route of metabolism, 5o(- reduction, and in turn this parameter showed a 
highly significant correlation with the production of its major component, 
5 o(androstanediol. However, only in the two perphenazine- treated groups did 
testosterone metabolism show a significant positive correlation with the net 
production of 5 a- dihydrotestosterone and the relationship between the net 
production of 5 x- dihydrotestosterone and 5 ot- androstanediol did not reach signif- 
icance in any of the groups. _. 
9. Effect of perphenazine on the metabolism of testosterone by tumours in 
vitro 
The possibility of a direct stimulatory effect of perphenazine on the 
metabolism of testosterone was investigated by performing tumour incubations 
in the presence of perphenazine. 
Two tumours taken from intact cycling rats in the dioestrus stage of the 
cycle were each divided into three portions which were then incubated in the 
presence of vehicle, 10 -5M perphenazine or 10 -4M perphenazine under the 
standard conditions described in the METHODS section. Perphenazine was first 
dissolved in a solution of ethanol /monopropylene glycol, so that addition of 50p1 
to the incubation mixture gave the desired final concentrations. After incub- 
ation, the levels of testosterone and its metabolites were assessed in the normal 
manner. The results are shown in Table 17. 
The levels of 50(- dihydrotestosterone and .5c- androstanediol produced by 
the first tumour were relatively low and accounted for slightly less than half of 
the total testosterone metabolised. The amounts of testosterone metabolised, 
and the quantities of 5c<- dihydrotestosterone and 5 a- androstanediol recovered 
were remarkably similar in all three incubates so that perphenazine appeared to 
be without effect in this tumour. The metabolism of testosterone and the 
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Table 17 
Effect of perphenazine on testosterone metabolism in vitro 
Addition to Testosterone metabolism (%) 
incubation total 
medium metab. 5 oc -DHT 5 o< -Adiol 5oc -red'n 
1. vehicle 52.25 2.78 15.74 18.52 
10-5M perphenazine 50.33 3.17 15.97 19.14 
10-4M perphenazine 56.50 3.85 14.28 18.13 
2. vehicle 33.12 11.18 37.11 48.29 
10-5M perphenazine 39.28 10.32 28.08 38.40 
10-4M perphenazine 45.43 7.50 25.45 32.95 
The vehicle was ethanol /monopropylene glycol 1:1, of which a 50)11 aliquot, 
with or without the requisite amount of perphenazine present, was added to a 
volume of 7.5ml prior to the start of the incubation. 
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formation of 5ot- reduced products in the second tumour were higher and 
perphenazine appeared to have exerted a dose -related inhibitory effect on these 
parameters in this tumour. 
10. Summary 
The administration of perphenazine to intact rats bearing actively growing 
DMBA- induced tumours raised plasma prolactin levels, lowered plasma oestradiol 
levels, stimulated tumour growth rate and increased the capacity of tumours to 
metabolise testosterone by 5x-reduction in vitro. In intact rats given CB 154, 
plasma levels of prolactin, but not oestradiol, were lowered, tumour growth was 
inhibited, but there were no significant changes in the total metabolism of 
testosterone, or its conversion to 5oc- dihydrotestosterone or 5cx- androstanediol. 
Ovariectomy caused a fall in plasma levels of oestradiol and prolactin, immed- 
iate tumour regression and a slightly decreased capacity for testosterone 
metabolism by tumours. When ovariectomised rats received perphenazine, 
plasma oestradiol levels remained low, but prolactin levels were raised to the 
same levels as those of intact rats given perphenazine, tumour regression was 
delayed but not completely prevented and the capacity of tumours to metabolise 
testosterone by 5ot- reduction was significantly higher than in tumours from the 
ovariectomised control group. Although the levels of testosterone metabolism 
and its conversion to 5o(- reduced products were higher in tumours from the 
ovariectomised control animals these levels did not differ significantly from 
those of the intact control group, and were lower than those of intact rats given 
perphenazine. 
When the correlations between parameters within each group were studied, 
there was no apparent relationship between plasma hormone levels, tumour 
growth rate and the metabolism of testosterone by tumours. A stimulatory 
effect of perphenazine has not been observed in vitro. 
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Legend for Tables 18 - 22 
"Days since DMBA" refers to the length of time from the administration of 
carcinogen to the allocation to a treatment group. 
"Initial" refers to values obtained immediately prior to the start of treatment, 
and "final" to those obtained at the end of treatment. 
5o( -red'n = 5x-DHT + 5o(- Adiol. 
unacc. metab. (unaccounted -for metabolism) = total metab. - 5o(- red'n. 
n.d. = not determined 
Details of the treatment regimes are given in Table 10. 
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Table 18 
Hormone levels and tumour parameters 















311E 118 13 21 7 1.06 LAx 
319E 113 12 11 52 0.42 RGr 
332E 110 15 13 13 0.39 RAx 
RIn 
381E 50 9 75 46 0.25 LAx 
7H 60 11 78 45 0.76 RNk 
LAx 
35H 84 15 7 15 0.34 RAx 
301K 95 17 34 48 0.36 RGr 
401K 43 12 12 22 1.92 RAx 
323L 126 16 8 5 0.58 LAx 
343L 100 14 21 5 0.81 LNk 
LGr 
385L 82 12 52 23 0.58 RTh 
mean 89.5 13.3 30.2 25.5 0.68 
s.d. 28.2 2.4 26.4 18.6 0.47 













311E LAx 2.60 3.00 0.57 0.16 2.65 
319E RGr 3.30 3.99 0.69 0.37 n.d. 
332E RAx 2.55 5.75 0.89 1.60 10.65 
RIn 1.40 4.37 0.67 1.36 7.18 
381E LAx 2.80 3.60 1.29 0.70 9.18 
71-1 RNk 0.90 1.30 0.41 0.25 n.d. 
LAx 1.50 1.40 0.81 -0.06 n.d. 
35H RAx 2.55 3.06 0.35 0.37 2.07 
301K RGr 4.50 6.51 2.08 0.87 8.66 
401K RAx 1.82 3.40 0.81 0.92 6.45 
323L LAx 4.10 4.83 1.16 0.42 11.70 
343L LNk 2.76 3.94 0.84 0.63 9.76 
LGr 5.25 6.96 1.06 0.93 16.81 
385L RTh 2.92 4.56 0.80 0.96 11.85 
mean 2.78 4.05 0.89 0.68 8.81 
s.d. 1.22 1.66 0.43 0.46 4.21 
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Testosterone metabolism (%) 
5 t -DHT 5 ac -Adiol 5 a -red'n 
5o( -Adiol 
% unacc. 
metab. 5 o( -red'n 
311E LAx 50.24 8.22 39.82 48.04 0.83 2.20 
319E R Gr 63.98 7.49 42.09 49.58 0.85 14.40 
332E RAx 60.68 3.17 34.63 37.80 0.92 22.88 
RIn 61.30 7.53 34.19 41.72 0.82 19.58 
381E LAx 52.25 10.56 26.39 36.95 0.71 15.30 
7H RNk 62.13 7.39 38.09 45.48 0.83 16.65 
LAx 50.76 4.88 30.96 35.84 0.86 14.92 
35H RAx 35.60 7.59 13.52 21.11 0.64 14.49 
3011K RGr 66.88 11.18 37.11 48.29 0.77 18.59 
4011K RAx 47.75 2.78 15.74 18.52 0.85 29.23 
323L LAx 49.64 4.23 32.15 36.38 0.88 13.26 
343L LN k 49.93 5.18 37.82 43.00 0.88 6.93 
LGr 39.73 4.60 22.57 27.17 0.83 12.56 
385L RTh 61.47 4.43 44.14 48.57 0.91 12.90 
mean 53.74 6.37 32.09 38.46 0.83 15.28 
s. d. 9.56 2.59 9.39 10.13 0.08 6.46 
Table 19 
Hormone levels and tumour parameters 















309E 116 14 23 87 0.10 RNk 
LIn 
318E 111 14 63 90 0.61 RAx 
333E 109 14 46 67 0.24 RNk 
343E 158 17 44 19 0.92 RIn 
357E 84 14 13 72 0.27 LAx 
23H 87 16 56 81 0.12 RAx 
60H 145 15 10 84 0.23 LGr 
65H 116 16 5 100 0.56 LNk 
87H 137 14 40 67 0.28 RGr 
mean 118.1 14.9 33.3 74.1 0.37 
s.d. 24.9 1.2 21.2 23.4 0.27 
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309E RNk 3.22 8.28 1.39 1.30 7.48 
LIn 1.12 4.25 0.83 1.47 2.89 
318E RAx 1.65 4.80 0.39 2.24 8.29 
333E RNk 1.44 4.32 0.47 1.77 8.66 
343E RIn 1.87 5.52 0.38 1.68 7.45 
357E LAx 2.55 6.67 0.86 1.98 7.36 
23H RAx 2.24 2.85 0.65 0.21 n.d. 
60H LGr 1.92 4.00 0.46 0.88 6.61 
65H LNk 2.34 4.94 0.97 1.12 12.10 
87H RGr 2.21 4.40 0.61 1.23 11.00 
mean 2.06 5.00 0.70 1.39 7.98 
s. d. 0.60 1.52 0.32 0.58 2.63 
R-q3 






Testosterone metabolism ( %) 
5 oc -DHT 5 a -Adiol 5 a- red'n 
5 a -Adiol 
% unacc. 
metab. 5a -red'n 
309E RNk 82.22 32.75 49.18 81.93 0.60 0.29 
LIn 87.04 23.92 57.44 81.36 0.70 5.68 
318E RA x 48.02 4.27 37.39 41.66 0.90 6.36 
333E RNk 53.01 5.53 34.27 39.80 0.86 13.21 
343E RIn 71.26 10.30 53.80 64.10 0.84 7.16 
357E LA x 58.28 4.09 33.10 37.19 0.89 21.09 
23H RAx 70.83 13.02 57.08 70.28 0.81 0.55 
60H LGr 68.93 28.23 40.30 68.53 0.59 0.40 
65H LNk 66.21 20.29 43.79 64.08 0.68 2.13 
871-I RGr 70.69 30.25 40.23 70.48 0.57 0.21 
mean 67.65 17.27 44.66 61.94 0.74 5.71 
s.d. 12.07 11.19 9.16 16.62 0.13 6.58 
R--q4 
Table 20 
Hormone levels and tumour parameters 















341L 95 13 71 4 1.60 LTh 
34.5L 96 12 79 5 2.02 LAx 
LIn 
351L 95 13 13 6 0.97 LTh 
354L 130 12 14 3 1.08 LCh 
RIn 
361L 97 14 38 6 1.24 LTh 
LAn 
366L 72 12 5 9 0.60 RGr 
384L 93 12 41 5 0.69 RAx 
RIn 
mean 96.9 12.6 37.3 5.4 1.17 
s.d. 17.0 0.8 29.1 1.9 0.50 
R -95 













341L LTh 5.00 3.00 1.46 -1.08 15.84 
345L LAx 2.55 1.65 0.51 -1.97 14.41 
LIn 10.00 11.70 2.77 +0.99 9.71 
351L LTh 7.80 6.67 2.42 -0.61 12.73 
354L L Ch 5.25 7.13 2.50 +1.10 9.08 
RIn 3.52 2.04 0.62 -0.86 n.d. 
361L LTh 5.72 4.00 1.12 -0.86 11.42 
LAn 4.56 2.88 0.70 -0.84 10.37 
366L RGr 8.20 9.24 3.14 +0.58 8.36 
384L RAx 4.20 6.35 1.81 +1.60 11.87 
RIn 3.96 2.56 1.61 -0.84 n.d. 
mean 5.52 5.20 1.70 -0.25 11.54 
s.d. 2.25 3.27 0.92 1.13 2.49 
(, -9G 






Testosterone metabolism ( %) 
50c -DHT 5o( -Adio1 50t -red'n 
5 a -Adiol 
% unacc. 
metab. 5o( -red'n 
341L LTh 50.08 3.98 27.36 31.34 0.87 18.74 
345L LAx 55.55 3.71 33.04 36.75 0.90 18.70 
LIn 61.97 8.94 39.51 48.45 0.82 13.52 
351L LTh 63.15 5.27 49.00 54.27 0.90 8.88 
354L L Ch 56.76 13.29 35.61 48.90 0.73 7.87 
RIn 56.27 5.60 41.09 46.69 0.88 9.58 
361L LTh 47.91 4.92 35.00 39.92 0.88 7.99 
LAn 52.35 14.11 32.36 46.47 0.70 5.88 
366L RGr 56.82 17.90 37.41 55.31 0.67 1.51 
384L RAx 55.53 4.00 37.05 41.05 0.90 14.48 
RIn 60.47 4.59 42.79 47.38 0.90 13.09 
mean 56.07 7.85 37.29 45.14 0.83 10.93 
s.d. 4.50 4.99 5.80 7.25 0.09 5.32 
Table 21 
Hormone levels and tumour parameters 















306K 89 14 28 2 0.33 LNk 
313K 90 11 34 4 0.26 LAn 
330K 106 14 52 12 0.10 RTh 
407K 142 7 10 7 0.15 LAx 
26L 113 8 8 4 0.07 RNk 
29L. 113 8 4 4 0.05 LNk 
31L 108 S 11 8 0.12 LAx 
48L 110 8 116 11 0.08 LIn 
65L 98 9 30 7 0.04 RTh 
85L 104 11 78 8 0.00 LSh 
mean 107.3 9.6 37.1 6.7 0.12 
s.d. 14.9 2.8 35.9 3.2 0.10 
R-98 













306K LNk 4.83 3.30 1.39 -0.77 11.75 
313K LAn 7.75 6.16 1.81 -1.01 5.08 
330K RTh 4.80 2.38 1.69 -1.21 14.00 
407K LAx 6.75 3.80 1.48 -2.95 12.54 
26L RNk 4.84 2.56 0.86 -2.00 4.86 
29L LNk 6.38 3.57 0.76 -2.46 9.83 
31L LAx 5.20 3.08 0.73 -2.47 13.73 
48L LIn 6.90 2.85 0.93 -3.54 7.36 
65L RTh 16.34 9.86 4.02 -5.04 7.01 
85L LSh 7.36 3.20 2.24 -2.65 9.22 
mean 7.12 4.08 1.59 -2.41 9.54 
s. d. 3.43 2.29 0.99 1.28 3.41 






Testosterone metabolism ( %) 
5 i& -DHT 5 a -Adiol 5 a -red'n 
5 a -Adiol 
% unacc. 
metab. 5oç -red'n 
306K LNk 41.40 1.57 13.57 15.14 0.90 26.26 
313K LA n 68.33 9.05 36.62 45.67 0.80 22.66 
330K RTh 69.07 4.72 42.26 46.98 0.90 22.09 
407K LAx 36.68 6.05 22.90 28.95 0.79 7.73 
26L RNk 43.93 3.98 28.47 32.45 0.88 11.48 
29L LN k 30.11 5.84 17.83 23.72 0.75 6.39 
31L LAx 42.83 2.57 28.91 31.48 0.92 11.35 
48L LIn 23.00 4.01 13.68 17.69 0.77 5.31 
65L RTh 23.07 4.17 12.31 16.48 0.75 6.59 
85L LSh 22.71 3.29 13.00 16.29 0.80 6.42 
mean 40.11 4.53 22.96 27.49 0.83 12.63 
s. d. 17.18 2.09 10.74 11.84 0.07 7.96 
R-oo 
Table 22 
Hormone levels and tumour parameters 















378E 69 14 46 92 0.22 RCh 
RAx 
380E 122 14 35 81 0.12 LGr 
397E 100 14 12 105 0.29 RCh 
RAx 
26H 98 14 17 44 0.06 RAx 
45H 71 14 88 102 0.09 RAx 
269K 97 14 55 128 0.15 LAx 
297K 96 14 8 63 0.53 RAx 
LAx 
mean 93.3 14 37.3 87.9 0.21 
s.d. 18.3 0 28.5 28.0 0.16 
R-toi 













378E R Ch 2.80 2.33 1.61 -1.04 7.91 
RAx 3.30 4.43 1.72 +0.50 4.21 
380E L Gr 3.00 2.66 0.58 -0.16 11.05 
397E R Ch 2.95 4.75 0.55 0.00 8.70 
RAx 1.57 1.72 1.16 -0.45 n.d. 
26H RAx 3.91 3.48 1.09 -0.55 10.55 
45H RAx 3.20 3.24 1.68 -0.50 10.77 
269K LAx 3.04 4.51 0.52 +0.83 6.32 
297K RAx 3.15 2.60 0.55 -1.07 5.64 
LAx 1.40 3.45 0.61 +0.84 7.79 
mean 2.83 3.32 1.01 -0.16 8.10 
s.d. 0.77 1.01 0.51 0.70 2.42 
R-O2 






Testosterone metabolism ( %) 
5a -DHT 5 oc-Adiol 5 of -red'n 
5a -Adiol 
% unacc. 
metab. 5a -red'n 
378E R Ch 77.73 8.83 54.74 63.57 0.86 14.16 
RAx 54.88 8.49 23.64 32.13 0.74 22.75 
380E LGr 62.32 10.94 48.74 59.68 0.82 2.64 
397E RCh 78.35 26.43 45.11 71.54 0.63 6.81 
RAx 65.10 15.13 38.55 53.68 0.72 11.42 
26H RAx 54.00 5.20 33.76 38.96 0.87 15.04 
45H RAx 28.34 2.08 10.84 12.92 0.84 15.42 
269K LAx 42.19 5.08 27.19 32.07 0.85 10.12 
297K RAx 62.49 5.54 32.76 38.30 0.86 24.19 
LAx 51.06 1.99 16.90 18.89 0.89 32.17 
mean 57.64 8.97 33.22 42.17 0.81 15.47 
s.d. 15.26 7.33 14.02 19.39 0.08 8.78 
R-iO3 
W. Testosterone metabolism by DMBA- induced mammary tumours 
at various stages of the oestrous cycle 
From the results described in the previous section it appeared that a 
change in hormonal status of approximately two weeks duration could result in 
an alteration of the capacity of DMBA- induced mammary tumours to metabolise 
testosterone in comparison with that of tumours taken from control rats in the 
dioestrus stage of the oestrous cycle. Since the secretion of pituitary and 
ovarian hormones undergoes cyclic changes it was decided to measure testosterone 
metabolism by tumours removed from untreated rats on different days of the 
oestrous cycle. 
1. Experimental design 
For this study actively growing tumours were taken from rats which had 
just shown at least three regular 4 -day cycles. Immediately prior to tumour 
excision, at between 1030 and 1200 hours, blood was removed from the tail vein 
for the assay of plasma prolactin and from the aorta for the assay of plasma 
oestradiol. Tumours were divided into portions for histological examination, 
measurement of DNA content and testosterone metabolism under the standard 
conditions described in the METHODS section. Animals were allocated for 
sacrifice on the different days of the cycle on the basis of tumour size, tumour 
growth and "days since DMBA" so that, as far as possible, the mean values of 
these parameters were similar in all four groups. 
The individual results from each group are given in Tables 24 - 27. An 
exceptionally high level of plasma oestradiol was found in one rat of the 
metoestrus group and two tumours, one from the oestrus group and one from the 
dioestrus group, showed extremely low formation of 5o¿- reduced products. These 
outlying values, along with that of testosterone metabolism in the first - 
mentioned tumour which was also exceptionally low, were not used for the 
R-10 4. 
intergroup comparisons by variance analysis (Table 23), or for the determination 
of the simple coefficient of correlation between parameters (Table 28). 
2. Plasma levels of oestradiol and prolactin 
At the particular time of sampling employed no significant differences in 
the mean plasma prolactin levels on the various days of the oestrous cycle were 
observed. In contrast the levels of oestradiol were significantly higher at 
proestrus than on all other days of the cycle and the oestradiol levels at 
dioestrus were significantly higher than at oestrus and metoestrus. 
3. Metabolism of testosterone by tumours 
Total testosterone metabolism, 5o(- dihydrotestosterone production, 
5 oC- androstanediol production and 5a-reduction in tumours taken at different 
stages of the cycle were compared by variance analysis (Table 23). There were 
no significant differences between the different groups with regard to any of the 
parameters. It can be seen from Figures 30 - 33 which show the outlying values 
omitted from the variance analysis that the inclusion of these figures would not 
have altered the outcome of the statistical analysis. 
Although a statistically significant difference between groups could not be 
detected it was noticeable that tumours removed at metoestrus tended to show 
high testosterone metabolism ( >50 %) and high 50!- reduction (>45%). In contrast 
five of the six tumours removed at proestrus had 5o(- reductase values of below 
45%. 
4. Correlations between parameters determined on an individual basis 
The numbers in each group were too small to justify separate group 
analysis so all data were pooled to determine the simple coefficients of 
correlation (r) between parameters as described in the previous section. Since 




Hormone levels and tumour parameters during the oestrous cycle - 
















Proestrus 139 37 4.41 ** 1.46 5.33 
Oestrus 126 40 0.24 1.12 5.06 
Metoestrus 126 45 0.29 1.20 5.12 
Dioestrus 120 32 0.91* 0.88 4.62 
within s.d. 25.8 18.6 0.42 0.62 2.58 
group d.f. 19 19 18 23 23 
Stage DNA Testosterone metabolism (%) 
of (pg /mg total 
5(x-Adiol 
cycle tissue) metab. 5 oc -DHT 5x-Adiol 5a -red'n 50(-red'n 
Proestrus 9.10 50.02 8.76 29.25 38.01 0.77 
Oestrus 10.48 56.39 7.24 40.96 48.20 0.84 
Metoestrus 11.47 65.16 12.90 44.38 57.27 0.78 
Dioestrus 8.91 52.20 7.35 39.93 47.27 0.85 
within 1 s.d. 2.72 14.26 5.27 11.95 15.25 0.08 
group j d.f. 22 22 21 21 21 23 
Intercomparisons of the mean values of all parameters were made using variance 
analysis plus the Student -Newman -Keuls test. 
* and ** = significantly different from values at other stages of the cycle (p< 0.05 
and p <0.01 respectively). 
R-ioG 
Figure 30. Testosterone metabolism by DMBA -induced mammary tumours 
removed at different stages of the oestrous cycle 









proestrus oestrus met oestrus 
Stage of cycle 
dio estrus 
Tumours were removed between 1030 and 1200 hours on the different days of 
the oestrous cycle and incubated as described in the METHODS section. 
Each point represents the value from an individual tumour. Horizontal bars 
indicate the means and s.e. means for each group. Statistical analyses are 
given in Table 23. 
R-1 0'7 
Figure 31. Testosterone metabolism by DMBA -induced mammary tumours 
removed at different stages of the oestrous cycle 
(b) Conversion to Sot -dihydrotestosterone 
30- 
Conversion 
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See legend of Figure 30 
Figure 32. Testosterone metabolism by DMBA- induced mammary tumours 
removed at different stages of the oestrous cycle 
(c) Conversion to 5oC- androstanediol 
Conversion 
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See legend of Figure 30 
N -109 
Figure 33. Testosterone metabolism by DMBA- induced mammary tumours 
removed at different stages of the oestrous cycle 
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See legend of Figure 30 
In this group of tumours there also appeared to be no significant correl- 
ation between the parameters of testosterone metabolism and "days since 
D MBA", tumour size, tumour growth and tumour DNA content (Table 28). 
Plasma levels of prolactin and oestradiol showed a significant negative 
correlation with 5d.- androstanediol production and the closely related 5a -red- 
uction, although the relationship with prolactin just achieved significance at the 
5% level. 
As noted in the previous section there was a strong positive correlation 
between total testosterone metabolism, 5o4- reduction and 5x- dihydrotesto- 
sterone production. In this series of tumours 5cx- dihydrotestosterone production 
showed a positive correlation with testosterone metabolism, 5 a- androstanediol 
production and therefore 5 v- reduction. 
5. Summary 
When inter -group comparisons of the various parameters were made, only 
the expected differences in plasma levels of oestradiol were significant. 
Although the capacity of tumours to metabolise testosterone by 5oc- reduction 
was not significantly different between the four stages of the cycle, the 
numerical differences between the metoestrus and proestrus stages may have 
attained significance with a greater number of observations. 
R- iIi 
Table 24 





















6M 137 49 4.25 RGr 0.75 4.16 
9M 116 38 4.86 LCh 2.44 11.20 
13M 181 43 3.39 RGr 3.00 6.00 
33M 172 37 5.36 RIn 0.68 3.60 
LNk 0.52 2.04 
153M 88 17 4.19 RIn 1.38 4.96 
mean 139 37 4.41 1.46 5.33 









Testosterone metabolism ( %) 
5c& -DHT 5o4-Adiol 50t -red'n 
5ot -Adiol 
5o4-red'n 
6M RGr 2.41 57.28 13.17 23.40 36.57 0.64 
9M LCh 7.33 42.36 11.83 29.57 41.40 0.71 
13M RGr 6.91 42.27 12.24 23.78 36.02 0.66 
33M RIn 11.72 44.33 3.28 22.88 26.16 0.87 
LNk 12.64 48.99 3.48 26.65 30.13 0.88 
153M RIn 13.63 64.86 8.58 49.22 57.80 0.85 
mean 9.10 50.02 8.76 29.25 38.01 0.77 
s.d. 4.30 9.22 4.45 10.10 11.06 0.11 
R- 11 
Table 25 





















390L 160 52 0.51 LAx 1.03 6.72 
10M 130 25 0.27 RAx 1.13 2.52 
19M 134 48 0.00 RAx 1.45 6.51 
23M 107 70 0.34 LAx 1.28 5.25 
115M 112 14 0.11 RTh 1.21 3.42 
RAn 1.19 6.50 
132M 114 33 0.18 LIn 0.57 4.50 
mean 126 40 0.24 1.12 5.06 









Testosterone metabolism ( %) 
501.-DHT 50( -Adiol 5 q -red'n 
5 «(-Adiol 
5c-red'n 
390L LAx 7.29 16.26* 1.27* 3.50* 4.77* 0.73 
10M RAx 8.47 60.66 8.97 43.13 52.10 0.83 
19M RAx 10.70 38.90 3.31 23.51 26.82 0.88 
23M LAx 10.44 39.13 2.80 26.25 29.05 0.90 
115M RTh 12.73 78.38 12.80 62.77 75.57 0,83 
RAn 12.55 59.54 12.09 41.53 53.62 0.77 
132M LIn 11.20 61.71 3.45 48.59 52.04 0.93 
mean 10.48 50.65 6.39 35.61 42.00 0.84 
s.d. 2.01 20.51 4.79 19.42 23.27 0.07 
Table 26 





















391L 146 22 0.28 RIn 0.68 4.14 
27M 116 38 0.25 RAn 2.19 6.44 
LGr 0.63 4.37 
31M 120 45 0.18 LAx 1.70 3.84 
139M 135 44 4.35* LTh 1.28 6.12 
151M 144 38 0.43 LNk 1.10 5.70 
164M 95 85 0.33 RCh 0.80 5.25 
mean 126 45 0.97 1.20 5.12 









Testosterone metabolism ( %) 
5a-DHT 5o( -Adiol 5o( -red'n 
5a -Adiol 
5ot -red'n 
391L RIn 8.05 68.55 11.80 46.55 58.35 0.80 
27M RAn 12.39 68.11 13.18 50.65 63.83 0.79 
LGr 10.90 88.49 27.53 51.71 79.24 0.65 
31M LAx 9.02 61.28 11.14 44.39 55.53 0.80 
139M LTh 11.40 53.71 10.13 36.60 46.73 0.73 
151M LNk 15.16 56.69 11.73 36.38 48.11 0.76 
164M RCh 13.34 59.31 4.76 44.36 49.12 0.90 
mean 11.47 65.16 12.90 44.38 57.27 0.78 
s.d. 2.45 11.67 7.00 6.09 11.48 0.07 
Table 27 





















317E 96 67 1.26 RNk 1.16 3.15 
5H 107 36 0.67 LCh 0.56 4.20 
14M 118 21 0.96 LAx 1.43 12.80 
45M 100 28 0.52 RIn 0.84 2.40 
113M 155 18 0.54 LGr 0.77 3.96 
127M 141 21 1.50 RNk 1.16 3.15 
RAx 0.21 2.70 
mean 120 32 0.91 0.88 4.62 









Testosterone metabolism ( %) 
5a -DHT 5&. -Adiol 50c -red'n 
5K-Adiol 
5d -red'n 
317E RNk n.d. 39.97 3.90 28.27 32.17 0 .88 
5H LCh 7.75 31.26 0.81* 4.06* 4.87* 0.83 
14M LAx 7.03 58.00 8.36 35.93 44.29 0.81 
45M RIn 8.49 60.67 6.58 46.36 52.94 0.88 
113M LGr 10.61 85.33 15.04 66.66 81.70 0.82 
127M RNk 9.40 35.20 4.97 22.65 27.62 0.82 
RAx 10.16 54.96 5.23 39.69 44.92 0.88 
mean 8.91 52.20 6.41 34.80 41.22 0.85 
s. d. 1.40 18.65 4.46 19.62 23.76 0.03 
Legend for Tables 24 - 27 
"Days since DMBA" refers to the length of time from the administration 
of the carcinogen to the allocation to a treatment group. 
5d -red'n = 5c4-DHT + 5x -Adiol 







= values not listed for variance analysis or the determination 
of the simple coefficient of correlation. 





6 = tumour DNA content 










5g -Adiol production 
5u- reduction 
Table 28 
Correlations between parameters measured in untreated rats 
throughout the oestrous cycle 
Parameter 2 3 4 5 6 7 8 9 10 11 
1 -.19 .40* .01 -.16 -.14 -.19 .00 -.35 -.27 -.25 
2 -.01 .10 .01 -.04 -.39 -.26 -.41* -.41* .09 
3 .11 .03 -.22 -.37 -.16 -.50* -.45* -.18 
4 .54 -.19 -.29 -.15 -.20 -.11 -.41* 
5 -.15 -.14 .14 -.14 -.07 -.31 
6 .20 -.10 .35 .24 .41* 
7 .70 ** .90 ** .96 ** -.19 
8 .47* .72 ** -.78 ** 
9 .95 ** .09 
10 -.20 
Data from the four stages of the oestrous cycle were pooled to calculate 
the simple coefficient of correlation (r) for the corresponding parameters listed 
vertically and horizontally. 
* =p {0.05, * *= p <O.01,d.f. =23 
V. Conversion of testosterone to androst- 4- ene -U, 178-diol 
by DMBA - induced rat mammary tumours 
In addition to testosterone, 5a- dihydrotestosterone and 5a- androstanediol 
(3a), authentic androst- 4- ene -30(, 17(3-diol was also added as a non - 
radioactively labelled carrier (500pg) to the last 12 incubates worked up for the 
measurement of testosterone metabolism by rat mammary tumours removed at 
different stages of the oestrous cycle (Section IV). 
The initial separation of steroids extracted from these incubates was 
performed in solvent system Ib in preference to Ia to achieve a greater 
separation of androst- 4- ene -3a, 17(3 -diol from the 5a- androstanediol band. 
The band containing androst- 4- ene -3 17 -diol, visualised under u.v. light, was 
scraped from the plate and the eluate incubated with manganese dioxide, a 
material reported to preferentially oxidise allylic alcohols (see METHODS). The 
products of this reaction were run in solvent system III and the two bands 
corresponding to testosterone and 4- androstenedione (identified under u.v. light 
by characteristic colour and mobilities identical to those of the authentic 
steroids) were removed for measurement of specific activity. The testosterone 
derivative accounted for approximately half of the carrier added and 
4- androstenedione derivative for about an eighth. When these plates were 
scanned it was observed that in addition to radioactive peaks running with 
testosterone and 4- androstenedione a peak ran with the same mobility as 
authentic androst- 4- ene -3o(, 17/3 -diol, indicating that the reaction with mang- 
anese dioxide was incomplete. 
The specific activity of the testosterone derivative, designated 
"testosterone 1" in Table 29, was consistently higher than that of the 
4- androstenedione derivative. Therefore, the acetate was prepared from 
testosterone and run in the standard manner. The specific activity of 
testosterone acetate was lower than that of testosterone 1 and similar to that of 
Table 29 
Evidence for the identification of androst- 4- ene -3á, 17ß -diol 

















33M LNk 1,997 2,171 2,002 2,084 2,028 7.25 
33M RIn 1,853 2,087 1,970 2,025 1,949 6.76 
113M LGr 351 694 325 324 333 1.09 
115M RTh 449 464 422 437 436 1.45 
115M RAn 487 507 465 472 475 1.61 
127M RNk 975 1,045 1,033 1,080 1,029 3.24 
127M RAx 1,241 1,345 1,289 1,273 1,268 4.05 
132M LIn 1,315 1,340 1,296 1,302 1,304 4.26 
139M LTh 616 688 626 611 618 1.93 
151M LNk 680 734 651 666 666 2.19 
153M RIn 665 704 617 678 653 2.18 
164M RCh 874 1,024 902 917 898 3.10 
After the initial separation of precursor and metabolites in solvent system 
Ib, androst- 4- ene -3o(, 17ß -diol was oxidised with manganese dioxide to yield 
4- androstenedione and testosterone 1 which were separated in solvent system III. 
Testosterone 1 was converted to testosterone acetate which was then hydrolysed 
to yield testosterone 2. Testosterone 1 was judged impure and not used for 
calculation of the percentage conversion. 
the 4- androstenedione derivative. Hydrolysis of testosterone acetate back to 
testosterone (testosterone 2) did not alter the specific activity. Since the 
specific activities of the 4- androstenedione, testosterone acetate and testo- 
sterone derivatives appeared to be constant these were averaged to calculate the 
percentage formation of androst- 4- ene -3o1., 17(3 -diol. It was assumed from the 
higher specific activity of testosterone 1 that impurities were present, possibly 
products of the oxidation of contaminant 5K- androstanediol by manganese 
dioxide. 
It was of interest to compare the conversion of testosterone to androst- 
4-ene-3d, 17 (3 -diol with the formation of other products and with the total 
metabolism of testosterone. In Table 30 tumours are listed in descending order 
of their ability to convert testosterone to androst- 4- ene -3a, 17(3 -diol. It can 
be seen that pairs of tumours from individual rats converted testosterone to 
androst- 4- ene -3tx, 17/S -diol to a similar extent. The levels of 5a- dihydrotesto- 
sterone but not those of 5 oç- androstanediol recovered were also similar in the 
same pairs of incubates. 
The quantities of androst- 4- ene -3o1, 170-diol produced by these tumours 
were remarkably high, in some cases higher than the net production of 
5o(- dihydrotestosterone. The higher production of androst- 4- ene -3o1, 170-diol 
appears to have occurred in tumours in which larger quantities of total 
testosterone metabolism were unaccounted for by 5u-reduction. 
Before its identification there was an impression gained that the radio- 
active peak now attributed to androst- 4- ene -3K, 170-diol was greater when 
those of the 5á- reduced metabolites were smaller than usual. The results from 
these 12 tumours would seem to support this notion, with the greatest 
5o(- reduction occurring in the tumours with the lowest formation of androst- 
4- ene -3of, 17(3 -diol. 
By the simple coefficient of correlation test the formation of androst- 
4 -ene -3 oç, 17(3 -diol showed a significant positive correlation with testosterone 
Table 30 
Metabolism of testosterone to androst-4-ene-3 o(, 17(3 -diol 
by DMBA- induced rat mammary tumours 
Rat and total 
tumour metab. 
Testosterone metabolism % 
5o( -DHT 50( -Adiol 5a -red'n 
Total - 
5a -red'n 44diol(3o&) 
33M LNk 46.99 3.48 26.65 30.13 16.86 7.25 
33M RIn 44.33 3.28 22.88 26.16 18.17 6.76 
132M LIn 61.71 3.45 48.59 52.04 9.67 4.26 
127M RAx 54.96 5.23 39.69 44.92 10.04 4.05 
127M RNk 35.20 4.97 22.65 27.62 7.58 3.24 
164M RCh 59.31 4.76 44 . 36 49.12 10.19 3.10 
151M LNk 56.69 11.73 36.38 48.11 8.58 2.19 
153M RIn 64.86 8.58 49.22 57.80 7.06 2.18 
139M LTh 53.71 10.13 36.60 46.73 6.98 1.93 
115M RAn 59.54 12.09 41.53 53.62 5.92 1.61 
115M RTh 78.38 12.80 62.77 75.57 2.81 1.45 
113M LGr 85.33 15.04 66.66 81.70 3.63 1.09 
All of these tumours comprised part of the study in Section IV and 
are listed above in descending order of their ability to form androst- 4- ene -3o, 
17ß -diol (a4diol (300). Total - 5o( -red'n = the metabolism of testosterone 
not accounted for by the formation of 5o( -DHT and 5a Adiol. 
R-iZ1 
metabolism unaccounted -for by 5oc- reduction and a significant negative correl- 
ation with 5o(- reduction itself (p< 0.05). 
VI. The effect of 5K-reduced metabolites on the growth 
of DMBA- induced rat mammary tumours 
Since 5o(-reduced metabolites appear to be responsible for mediating the 
effects of testosterone in many androgen responsive tissues, information on the 
effect of these steroids on mammary tumour growth might help in the under- 
standing of the significance of the metabolism of testosterone by tumours. 
Although the effects of testosterone propionate and 5X- androstane - 30(,17(3 -diol 
dipropionate on the growth of DMBA- induced mammary tumours have been 
studied, the effects of synthetic C -19 steroids have received more attention 
(Griswold, Skipper, Laster, Wilcox & Schabel, 1966; Heise & Gorlich, 1966; 
Teller, Stock, Stohr, Merker, Kaufman, Escher & Bowie, 1966). No study has 
reported the effect of different 5o(- reduced steroids on DMBA- induced rat 
mammary tumours. It was therefore decided to complement the steroid 
metabolism work with a study of the effects of 5o(- reduced metabolites of 
testosterone on tumour growth. 
The effects of the 5 ot- reduced products on the oestrous cycle and on 
plasma prolactin levels were also monitored. A recovery period was incorp- 
orated into the experimental design to examine the reversibility of any changes 
occurring during the treatment period. This meant that the effects of 
treatment on plasma oestradiol levels (which requires the collection of relatively 
large volumes of blood, obtainable only at sacrifice) could not be measured. 
1. Experimental design 
(1) Tumours were induced as described in the METHODS section. 
(2) Rats bearing at least one actively growing tumour and exhibiting a 
regular cyclic pattern of vaginal smears were studied. Blood was 
withdrawn from the tail vein on the morning of dioestrus, and the 
animals were randomly allocated to one of 4 treatment groups (10 
animals per group). 
R- i24 
(3) The rats, 180 - 270g body weight, received 6 daily s.c. injections/ 
week of either vehicle, 5o(- dihydrotestosterone, 5o(- androstane -3ot, 
17/3 -diol or 5 %- androstane -3p,17(á -diol. The steroids were dis- 
solved or suspended in corn oil containing 10% ethanol at a concen- 
tration of 5mg /ml and 0.2ml (= lmg steroid), given as the daily 
injection. 
(4) On the presentation of a dioestrus -type smear close to the 12th day 
after the commencement of treatment, treatment was stopped and a 
second sample of blood taken from the tail vein (i.e. 24 hours after 
the last injection of steroid or vehicle). 
(5) No further treatment was given for approximately 12 days when 
another blood sample was taken from the tail vein on the morning of 
dioestrus. Tumours were excised, gross appearance noted and sect- 
ions taken for histology. 
Throughout the pretreatment (stage 1), treatment (stage 2) and recovery 
(stage 3) periods the oestrous cycle was assessed from daily vaginal smears and 
tumour measurements made 2 or 3 times per week. Blood samples were taken 
under ether anaesthesia between 1030 and 1200 hours and used for the measure- 
ment of plasma prolactin as described in the METHODS section. Tumours were 
discarded from the study if, after excision, they were not classified as 
adenocarcinoma or if necrotic tissue or pockets of fluid were found to contribute 
to the measurements of tumour size. 
The lengths of treatment and recovery periods varied slightly, due mostly 
to the stipulation that these should end on a day when a positive dioestrus -type 
vaginal smear was observed. However, despite individual variation the average 
lengths of these periods were similar in all groups. 
The results of this study are presented in Tables 31 - 35 and in Figs. 34 -39. 
Table 31 contains a summary of the individual results in Tables 32 - 35. Changes 
in tumour sizes in the different groups are diagrammatically represented by the 
R-1)-5 
histograms in Figs. 34 - 35. Growth patterns of the tumours on individual 
representatives of each group are shown in Figs. 36 - 39. 
2. Effect of androgens on the oestrous cycle 
Immediately prior to allocation to a treatment group all animals exhibited 
regular patterns of vaginal smears. In the majority of cases the cycle lasted 4 
days and, in others, 5 days. 
In the control group, given vehicle only, 9 of the 10 rats continued to 
exhibit a cyclic pattern of vaginal smears throughout the treatment and recovery 
periods. The remaining rat showed a constant oestrus pattern of cornified cells 
in the vaginal smears for the latter half of the treatment period and throughout 
the recovery period. 
Of the 10 rats which were given 50l- dihydrotestosterone, 6 presented a 
constant dioestrus pattern (many leukocytes present in vaginal smears) through- 
out the entire treatment period, 3 appeared to undergo one cycle before 
displaying constant dioestrus smears and the remaining rat cycled apparently 
normally throughout both the treatment and recovery periods. All of the 9 
animals in this group which exhibited constant dioestrus patterns by the end of 
the treatment period remained in this state for 5 to 7 days into the recovery 
period after which the normal cyclic pattern was resumed. 
Treatment with 5o(- androstane -307(3 -diol provided an essentially similar 
picture. Of the 10 animals in this group 6 displayed a constant dioestrus pattern 
throughout the treatment period and the remaining 4 appeared to undergo one 
cycle before the smear pattern was arrested in dioestrus. The pattern of 
constant dioestrus in the 50(- androstane -30k,17(3 -diol- treated group persisted for 
2 to 9 days into the recovery period. The constant dioestrus pattern was 
replaced in 9 rats by a normal cyclic pattern and in one rat by a pattern of 
constant oestrus. 
In contrast to 50i- dihydrotestosterone and 50- androstane -3o(,174-diol, 50(- 
androstane -3í3,17f3 -diol did not induce a constant dioestrus pattern of vaginal 
R -2. 
Table 31 


















Control 1 20.3 normal 1.75 16 7 0 16 0 0 
(N = 10 2 19.5 normal 1.84 14 8 6b 8 5 3b 
n = 29) 3 19.3 normal 2.27 15 7 7 8 4 4 
5d-DHT 1 24.8 normal 1.78 22 10 2 22 0 0 
(N = 10 2 20.1 persistent D 1.11 2 2 30c 2 2 18c 
n= 34) 3 36.0 normal 1.45 12 8 10 8 7 7 
5d Adiol(3o() 1 26.1 normal 2.04 22 8 0 22 0 0 
(N = 10 2 35.9 persistent D 1.19 1 7 22c 1 3 19c 
n = 30) 3 60.5a normal 1.27 7 8 14 6 6 10 
5d- Adiol(3(3) 1 51.1a normal 2.21 16 6 0 16 0 0 
(N = 10 2 29.5 normal 2.28 12 4 8b 9 3 4b 
n = 26) 3 26.4 normal 2.70 13 4 8 8 3 4 




significantly different from the corresponding values of the control group 
and from the values of the other stages within the relevant group (p< 0.05 
by variance analysis + Dunnett's test) 
significantly different from the respective pretreatment distributions 
(p <0.05 by Fisher's exact test) 
significantly different from respective pretreatment distributions and the 
control treatment distributions (p <0.001), and from the respective recov- 
ery distributions (p <,0.05 by Fisher's exact test) 















1 2 3 
Tumour 
size (cm2) 
Site + growth 
1 2 3 
132L 11 11 cyclic cyclic 13 20 19 RNk 0.64G 0.80G 1.00G 
RAx 1.265 1.08R 0.88R 
RIn 1.56S 1.44S 0.80R 
RGr 2.21G 2.36S 1.82R 
144L 11 14 cyclic cyclic 20 13 30 RAx 3.96G 4.50G 7.82G 
154L 11 11 cyclic cyclic 26 15 13 RNk 0.36G 1.20G 2.1OG 
RIn 2.70G 2.865 3.04S 
168L 16 5 cyclic cyclic 31 22 13 LCh 1.08S 0.995 0.99S 
RAx1 0.80S 0.36R 0.36S 
RAx2 3.80G 4.75G 4.75S 
RAx3 2.88G 2.08R 1.82R 
LGr - - 2.34G 2.52G 
169L 13 8 cyclic cyclic 14 8 16 LNk1 1.40S 1.68G 1.82G 
LNk2 0.60G 0.60S 0.64S 
RCh 2.345 1.92R 1.76R 
RAn - - 0.48G 0.99G 
R- 12.8 
Stage: 
















1 2 3 
185L 15 22 cyclic cyclic 16 22 43 RNk 2.70G 2.86S 1.30R 
LAx - - - - 1.20G 
LGr - - 1.82G 5.72G 
LAn 0.80G 0.88S 0.81S 
271L 13 22 cyclic cyclic 9 14 13 LNk1 1.92G 2.70G 3.78G 
LNk2 1.08G 0.80R 1.08G 
RNk 0.48S 0.48S 1.08G 
290L 13 22 1 cycle and 
stuck in 0 
stuck in 0 16 27 24 LAx 1.80G 1.20R 0.72R 
298L 13 12 cyclic cyclic 50 39 15 RNk1 0.25G 1.30G 3.00G 
RNk2 - - 0.80G 0.80S 
RAx 2.16G 2.52G 2.89G 
300L 16 12 cyclic cyclic 8 15 7 LNk - - 1.95G 3.15G 
RNk 3.52G 5.20G 7.25G 
Stage: 






Rat (days) (ng /ml) + growth 
2 3 1 2 3 1 2 3 
mean 13.2 13.9 20.3 19.5 19.3 1.75 1.84 2.27 
n 10 10 10 10 10 23 28 29 
mean of initial tumours (n = 23) 

















static (S) 7 8 7 
partially 6 7 
regressed (R) 0 6 7 




The effect of androgens on tumour growth - 
















1 2 3 
43L 12 10 stuck in D cyclic 11 6 5 RNk 0.48S - R - - 
by day 5 LAn 3.20G 1.08R 1.1OS 
RAn 0.80S 0.36R - R 
69L 12 16 1 cycle and cyclic 18 29 95 LNk 0.90R - R - 
stuck in D by day 5 RNk 2.24G 1.30R 0.77R 
LLAxl 0.365 - R - - 
LAx2 3.06G 1.20R 1.08S 
RAx 1.43R 0.40R 0.80G 
105L 13 8 stuck in D cyclic 
by day 4 
12 6 18 LGr 4.83G 6.44G 8.12G 
116L 12 14 stuck in D cyclic 52 22 17 RNk 1.82G 0.72R 0.63S 
by day 7 LAxl 1.1OG 0.48R 0.25R 
LAx2 0.64S 0.48R - R 
RIn 1.10G 0.80R - R 
RGr 0.36S - R - - 
203L 12 15 1 cycle and cyclic 30 31 33 LNk1 1.65G 1.10R 0.48R 
stuck in D by day 6 LNk2 0.64G 0.25R - R 
LAx 3.80G 1.30R 0.48R 
RIn 3.60G 3.00R 4.68G 
R-131 
Stage: 











1 2 3 
Tumour 
size (cm2) 
Site + growth 
1 2 3 
209L 13 21 stuck in D cyclic 16 19 36 RNkl 1.20G 0.88R 0.90S 
by day 5 RNk2 0.96G 0.96S 1.30G 
LCh 1.40G 0.72R 1.40G 
RAx 2.08S 0.63S 0.99G 
217L 13 21 stuck in D cyclic 50 41 58 RNkl 1.30S 0.80R 1.82G 
by day 6 RNk2 0.96G 0.25R 0.25S 
RGr 2.52G 1.04R 2.10G 
219L 13 14 cyclic cyclic 5 11 26 RNk 0.25G - R 1.82G 
LCh 0.64G 0.725 0.72S 







LAn 1.685 1.08R 0.90R 
233L 11 19 stuck in D cyclic 
by day 6 
29 24 15 RAx 2.55G 0.96R 0.72R 
234L 14 10 1 cycle and cyclic 25 12 57 RNk 2.88S 1.20R 1.30S 
stuck in D by day 7 LAx 2.25G 1.17R 1.17S 
fL- 13 2 
Stage: 






Rat (days) (ng /ml) + growth 
2 3 1 2 3 1 2 3 
mean 12.5 14.8 24.8 20.1 36.0 1.78 1.11 1.45 
n 10 10 10 10 10 34 28 26 
mean of initial tumours (n = 34) 










grown (G) 22 2 12 
new 0 2 
static (S) 10 2 8 
partially 24 6 
regressed (R) 2 30 10 




The effect of androgens on tumour growth - 
















1 2 3 
70L 12 19 1 cycle and cyclic 14 21 99 LAxl 0.90S 0.90S 1.00S 
stuck in D by day 9 LAx2 2.80G 1.80R 2.70G 
LAx3 0.56G 0.48S 0.48S 
RIn 0.80S - R - - 
LAn 2.38G 1.54R - R 
RAn 2.85G 1.54R 0.88R 
112L 13 11 1 cycle and cyclic 21 80 108 RNk 1.30G 0.48R 0.25R 
stuck in D by day 9 LCh 4.18S 2.04R 0.96R 
LAxl 1.30S 0.80R - R 
LAx2 0.36S 0.36S 0.25R 
RAx1 1.40G 0.72R - R 
RAx2 1.005 0.36R - R 
RGr 3.96G 1.50R 0.72R 
113L 13 10 stuck in D cyclic 7 34 39 LAx 2.70S 2.52S 3.06G 
by day 3 RAxl 1.40G 1.30S 0.80R 
RAx2 5.72G 2.24R 1.80R 
LIn 2.52G 2.70S 2.24R 
164L 13 16 stuck in D cyclic 37 68 25 RTh 2.56G 0.64R 1.50G 
by day 6 LIn 1.20G 0.36R 0.80G 
RIn 1.96G 0.25R 0.25S 
R-134 
Stage: 





208L 14 11 
246L 14 11 
247L 11 12 
254L 14 23 
276L 14 14 




1 cycle and cyclic 
stuck in D by day 2 
1 cycle and cyclic 
stuck in D by day 8 
stuck in D cyclic 
by day 6 
1 cycle stuck in 0 
stuck in D from day 7 
stuck in D cyclic 
by day 5 
stuck in D cyclic 









1 2 3 
8 15 16 LTh 1.43G 0.99R 0.885 
17 67 128 RNkl 2.08G 2.40G 2.70G 
RCh 2.24G 1.30R 1.30S 
RTh 1.68G 0.72R 0.36R 
78 31 70 RThl 3.52G 2.40R 2.28S 
43 18 90 RCh 1.17G 0.25R 0.36G 
RAx 2.21G 0.90R 0.96S 
26 19 16 RAx 1.43G 0.40R - R 
10 6 14 RNk 2.70G 1.87R 2.94G 
RAx 0.815 0.80S 0.905 
R- l35 
Stage: 
Table 34 (continued) 
Rat 
Plasma Tumour 
Period prolactin size (cm2) 
(days) (ng /ml) + growth 
2 3 1 2 3 1 2 3 
mean 12.9 13.9 26.1 35.9 60.5 2.04 1.19 1.27 
n 10 10 10 10 10 30 29 24 
mean of initial tumours (n = 30) 










grown (G) 22 1 7 
new 0 0 
static (S) 8 7 8 
partially 21 9 
regressed (R) 0 22 14 
totally 1 5 
Stage: 
Table 35 
The effect of androgens on tumour growth - 
















1 2 3 
71L 13 10 cyclic cyclic 12 3 4 RNk 2.70G 1.95R 1.50R 
87L 14 15 cyclic cyclic 21 21 10 LCh 1.43G 1.80G 2.24G 
LAx - - 0.25G 0.70G 
RAx 0.81S 0.96G 1.1OG 
RInl 1.1OS 0.64R 0.80G 
RIn2 3.23G 3.20S 3.045 
114L 14 19 cyclic irregular 97 29 41 RAx 4.83G 4.805 5.75G 
LGr 0.80G - R - - 
LAn - - 0.90G 0.25R 
RAn 1.26G 1.68G 2.52G 
117L 15 12 cyclic cyclic 22 7 35 LNk 0.99S 0.64R - R 
LCh 2.38S 2.38S 2.38S 
LAxl 0.36G 0.63G 1.17G 
LAx2 3.04G 2.52R 2.21R 
LAx2 3.04G 2.52R 2.21R 
RTh - - - - 0.60G 
Stage: 
















1 2 3 
292L 10 14 cyclic cyclic 66 60 25 RAx 2.08G 2.38G 2.34S 
301L 13 14 cyclic cyclic 27 13 42 RNkI 0.88G 1.30G 1.12R 
RCh 0.885 0.64R 0.42R 
RIn 0.80S 0.48R 0.36R 
LGr 4.42G 5.58G 4.74R 
325L 13 8 cyclic cyclic 17 10 42 LAx 6.75G 8.99G 14.44G 
331L 10 11 cyclic cyclic 105 97 27 LAx 1.96G 2.70G 2.70S 
3351- 11 18 cyclic irregular 77 27 53 LAx 2.52G 2.52S 2.88G 
356L 11 9 cyclic cyclic 67 28 27 RAx 1.95G 0.99R 1.54G 
LGr - - - - 2.04G 
RGr 3.40G 4.40G 8.00G 
R-138 
Stage: 






Rat (days) (ng /ml) + growth 
2 3 1 2 3 1 2 3 
mean 12.4 13.0 51.1 29.5 26.4 2.21 2.28 2.70 
n 10 10 10 10 10 22 23 24 
mean of initial tumours (n = 22) 

















static (S) 6 4 4 
partially 7 7 
regressed (R) 0 8 8 
totally 1 1 
R-13q 
Regression analyses of tumour size in Tables 32 - 35 







1 -2 -3 
tumour size 1 -2 
(all) 29 2 -3 
1 -2 -3 
tumour size /rat 1 -2 
10 2 -3 
1 -2 -3 
50.- dihydrotestosterone 
tumour size 1 -2 
(all) 34 2 -3 
1 -2 -3 
tumour size /rat 1 -2 
1.0 2 -3 
















































Regression analyses of tumour sizes in Tables 32 -- 35 
Parameter n Stages Analysis F -value p 
5o(- androstane -3 0., 17(3 -diol 
tumour size 1 -2 linear regression 33.84* <0.001 
(all) 30 2 -3 linear regression 1.76- NS 
1 -2 -3 linear regression 42.57* <0.001 
deviation 7.51* <0.01 
tumour size /rat 1 -2 linear regression 15.26* {0.01 
10 2 -3 linear regression 0.78- NS 
1 -2 -3 linear regression 15.61* <0.001 
deviation 2.75 - NS 
5ol- androstane -3 f2, 17ç -diol 
tumour size 1 -2 linear regression 0.58 - NS 
(excluding new) 22 2 -3 linear regression 2.18 - NS 
1 -2 -3 linear regression 3.44 - <0.10 
deviation 0.40 - NS 
tumour size 1 -2 linear regression 1.15 - NS 
(all) 26 2 -3 linear regression 3.32- 4,0.10 
1 -2 -3 linear regression 5.42* <0.05 
deviation 0.53 - NS 
tumour size /rat 1 -2 linear regression 1.95 - NS 
10 2 -3 linear regression 2.13 - NS 
1 -2 -3 linear regression 4.45* 40.05 
deviation 0.30 - NS 
smears, but instead appeared to permit the continuation of normal oestrous 
cycles throughout the treatment period. During the recovery period the cyclic 
pattern continued in all but 2 rats. Both of these rats exhibited a constant 
dioestrus pattern for the first part of the recovery period followed by a series of 
smears resembling those found in oestrus. 
3. Effect of androgens on plasma prolactin levels 
With the exception of animals whose vaginal smear pattern was described 
as stuck in oestrus or irregular, all blood samples were taken on a day on which 
the rats exhibited a vaginal smear characteristic of dioestrus. Frequently 
several rats had to be handled simultaneously and stress factors could not always 
be avoided. 
Considerable ranges of prolactin values were obtained at certain stages. 
Since the variance differed markedly between sets of figures, a logarithmic 
transformation of data was performed before statistical analysis. When the 
prolactin values for the different stages of each group were compared only 2 
differed significantly from all the others (Table 31). The pretreatment prolactin 
levels of the 50t- androstane -3 (1,170 -diol- treated group and the levels after 
recovery of the 5«- androstane 3o4,17/3 -diol- treated group were significantly 
higher than the control values of the corresponding stages and significantly 
higher than the other 2 stages within their respective groups. 
Neither of these elevations is readily explicable, especially that of the 
values obtained for the 5 o(- androstane -3 (3,17/3 -diol group prior to treatment at 
which stage all animals were untreated and were randomly allocated to each 
group. It is feasible that an uneven distribution of stress factors, leading to 
raised plasma prolactin levels at the time of blood sampling, could account for 
these differences. 
At the end of the treatment period no differences in plasma prolactin 
levels were observed between steroid -treated and control rats. In the cycling 
rats of the control group samples were taken in dioestrus, a stage of the cycle in 
(\ -142 
which plasma prolactin levels are relatively low. Therefore, the values obtained 
for the control group, and probably the 50C androstane -3 0,17ß -diol- treated 
group, would not be representative of those throughout the treatment period 
during which far higher levels would have been attained at proestrus stages. On 
the other hand cyclic surges in plasma prolactin levels may not have occurred in 
the two groups showing constant dioestrus vaginal smears. The prolactin values 
obtained at the end of treatment in the 5 o(- dihydrotestosterone - and 5 v(- 
androstane -30c,17ß -diol- treated groups were representative of the levels 
throughout the treatment period. As these were similar to the levels in 
dioestrus of cycling rats, it may be that by abolishing the cyclic surges of 
prolactin release, overall secretion was reduced by these 2 androgens. 
4. Effect of androgens on tumour growth 
From the regular measurements of tumour size it was possible to chart the 
growth pattern of the individual tumours as shown representatively in Figs. 36 - 
39. Since the assessment of tumour size by caliper could not be accurately 
made below 0.25cm2 (that is 0.5 x 0.5cm), only tumour sizes equal to or greater 
than these were recorded. The tumour sizes at the end of the pretreatment, 
treatment and recovery periods are given in the table along with a classification 
of growing rate into one of 3 broad categories: growing, static or regressing. 
Tumours showing changes in size of 10% or less over a 2 week period were 
classified as static. Changes in excess of 10% were classified as grown or 
regressed according to the direction of growth. 
In control animals the initial tumour number was increased from 23 to 29 
by the appearance of 5 new tumours in the treatment period and one in the 
recovery period. In the control group the highest proportion of growing tumours 
was seen in the pretreatment period whereas the proportion of tumours regress- 
ing was higher in the treatment and recovery period. A similar trend from 
growth to regression was also seen if one only considers tumours which were 
actively growing at the start of the treatment period (Table 32). This trend was 
R-í43 
Figures 34 and 35. Effect of androgens on the size of 
DMBA- induced mammary tumours by mean tumour size 







Stage 1 2 3 
control 
1 2 3 1 2 3 1 2 3 












Stage 1 2 3 
control 
1 2 3 1 2 3 1 2 3 
5d -DHT 5d- Adiol(3d) 5d- Adiol(3/3) 
treatment group 
8-144 
Figure 36. Effect of androgens on the growth of 
individual DMBA- induced mammary tumours 
(a) Control 




pretreatment (1 ) treatment (2 ) recovery ( 3 ) 
i V///////////////////////////Z4 
-15 -10 -5 0 5 10 
time - days 
15 20 25 
6 daily s.c. injections of corn oil (0.2m1) were given each week of the 
treatment period. 
R- 145 
Figure 37. Effect of androgens on the growth of 
individual DMBA- induced mammary tumours 
(b) 5o -dihydrotestosterone 






pretreatment(1) treatment ( 2 ) 
1 P / // / i recovery ( 3 ) J 
R Nk 1 
RGr 
RNk2 
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time - days 
6 daily s.c. injections of 5a- dihydrotestosterone (lmg) were given each week 
of the treatment period. 
(2.-1.40 
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Figure 38. Effect of androgens on the growth of 
individual DMBA- induced mammary tumours 
(c) 5 oc- androstane -3a , 1713 -diol 
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-10 -5 0 5 10 
time - days 
15 20 25 30 
6 daily s.c. injections of 5&4.- androstane -3a, 1713 -diol (1mg) were given each 
week of the treatment period. 
ti-147 
Figure 39. Effect of androgens on the growth of 
individual DMBA- induced mammary tumours 
(d) 5o,- androstane -3A, l713 -diol 
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time - days 
LAx 
6 daily s.c. injections of 5o4.- androstane -3(3, l7ß -diol (lmg) were given each 
week of the treatment period. 
(L -148 
significant at the 5% level and emphasises the need for a control group in a study 
where static and spontaneously regressing tumours are encountered. The reason 
that less regressing tumours were seen in the pretreatment period is probably 
that animals were considered for use at an early stage of tumour growth and 
were allocated to the groups before extensive spontaneous regression became 
evident. 
Despite this degree of spontaneous regression in the control rats treatment 
with both 5o4.- dihydrotestosterone and 5«- androstane -3x,17(3 -diol could be seen 
to greatly increase the number of regressing tumours. After cessation of 
treatment the distribution of growing, static and regressing tumours in the 
5 off- dihydrotestosterone -treated group resembled that of the control group, but a 
less complete recovery was seen with 50(- androstane -3a,17/á -diol. In the 
50k- dihydrotestosterone -treated group 2 tumours appeared during the recovery 
period at sites where tumours had become impalpable during the treatment 
period. It was assumed for statistical analysis that these were regrowths of the 
original tumours although the possibility that they were completely new tumours 
cannot be discounted. This possibility excepted, no new tumours appeared in 
either the 5c(- dihydrotestosterone - or 5 a- androstane -3 0,17 S -diol- treated group 
throughout both treatment and recovery periods. 
In the 5o(- androstane -3/3,17(3 -diol- treated group 4 new tumours appeared 
after the start of treatment, 2 in the treatment and 2 in the recovery period. 
However, in each of these periods a tumour regressed totally. No significant 
differences between the distributions of growing, static and regressing tumours 
of the control and 5o(- androstane -3,17(3 -diol- treated- groups were detected at 
any of the three stages. 
The effect of the androgens was also assessed in terms of actual tumour 
size. This parameter was analysed by regression analysis which considers the 
extent of changes in tumour size without taking into account the absolute values. 
In the 5o(- dihydrotestosterone - and 5o(- androstane -301,170 -diol- treated groups 
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in which no new tumours appeared, the number of tumours present initially could 
simply be used for the analysis of results. However, in the other 2 groups new 
tumours arose and there was a choice of considering only the tumours present at 
the start of the treatment or also including new tumours and ascribing to them a 
size just above zero (e.g. 0.01cm2) in the periods before they became palpable. 
Both methods have drawbacks, the first obscures the possibility that the lack of 
new tumours in the 501- dihydrotestosterone - and 5oí- androstane -3oí,17/3 -diol- 
treated animals may be regarded as a part of the effect of these steriods, and 
the second may introduce an arithmetical bias causing mean pretreatment values 
to be artifically lowered. The simplest solution was to perform analyses on both 
tumours present initially and on all tumours in the control and 5íx- androstane- 
3(3,170 -diol- treated groups. An alternative approach, which was applied to all 4 
groups, was to sum the tumour size for each rat and use these values for 
analysis. It can be seen from the regression analyses and from the histograms 
(Figs. 34 and 35) that these different methods of analysis gave essentially the 
same picture. 
In the control group the mean tumour size increased during both the 
treatment and recovery periods. Apart from the difference between pretreat- 
ment and treatment sizes for existing tumours only, all other differences were 
significant. The increase in tumour size appeared to be a function of time, with 
almost no deviation from linearity. 
The administration of 5a -dihydrotestosterone caused a highly significant 
reduction in tumour size by the end of the treatment period. This regression in 
tumour size did not persist after the termination of treatment and the mean 
tumour size increased numerically, but not significantly, during the recovery 
period. 
5oí- androstane -301,17(3 -diol likewise caused a highly significant decrease 
in tumour size. Tumour regression did not appear to continue after the 
cessation of treatment, and although regrowth of some tumours occurred, there 
was no increase in mean tumour size over this period. 
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Mean tumour size increased slightly during treatment with 5o(- androstane 
-30,1713 -diol, and to a greater extent over the recovery period which might 
suggest a slight check in the growth rate of tumours by 5 %- androstane -3(3, 
17/3 -diol. The general trend of increased tumour size over both treatment and 
recovery periods in this group was significant at the 5% level. 
5. Summary of the effects of androgen treatment 
Vehicle or 5o4- androstane- 3,11,17j -diol appeared to have little effect on 
the oestrous cycle, whereas 5a- dihydrotestosterone or 5o -androstane -3o(, 
17(3 -diol arrested the oestrous cycle in dioestrus. The pattern of constant 
dioestrus persisted for approximately 6 days after the termination of treatment 
when it was replaced by the normal cyclic pattern. The plasma prolactin levels 
in these non -cycling rats at the end of the treatment period were similar to 
those found in the dioestrus stage of cycling control rats. 
Both of the steroids which arrested the oestrous cycle also inhibited 
tumour growth and caused a profound reduction in tumour size. The regression 
of mammary tumours due to the administration of 50(- dihydrotestosterone and 
5vc- androstane -301,17/3-diol ceased after the termination of treatment, but 
there was frequently no regrowth of tumours during the recovery period. 506- 
androstane- 313,17(3 -diol, which did not appear to affect the oestrous cycle, did 
not induce tumour regression. 
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VII. Influence of the stage of cycle and plasma prolactin levels 
at the time of DMBA administration on subsequent tumour development 
1. Experimental design 
The mammary tumours for this thesis were induced by a single intragastric 
administration of 30mg of DMBA in 2m1 of cotton seed oil to female Sprague - 
Dawley rats, in groups of 5 - 25, at 47 - 55 days of age. Just prior to DMBA 
administration (1400 - 1600 hours), a sample of blood was taken for plasma 
prolactin assay and the stage of the oestrous cycle determined by a single 
vaginal smear. The animals were then palpated twice weekly for tumours for a 
period of 120 days after the administration of carcinogen. The number and size 
of all tumours were recorded. For the purposes of this study animals were 
divided into three separate categories: - 
(a) Early death: Possibly, but perhaps not always, as a result of the 
DMBA administration some animals developed ill health (e.g. 
anaemia or respiratory problems), and either died or were put to 
death. The majority of these early deaths occurred or were inflicted 
within two weeks of the carcinogen administration. Since it could 
not be ascertained whether or not tumours would have developed in 
these animals the plasma samples were not assayed for prolactin 
content. 
(b) Tumour -bearing: This group included all animals who, within 120 
days of treatment, developed one or more mammary tumours of at 
least 0.8 x 0.8cm. This group was not further subdivided since many 
of the rats were allocated to treatment regimes or were sacrificed 
before the end of the observation period. Not all of the tumours 
were examined histologically, but the incidence of tumours other 
than adenocarcinoma has been shown to be very low in rats of this 
age (Gruenstein, Meranze, Thatcher & Shimkin, 1966). 
(c) Non -tumour -bearing: All animals in this group were observed for at 
least 120 days after the administration of DMBA during which time 
any palpable lumps had not reached a size of 0.8 x 0.8 cm. 
Vaginal smears were taken from a total of 861 rats at the time of DMBA 
administration. Of these, 170 (19.7%) died during the observation period or had 
to be killed due to ill- health. According to the above definitions, 459 (66.4 %) of 
the remaining 691 rats developed tumours. 
2. Stage of cycle and tumour incidence 
A contingency table was constructed showing the frequency with which 
tumours occurred in rats at different stages of the cycle when given DMBA 
(Table 36). When the Chi -square test was applied to these data it was found that 
there was a significant difference between the distribution of tumour -bearing 
and non -tumour -bearing rats, over the four stages of the cycle. The source of 
this difference appears to lie with the two groups of rats which were in the 
proestrus and dioestrus stages of the cycle. Of the animals which were in 
proestrus on the day of DMBA administration, a greater proportion subsequently 
developed tumours, than in the other groups, whereas a lower than average 
incidence of tumours was found in animals which were in dioestrus on the day of 
DMBA administration. 
In contrast there was no significant difference between the distribution of 
animals which suffered early death and the rest of the population with regard to 
the stage of cycle on the day of DMBA administration (Table 37). It can be seen 
from the totals in this second table that a far greater number of rats were 
classified as being in the oestrus or dioestrus stage of the cycle than in the other 
two stages. The uneven distribution probably reflects the difference in duration 
of each stage of the cycle (Long & Evans, 1922), and the fact that when the 
oestrous cycle is interrupted, vaginal smears of either a constant oestrus- or 
constant dioestrus -pattern are seen. 
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Table 36 
Stage of cycle at DMBA administration 
and subsequent incidence of tumours 
Proestrus 
Stage of cycle when given DMBA 
Oestrus Metoestrus Dioestrus Totals 
Tumours 103 (90.3) 171 (167.4) 50 (51.8) 135 (149.5) 459 
No tumours 33 (45.7) 81 (84.6) 28 (26.2) 90 (75.5) 232 
Totals 136 252 78 225 691 
d.f. = 3, X2 = 9.9, therefore p.<0.05 
Table 37 
Stage of cycle at DMBA administration and subsequent health 
Proestrus 
Stage of cycle when given DMBA 
Oestrus Metoestrus Dioestrus Totals 
"Healthy" 136 (134.0) 252 (258.4) 78 (74.6) 225 (223.9) 691 
Early death 31 (33.0) 70 (63.6) 15 (18.4) 54 (55.1) 170 
Totals 167 322 93 279 861 
d.f. = 3,X 2 = 1.9, therefore no significant difference in frequency 
Open figures refer to the number of rats in each category. Expected values are 
given in brackets. 
3. Plasma prolactin and tumour incidence 
The levels of prolactin in the plasma of blood samples removed just prior to 
DMBA administration varied from 2 to 380ng /ml with an arithmetic mean of 
52.5ng /ml. The unsymmetrical continuous distribution of prolactin values 
appeared to be logarithmic- normal. Accordingly after transformation of the 
individual values to natural logarithms (In), a symmetrical normal distribution 
was obtained. This transformation was used to compare the prolactin levels in 
the different categories in Table 38. Rats were divided into categories according 
to the stage of cycle at DMBA administration and the subsequent presence or 
absence of tumours. 
It can be seen that at each stage of the cycle, the mean plasma prolactin 
level was lower in rats which subsequently bore no tumours compared to those 
which did. In proestrus and dioestrus, the difference between prolactin levels in 
tumour -bearing and non -tumour -bearing rats was significant, and in the other 
two stages of the cycle, the difference just failed to reach significance. When 
considered as a whole there was a highly significant systematic difference over 
all stages resulting in a p value of less than 0.001 when the plasma prolactin 
levels of all non -tumour -bearing rats were compared to those of all tumour - 
bearing rats. 
In both tumour -bearing and non -tumour -bearing rats the plasma prolactin 
levels taken in oestrus were significantly higher than those taken in metoestrus 
and dioestrus. 
4. Onset of the oestrous cycle 
Since different strains of rats begin to cycle at different ages (Boyland & 
Sydnor, 1962), it was of interest to determine the onset of the oestrous cycle in 
relation to the time of DMBA administration in the rats used in this study. 
Therefore, a sample group of 9 rats was studied from an age of 30 to 56 days. 
The vaginal plate in these rats opened between 32 and 36 days of age giving 
a constant dioestrus smear pattern for 5 - 7 days which was followed by 
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Table 38 
Prolactin levels at DMBA administration 
and subsequent tumour induction 
Proestrus Oestrus Metoestrus Dioestrus All 
Tumours 3.72 3.88 3.55 3.61 3.73 
(41.4) (48.5) (34.7) (36.9) (41.7) 
No tumours 3.28* 3.70 3.22 3.37* 3.45 ** 
(26.5) (40.6) (25.1) (29.0) (30.3) 
All 3.61 3.82 3.43 3.51 3.64 
(36.9) (45.7) (30.9) (33.5) (38.1) 
within group 
pooled s.d.'s 
Tumours = 0.82, d.f. = 455 
No tumours = 0.75, d.f. = 228 
Open values are means of the In prolactin concentration and the bracketed 
values below are the geometric means. The number of rats comprising each 
category are the same as in the corresponding cells in Table 36. 
Variance analysis plus the F -test revealed a significant systematic differ- 
ence between tumour -bearing and non -tumour -bearing rats across all stages of 
the cycle. 
* and ** = significantly lower than corresponding values for tumour- 
bearing rats at p<0.05 and p<0.001 respectively. 
Prolactin levels at oestrus were significantly higher than at metoestrus and 
dioestrus, p< 0.05 by the Student -Newman -Keuls test. 
proestrus of the first cycle at 37 - 42 days of age. By 50 days of age, regular 
4 -day cycles were detected in 6 of the 9 rats, 2 appeared to undergo 5 -day 
cycles and the remaining rat gave an irregular smear pattern. It can therefore 
be concluded that, in this study, the majority of rats were probably in the second 
or third oestrous cycle when they received DMBA. 
5. Summary 
Both the stage of the cycle and the level of prolactin at the time of DMBA 
administration appear to have affected the likelihood of an individual developing 
tumours over the following 120 days. Rats in proestrus at the time of DMBA 
administration had a slightly higher than normal tumour incidence, whereas the 
reverse was true for those in dioestrus. Irrespective of the cycle, tumour - 
bearing rats had higher mean levels of plasma prolactin at the time of DMBA 
administration, compared to non -tumour -bearing rats. 
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DISCUSSION 
The presence of enzymes which metabolise steroids 
in a target tissue endow that tissue with the potential 
to control its local hormonal environment by the syn- 
thesis or inactivation of biologically active forms of 
steroids. In many androgen sensitive tissues it has 
been demonstrated that the expression of the androgenic 
effects of testosterone, the classical androgen, requires 
the presence of 5a- reductase to effect its conversion to 
the active form, 5a- dihydrotestosterone (King s Mainwaring, 
1974). 
In common with certain human breast cancers, adeno- 
carcinomas induced in the rat by the administration of 
DMBA appear to be androgen sensitive in that they re- 
gress on appropriate administration of androgens (Co- 
operative Breast Cancer Group, 1964; Griswold, Skipper, 
Laster, Wilcox s Schabel, 1966). Both the human and rat 
mammary cancers are capable of converting testosterone 
by 5a- reduction to 5a- dihydrotestosterone (Miller, 
Forrest e Hamilton, 1974). It was, therefore, proposed 
to measure the ability of DMBA- induced mammary tumours 
to metabolise testosterone by 5a- reduction, following 
alterations in the plasma levels of oestradiol and pro - 
lactin, the two hormones believed to be of greatest imp- 
ortance in controlling the growth of these tumours. An 
initial stimulus for this work was the finding that 
tumours induced and developed in rats rendered hyperpro- 
lactinaemic by perphenazine administration showed higher 
5a- reductase activity than their control counterparts 
(Miller, 1976 a). 
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Hormonal control of enzyme activity can be studied 
in different systems. The effect of individual hormones 
can be studied in vitro by incubating portions of tissue 
with precursor in the presence and absence of hormone. 
The disadvantages of such a system are that the integral 
hormonal environment of the body, which may be required 
for the effect of an individual hormone to be observed, 
is lost, and that hormone- induced changes in enzyme act- 
ivity, which require alterations in parameters such as 
protein or cell synthesis in vivo, will not be seen in 
short term in vitro incubations. The latter problem can 
be overcome by tissue or cell culture but the cell types 
surviving in these systems may not be representative of 
those in vivo and may show altered properties. A total 
in vitro approach also presents difficulties in relating 
hormonal effects on enzyme activity to those on the 
growth of the same tumour. 
A second approach is to administer radioactively - 
labelled testosterone to hormonally manipulated animals, 
shortly before excising the tumour, which can then be 
studied for its content of radioactive steroid. This 
method is attractive because the effect of the 
hormonal manipulation on tumour growth can be assessed, 
and in situ measurement of metabolite formation should 
give a good reflection of the relative activities of 
tumour enzymes. However administration of the precursor 
and the tumour bloo& supply may vary and affect repro- 
ducibility, metabolites formed at other sites may enter 
the tumour before excision, and variations in steroid 
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levels within a tumour may reflect variations in accum- 
ulation and not variations in metabolism. 
The approach adopted for the present study is a 
compromise of the two already described. Drug treat- 
ment and ovariectomy were used to alter the plasma levels 
of prolactin and oestradiol which were monitored, along 
with tumour size, before and during treatment. At the 
end of the treatment period tumours were excised and 
their capacity to metabolise testosterone assessed directly 
in vitro. Due to the complexity of hormonal interrel- 
ationships any single treatment probably alters the se- 
cretion of more than one hormone. It has therefore been 
necessary to integrate the data from different treatment 
regimes, in an attempt to determine which hormones may 
be involved in the control of 5a- reductase activity in 
the tumours. 
All incubations of tumour have been performed under 
fixed, standard conditions so that a comparison of the 
capacity of tumour to metabolise testosterone by 5a -red- 
uction could be made. A whole tissue homogenate of 
0.5 g of tumour was incubated for one hour, with 50 x 106 
d.p.m. testosterone in 7.5 ml Krebs -Ringer phosphate 
buffer, pH 7.4, containing an NADPH -generating system. 
5a- Reductase activity has been found in both nuclear 
and the crude cytoplasmic fractions of the ventral pro- 
state of rats (Baulieu s Robel, 1970; Frederiksen s 
Wilson, 1971), and of dogs (McGuire, Hollis s Tomkins, 
1960), and rat hypothalamus ( Cheng s Karavolas, 1975). 
It has recently been shown that 5a- reductase activity is 
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distributed almost equally in nuclear, mitochondrial 
and microsomal fractions of DMBA- induced rat mammary 
tumours (Mori, Tominaga E Tamaoki, 1978; Tamaoki, Mori, 
Kitamura E Tominaga, 1978). The 5a- reductase activity 
measured in the homogenates of whole tissue is therefore 
probably due to the action of enzymes located in different 
cell organelles. Although a measurement of overall 5a- 
reductase activity is probably most suitable for pre- 
liminary investigations such as these, it is possible 
that 5a- reductase activity of the various organelles 
could differ in their sensitivity to hormonal modulation. 
Estimations of the optimum pH for 5a- reductase act- 
ivity vary from about 6.6 to 7.0 depending on the system 
under study (Frederiksen E Wilson, 1971; Koninckx, 
Verhoeven, Heyns E de Moor, 1979). However the activity 
at pH 7.4 in these systems was still close to the max- 
imum. If 5a- reductase of DMBA -induced mammary tumours 
exhibits a similar pH dependence, then 5a- reductase act- 
ivity measured at pH 7.4, in this and other studies 
(King, Gordon e Helfenstein, 1964; Miller, Forrest s 
Hamilton, 1974; Mori, Tominaga E Tamaoki, 19 78), may be 
marginally below the maximum. This should not affect 
the intercomparison of tumour 5a- reductase capacity, 
since, assuming that pH dependence is alike in all 
tumours, the relative activities of 5a- reductase will al- 
ways be the same provided that a fixed pH is used. The 
optimum temperature for 5a- reductase activity in the rat 
ventral prostate preparation was found to be 3700 
(Bruchovsky E Wilson, 1968; Frederiksen e Wilson, 1971). 
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The concentration of testosterone precursor present 
at the start of the incubation was approximately 
100 ng /ml (= 3.5 x 10 -7M), which is almost 500 times 
greater than the highest concentration of testosterone 
in blood of female rats during the oestrous cycle (Dupon 
e Kim, 1973; Weizenbaum, Adler c Ganjam, 19 79). The 
concentration of the NADP* for the generation of NADPH 
by the reaction of added glucose -6- phosphate with 
glucose -6- phosphate dehydrogenase was 2 x 10 
-4M. 
These 
features, in combination with loss of both tissue and 
cellular spatial integrity during the homogenisation pro- 
cedure, create an artificial system. It cannot there- 
fore be assumed that the pattern of metabolism observed 
under these conditions will reflect the situation exist- 
ing in vivo. However it is hoped this system will 
measure the relative capacity of tumours to perform the 
5a- reduction of testosterone. 
The observation that 5a- reductase activity varied 
far less between duplicate portions of the same tumour 
than between tumours of the same rat or tumours of dif- 
ferent rats indicated the reproducibility of the method 
and the validity of its use comparing the capacity of 
different tumours to perform 5a- reduction, The varia- 
tions observed within tumours may have arisen from 
methodological limitations or from regional differences 
in enzyme activity within the tumour. The latter poss- 
ibility might occur if 5a- reductase levels were higher 
in a particular cell type since histological variations 
are sometimes observed within individual tumours (Huggins, 
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Briziarelli s Sutton, 1959; Young s Hallowes, 1973). 
It has been claimed that testosterone 5a- reductase is 
located predominantly in the stroma, with very little 
in epithelium of benign hyperplastic human prostate 
(Cowan, Cowan s Grant, 1976). 
The quantities of testosterone metabolised by DMBA- 
induced mammary tumours obtained from untreated rats, 
and incubated under the standard conditions, varied con- 
siderably. On average approximately half of the pre- 
cursor was metabolised after a one hour incubation per- 
iod. The majority of this metabolism was accounted for 
by 5a- reduction which was measured as the sum of the net 
production of 5a- dihydrotestosterone and 5a- androstane- 
diol. The production of 5a- androstanedione was so low, 
that it was decided not to measure its formation for in- 
clusion in the estimation of 5a- reduction. The 1.03% 
conversion of testosterone to 5a- androstanedione, after 
60 minutes in a time- course experiment, probably repres- 
ents the top end of the range of its production since a 
small, but distinct, radioactive peak, associated with 
5a- androstanedione, was observed on scanning the initial 
plate of that incubation, whereas the corresponding 
peaks were either smaller or absent on other initial 
plates. 
Although the 3a,17ß- isomer of 5a- androstanediol was 
added as a carrier steroid the methods employed give a 
measure of total 5a- androstanediol production, since all 
four isomers of 5a- androstanediol migrate together in 
the initial solvent system and subsequent oxidation 
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yields a common product, 5a- androstanedione (Miller, 
1976 b), When the 3a,173- and 3 [3,175- isomers of 5a- 
androstanediol were separated in solvent system V before 
oxidation, it was found that 3x,173- isomer accounted for 
most of the 5a- androstanediol production. Although the 
17a- isomers were not separately studied, it is possible 
that the 3ß,17ß- isomer could have been contaminated 
with the 3ß,17a- isomer which has a similar mobility in 
solvent system V (Berthou, Bardou c Floch, 1974). How- 
ever there are no reports of the formation of this lat- 
ter steroid by the DMBA- induced mammary tumour. Con- 
tamination by the 3a,17a- isomer is highly unlikely since 
it migrates more slowly than the other three isomers in 
solvent system V ( Berthou, Bardou s Floch, 1974). 
An interesting pattern of net production of 5a- 
reduced metabolites with time was seen. Over about the 
first 10 minutes, the net production rate of 5a- dihydro- 
testosterone exceeded that of 5a- androstane -3a,17ß -diol, 
but between 10 and 60 minutes this situation was reversed 
giving the greatest ratio of 5a- androstanediol to 5a- 
dihydrotestosterone at 60 minutes. However by 120 minutes 
the levels of 5a- dihydrotestosterone in the incubation 
again exceeded those of 5a- androstane -3a,17ß -diol, the 
latter actually decreasing during this period. In con- 
trast the production of 5a- androstane -33,173 -diol con- 
tinued to rise throughout the entire incubation period. 
The overall 5a- reduction rate almost mirrored the de- 
crease in precursor level, both proceeding rapidly over 
the first hour and then becoming markedly slower. 
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The pattern of metabolism can be interpreted as 
an irreversible conversion of testosterone to 5a- dihydro- 
testosterone which initially exceeds the further metab- 
olism of 5a- dihydrotestosterone to 5a- androstanediols. 
The 5a- dihydrotestosterone so formed can either be re- 
versibly converted to 5a- androstane- 3a,170-diol by the 
highly active 3a- hydroxysteroiddehydrogenase or irrevers-- 
ibly converted to 5a- androstane- 30,175-diol by the less 
active 30- hydroxysteroiddehydrogenase. The rapid con- 
version of 5a- androstane- 3a,17ß -diol but not its 313 - 
isomer to 5a- dihydrotestosterone has also been demon- 
strated in other tissues such as the rat prostate (Baulieu, 
Le Goascogne, Groyer, Feyel -Cabanes E Robel, 1975), and 
rat anterior pituitary (Pilven, Thieulant, Ducouret, 
Sampérez s Jouan, 19 76). From the results of the time - 
course experiments it appears that the DMBA- induced 
mammary tumour has a similar pattern of metabolism. 
This is schematically shown on Fig. 40. 
Although the fact that the net production of 5a- 
dihydrotestosterone between 60 and 120 minutes was 
greater than the total metabolism of testosterone over 
the same period can only be explained by the reverse 
conversion of 5a- androstane- 3a,17ß -diol to 5a- dihydro- 
testosterone, it is not readily apparent why the over- 
all direction of the reaction should have changed. 
When the metabolism of testosterone by the nuclear frac- 
tion of rat prostate was measured in the presence of 
varying concentrations of NADP+ it was found that al- 
though 5a- reduction remained constant at concentrations 
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greater than 10 -5M, this was accounted for mainly by 
the formation of 5a- dihydrotestosterone at lower con- 
centrations of NADP+ but at higher concentrations 5a- 
androstane- 3a,17ß -diol was the major metabolite formed 
(Frederiksen c Wilson, 1971). It is therefore possible 
that in the present study the high initial concentration 
of NADP+ favoured the conversion of 5a- dihydrotestosterone 
to 5a- androstane- 3a,17ß -diol, but that as NADP+ was con- 
verted to NADPH the reverse reaction became favoured. 
This explanation is further supported by the observation 
that in the time -course incubation performed without the 
addition of NADP+ or the other components of the NADPH- 
generating system, 5a- androstane -3a,17ß -diol formation 
was much lower than that of 5a- dihydrotestosterone and 
there was no indication of a reverse conversion of the 
diol to 5a- dihydrotestosterone. 
The omission of all components of the NADPH -gen- 
erating system profoundly reduced the initial rate of 
5a- reduction of testosterone by DMBA- induced mammary 
tumours, and also the further conversion of 5a- dihydro- 
testosterone to 5a- androstane- 3a,1713-diol, indicating 
the necessity of adding such a system to measure full 
5a- reductase capacity in a standard 60 minute incubation 
period. However it was remarkable that 5a- reductase act- 
ivity increased to such an extent during the course of 
the incubation that the formation of 5a- reduced products 
had reached the same level as that of the standard in- 
cubation within 120 minutes. Since it has been widely 
demonstrated that 5a- reductase in subcellular fractions 
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has an absolute requirement for NADPH (Wilson e Gloyna, 
1970; Frederiksen e Wilson, 1971), it would appear that 
the DMBA- induced tumour is capable of producing a sub- 
stantial quantity of NADPH. Indeed, the pentose- phosphate 
pathway and the presence of glucose -6- phosphate dehydro- 
genase, NADP- isocitrate dehydrogenase and NADP -malate 
dehydrogenase, which facilitate NADPH production, have 
all been demonstrated in the DMBA- induced tumour (Hilf, 
Goldenberg, Gruenstein, Meranze a Shimkin, 1970; Cohen 
e Hilf, 1974). It is possible, of course, that 5a- 
reductase of the DMBA- induced mammary tumour can utilise 
another co- factor such as NADH. 
A cessation of 5a- reductase activity in preparations 
where living cells are not maintained has been reported 
to occur within 100 -120 minutes at 37°C (Frederiksen e 
Wilson, 19 71). On the basis of other experimental data, 
it was concluded that the effect was not due to lack of 
co- factors nor product inhibition of the enzyme, but to 
the thermal denaturation of the enzyme at 37°C. Although 
the rate of 5a- reduction between 60 -120 minutes was 
slower than in the first hour, under the standard in- 
cubation of the present study, there was evidence of 
high 5a- reductase activity between 60 -120 minutes in 
the incubation without an added NADPH -generating system. 
This latter observation would suggest that the enzyme is 
not so labile in the whole tissue homogenate of DMBA- 
induced mammary tumours. This could be due to the pres- 
ence of some whole cells in the preparation. In any 
case, apart from the time- course studies, an incubation 
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period of 60 minutes was always used. 
In the light of observations mentioned above, it 
is interesting to compare the results of the present 
study with those of other workers in this field. In 
all preparations of the DMBA- induced mammary tumours 
so far studied 5a- reductase has been identified as the 
major route of testosterone metabolism (King, Gordon E 
Helfenstein, 1964; Miller, Forrest E Hamilton, 19 74; 
Mori, Tominaga e Tamaoki, 1978; Abul -Hajj, 1979). 
Some of these workers have found that the levels of 5a- 
dihydrotestosterone present at the end of the incubation 
period were greater than those of 5a- androstanediol 
(King, Gordon E Helfenstein, 1964; Miller, Forrest s 
Hamilton, 1974; Miller, 1976 a), whereas 5a- an.drostane- 
diol was always found in greater quantities than 5a- 
dihydrotestosterone at the end of the standard incuba- 
tion used in the present study. From the observations 
made during the time -course studies, the probable explan- 
ation for this difference is the use of a two -hour in- 
cubation period in all of these studies, compared with a 
one -hour period in the present study and also the lack 
of an NADPH supply in the earlier study of King, Gordon 
and Helfenstein (1964). This explanation is further sup- 
ported by reports of the recovery of more 5a- androstane- 
diol than 5a- dihydrotestosterone after incubation of one 
hour in the presence of NADPH (Miller, 1976 b; Mori, 
Tominaga E Tamaoki, 1978). 
To my knowledge there has been no positive identi- 
fication of the formation of androst- 4 -ene- 3a,17ß -diol 
D -11 
Figure 4c. Additions to metabolism of C -19 steroids by 


















by DMBA- induced rat mammary tumours. In this thesis, 
evidence is presented which suggests that a considerable 
amount of androst-4-ene- 3a,17ß -diol can be formed from 
testosterone by these tumours. 
A distinct region of radioactivity attributable to 
a material slightly more polar than 5a- androstane- 3a,178- 
diol was frequently observed on initial plates prepared 
from incubations of DMBA -induced mammary tumour with 
testosterone. On the basis of the identical behaviour 
of this material to that of authentic androst- 4 -ene- 
3a,17ß -diol, both chromatographically and chemically, 
and in particular the formation of a product with the pro- 
perties of testosterone on oxidation with manganese di- 
oxide, it was concluded that the material was in fact 
androst- 4 -ene- 3a,178-diol, It would appear that the 
formation of this metabolite accounts for a substantial 
amount of the metabolism of testosterone which is other- 
wise unaccounted for by the formation of ,5a- reduced pro- 
ducts. 
The steroidal allyl alcohol, androst-4-ene-3a,178- 
diol, was first reported following its synthesis by the 
reduction of testosterone with aluminium isopropoxide 
(Butenandt E Heusner, 1938), but, presumably because 
chemical reduction of testosterone yields very little 
3a- isomer (Jackman, Killen -Macbeth b Mills, 1949; 
Killen- Macbeth E Mills, 1949; Berthou, Bardou E Floch, 
1974), it is not available commercially and has received 
little attention. 
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Evidence has been presented for the formation of 
steroidal allyl alcohols by preparations of ovary and 
adrenal (Levy, Saito, Takeyama, Merrill e Schepis, 1963), 
liver (Lisboa s Gustafsson, 1970; Sanyal, Orr s Engel, 
1974), uterus (Lisboa e Holtermann, 1976; Junkerman, 
Runnebaum e Lisboa, 1977), and normal breast of mouse 
(Mori e Tamaoki, 1ß77) and rat (Tamaoki, Mori, Kitamura 
e Tominaga, 1978; Mori, Tominaga e Tamaoki, 1978). 
Smith and King (1966) found no evidence for the forma- 
tion of androst- 4 -ene- 3a,178-diol from testosterone by 
normal mammary glands and the spontaneous pregnancy - 
dependent mammary tumours of BR6 mice, but were able to 
demonstrate its production by all pregnancy- independent 
tumours investigated. They concluded that the differ- 
ences found between the two types of tumour could have 
been due to differences in the rate of either the syn- 
thesis or degradation of androst- 4 -ene- 3a,17ß -diol. In 
two recent publications (Tamaoki, Mori, Kitamura e 
Tominaga, 1978; Mori, Tominaga e Tamaoki, 1ß78), it 
was reported that although androst- 4 -ene- 3a,178-diol 
was the only metabolite of testosterone found in the 
normal rat mammary gland and was produced in substantial 
quantities, there was no evidence of its formation by 
the DMBA -induced rat mammary tumour. Since DMBA -induced 
mammary tumours are encapsulated and in the present 
study were removed in entirety before taking a portion 
from the centre, free of capsule, for metabolism studies, 
it is highly unlikely that the divergence in findings is 
due to contamination of the tumour with normal breast 
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tissue. However it is possible that the extent of 
androst-4-ene-3a,17p-diol formation is related to the 
presence of non -cancerous cells within the tumour and 
may give an index of the differentiation of tumours. 
The enzyue which catalysed the conversion of testosterone 
to androst- 4 -ene- 3a,17ß -diol in the normal mRmmary gland 
was found to reside in the cytoplasmic fraction (super- 
natant of homogenates centrifuged at 105,000 g for 60 
minutes), and had a preference for NADPH to NADH as co- 
factor. It was not clear whether this enzyme was the 
same as that which catalysed the reduction of the 5-teto 
group of 5a- reduced steroids (Mori, Tominaga e Tamaoki, 1978). 
Lisboa and Gustafsson (1970) found that the forma- 
tion of androst- 4 -ene- 3a,17ß -diol was inversely related 
to the formation of 5a- reduced products and concluded 
that the allyl alcohol was only formed when 5a- reductase 
activity was extremely low. The same inverse correla- 
tion was found in the present study, but the formation 
of androst-4-ene- 3a,17ß -diol still occurred when 5a- 
reductase activity was relatively high. Smith and King 
(1966) postulated that the further conversion of androst- 
4- ene- 3a,17ß -diol to 5a- androstane- 3a,170-diol was un- 
likely as 4- ene- 5a- steroiddehydrogenase in other tissues 
does not act in the presence of a 3- hydroxyl group 
(Rongone, 1962; Breuer, Dahn e Norymberski, 1963). 
However the formation of 4- androstenedione and testo- 
sterone from androst-4-ene- 3a,170-diol by chick liver 
has been reported (Ungar, Gut E Dorfman, 1957; Sanyal, 
Orr e Engel, 1974). Since no indications as to the 
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further metabolism of a.ndrost- 4- ene -5a 173 -diol were 
obtained in the present studies, only its formation 
from testosterone is indicated in Fig. 400 
The only relevant publication on the biological 
activity of androst- 4- ene- 3a,17P-diol which could be 
found was that of Huggins and Mainzer (1957), in which 
it was reported that the daily administration of 0.5 mg 
of the steroid was as effective as ovariectomy in caus- 
ing a regression of transplantable hormone -dependent 
mammary tumours. Whilst it is possible that this activ- 
ity was mediated via the conversion of androst- 4 -ene- 
3a, 173 -diol to testosterone the fact that it may be an 
inhibitor of mammary tumour growth, and is formed from 
testosterone as an alternative to 5a-reduction by DMBA- 
induced tumours, makes it worthy of further study. 
This may be facilitated by a recent report of a new and 
easier method of synthesis (Mori, Ikegami s Tamaoki, 1979). 
The assessment of plasma prolactin levels is ham- 
pered by the fact that the secretion of prolactin by 
the pituitary is rapidly raised by stressful situations, 
such as exposure to ether (Wuttke e Meites, 1970; 
Wakabayashi, Arimura c Schally, 1971; Stern e Voogt, 
1973). The two procedures which circumvent this prob- 
lem) decapitation without anaesthetic and withdrawal of 
blood through an indwelling cannula in the conscious 
animal, were not suited to the present studies which 
frequently required presacrifice sampling and which in- 
volved such large numbers of animals as to make the im- 
plantation of cannulae impractical. With practice it 
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was possible to complete the collection of blood from 
the tail vein of every rat within 120 seconds of its 
removal from the stable environment of the animal room, 
and within 90 seconds of its initial exposure to ether. 
It has been shown that plasma levels of prolactin are 
significantly raised two minutes after brief exposure 
to ether and remain elevated for about 15 minutes (Krulich, 
Hefco, Iilner s Read, 1974; Simone', Brooks e Welsch, 
1975; Mattheij s van Pijkeren, 1977). Whilst it is 
questionable whether the method employed in the present 
studies will have been rapid enough to avoid stress - 
induced effects on plasma prolactin, several workers 
have demonstrated that, in female rats, the release mech- 
anism for prolactin appears to be relatively insensitive 
to stress in dioestrus, the stage of the cycle in which 
most plasma prolactin measurements have been made (Neill, 
1970; Riegle s Meites, 1976; Mattheij, Kuipers, 
Sterrenberg s Swarts, 1979). 
Although not ideal, the method employed was satis- 
factory in that plasma prolactin levels were found to be 
significantly altered in the expected directions by the 
various treatments employed. It is likely that the rel- 
atively higher levels of plasma prolactin found at the 
oestrus stage of the cycle in rats at the time of DMBA 
administration resulted from stress -induced effects. Al- 
though Pearson, Llerena, Llerena, Molina and Butler (1969) 
also found prolactin levels higher in the oestrus stage 
of the cycle, according to Neill (1970 e 1972), prolactin 
levels are only elevated in proestrus and not in oestrus 
in unstressed rats. 
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The secretion of prolactin from the anterior pit- 
uitary is largely controlled by prolactin inhibitory 
factor which is released from the hypothalamus into the 
hypothalamic- hypophysial portal system ( Meites, Nicoll e 
Talwalker, 1963; Meites E Nicoll, 1966). Recent evi- 
dence has indicated that PIF is probably dopamine and 
that oestradiol, which, in the normal cycling rat, is 
the main physiological stimulus for prolactin release, 
acts both by inhibiting PIF release from the hypothalamus 
and by directly blocking the action of PIF at pituitary 
level (Labrie, Borgeat, Drouin, Beaulieu, Lagacé, 
Ferland E Raymond, 1979). Thus plasma levels of pro - 
lactin are dramatically elevated by the surge of oestra- 
diol at proestrus and fall sharply on ovariectomy 
(Pearson, Llerena, Llerena, Molina E Butler, 1969; 
Amenomori, Chen e Meites, 1970; Chen E Meites, 1970; 
Neill, Freeman E Tillson, 1971). 
Perphenazine, a phenothiazine, has been shown to 
powerfully stimulate prolactin secretion (Pearson, 
Llerena, Llerena, Molina E Butler, 1969; Ben -David, 
Danon E Sulman, 1970). Like oestradiol, perphenazine 
may act at a hypothalamic level ( Danon E Sulman, 1970), 
or directly on the pituitary (Shani, Givant, Sulman, 
Eylath E Eckstein, 1971; MacLeod s Lehmeyer, 1974). In 
the present study it was found that elevations in pro - 
lactin levels could not be reproducibly demonstrated in 
plasma collected 24 hours after the last of a series of 
daily injections of a commercial aqueous preparation of 
perphenazine. This result was perhaps not surprising, 
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since it has previously been shown that 24 hours after a 
single injection of a similar preparation plasma pro - 
lactin levels had returned almost to pre -injection values 
(Pearson, Llerena, Llerena, Molina s Butler, 1969; Ben - 
David, Danon s Sulman, 1970). 
When corn oil was used as a vehicle for perphena- 
zine a single s.c. injection of this preparation induced 
almost as rapid a rise in plasma prolactin levels as that 
reported for the aqueous preparations. However plasma 
prolactin levels were still significantly raised 24 hours 
after the injection of perphenazine in corn oil. The 
longer lasting effect of the corn oil preparation is 
probably due to a slower release of perphenazine from 
the corn oil injection depot. Using corn oil as a 
vehicle, elevated plasma prolactin levels were also 
found 24 hours after the last of a series of daily in- 
jections of perphenazine. In agreement with others per- 
phenazine was found to be equally effective in raising 
plasma prolactin levels in intact and ovariectomised 
rats (Pearson, Llerena, Llerena, Molina e Butler, 1969). 
Although plasma prolactin levels were clearly elevated 
by perphenazine two points should be borne in mind when 
comparing levels in intact control and perphenazine - 
treated rats. The first is that peak plasma prolactin 
levels in perphenazine -treated rats were probably 
reached in less than 24 hours and the second is that in- 
tact control rats were always killed in dioestrus when 
plasma prolactin levels are much lower than those of 
proestrus (Butcher, Collins s Fugo, 19 74). 
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In common with other ergot alkaloids, CB 154 has 
been shown to inhibit prolactin secretion mainly by 
acting as a potent dopamine agonist at pituitary level 
(Zeilmaker c Carlsen, 1962; Pasteels s Ectors, 1970; 
Lu, Koch c Meites, 1971). When administered in corn 
oil, CB 154 caused a profound reduction in plasma pro - 
lactin levels which lasted over 24 hours. 
The low levels of plasma oestradiol found at oest- 
rus and metoestrus and the high levels found at proest- 
rus in intact untreated rats in the present study cor- 
respond to those reported in more detailed studies 
(Brown -Grant, Exley e Naftolin, 1970; Butcher, Collins 
s Fugo, 1974). Oestradiol levels at dioestrus showed 
some variation and were on average above those of oest- 
rus and metoestrus. The degree of variation is probably 
related to the gradual rise in oestradiol levels seen 
throughout the dioestrus stage of the cycle (Brown- Grant, 
Exley e Naftolin, 1970; Butcher, Collins c Fugo, 1974). 
Although the presence of oestradiol in plasma at 
sacrifice could be taken as a positive indication of 
ovarian function, due to the extremely cyclic nature of 
oestradiol release, it could not be assumed from a 
single plasma sample with negligible oestradiol that 
ovarian function was inhibited. It was therefore de- 
cided to examine the effects of the two drugs on plasma 
oestradiol levels in intact rats over a period of eight 
days. Because of the relatively large volume of plasma 
required for oestradiol determination a method of pool- 
ing daily samples for individual rats was devised. 
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Since the method had the shortcoming that samples were 
taken at only one time in the day, this time was chosen 
to correspond with peak oestradiol leveler in proestrus 
in the cycling rats (Yoshinaga, Hawkins c Stocker, 1969; 
Brown -Grant, Exley s Naftolin, 1970; Butcher, Collins s 
Fugo, 1974). Therefore the oestradiol concentration in 
the cumulative sample pooled from eight consecutive 
daily samples from a control rat is probably the result 
of the high oestradiol concentrations in the two proest- 
rus samples being diluted by the much lower concentra- 
tions of the other daily samples. 
The levels of oestradiol in the cumulative plasma 
samples covering the 5th to the 12th day of perphenazine 
administration were on the borderline of sensitivity of 
the radioimmunoassay. This means that, unless plasma 
oestradiol levels rose rapidly outside the time of 
sampling, perphenazine treatment profoundly reduced oest- 
radiol secretion. Although it has been known for some 
time that perphenazine treatment induces a constant di- 
oestrus -type vaginal smear pattern (Ben- David, 1968), 
which is indicative of loss of ovarian cyclicity, as far 
as I am aware no other measurements of the long term 
effect of perphenazine on plasma oestradiol have been re- 
ported. Chatterton, Chien and Ward (1974) reported re- 
duced levels of serum oestradiol after three daily doses 
of perphenazine, but in such a time the full effect of 
inhibiting the oestrous cycle will not have been observed. 
Also, in the female rat extremely low levels of oestra- 
diol were also found up until the 10th day of pseudo- 
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pregnancy, a condition which is also associated with a 
constant dioestrus -type smear (Welschen, Osman, Dullart, 
de Greef, Uilenbroek s de Jong, 1975). 
The reduction in oestradiol secretion by the ovary 
probably results from the inhibition of the preovulatory 
release of luteinising hormone, due partly to a direct 
action of prolactin (Beck, Engelbart, Gelato s Wuttke, 
19 77), and also to the raised levels of plasma progest- 
erone (Chatterton, Chien s Ward, 1974; Chatterton, 
Chien, Ward s Miller, 1R75; Wynn, Harris s Chatterton, 
1976). Since prolactin is luteotrophic in the rat 
(Astwood, 1941; Evans, Simpson, Lyons s Turpeinen, 1941; 
Everett, 1956), and high prolactin levels are associated 
with increased progesterone secretion and a constant di- 
oestrus -type vaginal smear (Chatterton, Chien s Ward, 
1974; Welschen, Osman, Dullart, de Greef, Uilenbroek s 
de Jong, 1975; Tomogane, Ota s Yokoyama, 1975), it is 
possible that oestradiol levels are suppressed not only 
by perphenazine -induced hyperprolactinaemia, but by all 
other procedures which elevate plasma prolactin suffic- 
iently to arrest the vaginal smear pattern in dioestrus. 
Oestradiol levels were also extremely low in plasma 
collected at sacrifice in the non -tumour- bearing rats 
given perphenazine. However three of the rats in the 
group of intact tumour- bearing given perphenazine had 
sacrifice oestradiol levels at least twice as high as 
the limit of sensitivity of the assay. The difference 
in oestradiol levels between the two perphenazine- treated 
groups was probably due to the fact that all non -tumour- 
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bearing rats used for the cumulative collection study 
were sacrificed on the 12th day of treatment whereas 
treatment was sometimes a few days longer in the tumour - 
bearing rats. It is possible that with more than 12 
days of treatment some of the tumour -bearing rats were 
about to start cycling again. 
The levels of oestradiol in both cumulative and 
sacrifice plasma samples from non -tumour -bearing rats 
given CB 154 did not differ significantly from those of 
the control group. In the study on tumour -bearing rats, 
however, the plasma levels of oestradiol in CB 154 - 
treated rats at sacrifice were higher than those of the 
corresponding control group. It is possible that this 
was a chance observation, but all animals were in dioest- 
rus at sacrifice. The observation may merit further in- 
vestigation since it has been observed that ovaries are 
considerably enlarged by CB 154 treatment (Heuson, 
Waelbroeck -van Gaver e Legros, 1970; Gala s Boss, 1975). 
The difference in oestradiol levels, if real, may indic- 
ate a difference in overall output, or shift in the tim- 
ing of the oestradiol surge. 
Earlier reports have stressed the heterogeneous nat- 
ure of rat mammary tumours induced by DMBA with regard 
to their histological appearance (Huggins, Briziarelli s 
Sutton, 1959; Young s Hallowes, 1973), biochemical pro- 
perties (Hilf, Goldenberg, Gruenstein, Meranze a Shimkin, 
1970), spontaneous growth rate (Young, Cowan e Sutherland, 
1963; Heise e Gorlich, 1966), and response in growth 
rate to various hormonal manipulations (Segaloff, 1968; 
D-23 
Nagasawa, Chen s Meites, 1973; Bradley, Kledzik E Meites, 
1976). Only tumours which were actively growing at the 
time of allocation to a treatment group were included 
for the study of the effect of various treatment regimes 
on tumour growth and testosterone metabolism. However, 
it was not possible to determine how the growth of these 
tumours would have progressed over the same period had 
the animals remained untreated. 
Even after the preselection of actively growing 
tumours, noticeable variations were observed in the res- 
ponse of these tumours to certain treatment regimes. 
These variations were related to individuality of the 
tumours rather than to the differences in the response of 
individual rats to hormonal manipulation. Despite indiv- 
idual tumour variations, significant differences were ob- 
served between the tumour growth patterns of the various 
treatment groups. 
The increased growth rate of DMBA- induced mammary 
tumours in perphenazine -treated intact rats was similar 
to that observed on the administration of other drugs 
capable of raising plasma prolactin levels (Meites, 19 70; 
Meites, Lu, Wuttke, Welsch, Nagasawa c Quadri, 1972; 
Quadri, Kledzik s Meites, 1973). When perphenazine ad- 
ministration was started after DMBA treatment, but be- 
fore the initial appearance of tumours, both the number 
and growth rate of resultant tumours were greater than 
in control rats (Pearson, Llerena, Llerena, Molina s 
Butler, 1969). 
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The administration of CB 154 to intact rats has 
been reported to cause an inhibition in the growth of 
67% of DMBA -induced mammary tumours (Heuson, Waelbroeck- 
van Gaver s Legros, 1970), or to have only a slight in- 
hibitory effect on tumour growth (Cassell, Meites s 
Welsch, 1ß71; Teller, Stock, Hellman, Mountain, Bowie, 
Rosenberg, Boyar s Badinger, 1977). Although comparisons 
are difficult because of the different dosage regimes 
adopted (which may account for the discrepancy in the 
published results), the general inhibition in tumour 
growth without much reduction in mean tumour size found 
in this study appears to lie between the differing effects 
described by the other workers. 
The alterations in tumour growth rate observed 
after the administration of perphenazine or CB 154 to 
intact rats are in accord with the accepted view that 
prolactin plays an important role in maintaining and 
stimulating the growth of DMBA- induced mammary tumours. 
However tumour growth rate was not always stimulated by 
perphenazine nor did all tumours regress on CB 154 ad- 
ministration. Others have found that some DiVIBA- induced 
mammary tumours are prolactin insensitive or independent 
(Bradley, Kledzik s Meites, 1976), an observation which 
may be related to the presence of prolactin receptors in 
some, but not all, tumours (de Sombre, Kledzik, Marshall 
e Meites, 1976). Kelly, Bradley, Shiu, Meites a Friesen 
(1974) reported a continuous range of values for pro - 
lactin receptor content in DMBA -induced mammary tumours 
which, they claimed, correlated directly with prolactin 
responsiveness. 
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In the present study all tumours regressed in ovari- 
ectomised rats given only corn oil vehicle. In contrast, 
other workers have generally found that only 75-90% of 
DMBA- induced mammary tumours regress after ovariectomy 
(Young, Cowan c Sutherland, 1963; Teller, Kaufman, 
Bowie s Stock, 1969; Bradley, Kledzik e Meites, 1976). 
Although the number of tumours described in the present 
study was small, ovarian independent tumours have very 
rarely been found in this colony of rats (Scott, Murphy 
E Hawkins, 19 79). The reason for this high ovarian de- 
pendency may in part be due to the early age at which 
the operation was performed (usually less than 120 days 
after DIViBA administration). It has been shown that the 
response to ovariectomy diminishes with increasing age 
(Griswold e Green, 1970; Bradley, Kledzik s Meites, 1976). 
Since in the female rat prolactin secretion is main- 
tained by oestradiol and therefore diminishes on ovari- 
ectomy, there has been much debate concerning the direct 
role of oestradiol in maintaining mammary tumour growth. 
In the present study, the elevation of plasma prolactin 
by perphenazine delayed, but in general did not prevent, 
the regression of tumours in ovariectomised rats. Sim- 
ilar tumour growth patterns have also been observed in 
ovariectomised -plus- adrenalectomised rats whose pro - 
lactin levels were raised by median eminence lesions 
(Welsch, Clemens s Meites, 1969; Sinha, Cooper s Dao, 
1973), or administration of ovine prolactin (Nagasawa s 
Yanai, 1970). These findings suggest that eventually, 
ovarian hormones are required for the maintenance of 
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tumour growth by prolactin. The greater regression of 
tumours in ovariectomised rats given corn oil compared 
to intact rats given CB 154, despite both groups having 
low prolactin levels, is also indicative of ovarian 
hormones playing a role in mammary tumour growth other 
than by maintaining the secretion of pituitary prolactine 
On the other hand, since some tumours in ovari- 
ectomised rats given perphenazine were still growing at 
the end of the treatment period it is difficult to dis- 
pute the claims that prolactin in the absence of ovarian 
hormones can maintain tumour growth (Kim e Furth, 1960; 
Pearson, Llerena, Llerena, Molina s Butler, 1969). Be- 
cause the tumours were required for in vitro studies at 
the end of the treatment period, it was not possible to 
ascertain whether the tumours in the group of ovari- 
ectomised rats given perphenazine would regressed 
after ovariectomy alone or would have regressed spon- 
taneously in the same period without treatment. These 
two possibilities could have been checked respectively, 
by discontinuing perphenazine treatment or by discontinu- 
ing treatment and grafting in ovaries. Since the pres- 
ent results and those of others (Leung, Sasaki s Leung, 
1975) have demonstrated marked differences in the re- 
quirements of individual tumours for ovarian hormones, 
some of the discordant results which have been presented 
regarding the requirement for ovarian hormones may be 
due to tumour selection. 
It is generally assumed that oestradiol is the 
ovarian hormone required for tumour growth since ovari- 
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ectomy- induced tumour regression is reversed by its ad- 
ministration (Sterental, Dominguez, Weissman E Pearson, 
1963; Dao, 1964; Bradley, Kledzik e Meites, 1976). 
However in the present study it was found that, in in- 
tact rats, perphenazine could reduce plasma oestradiol 
levels to around the limits of sensitivity of the radio - 
immunoassay and yet stimulate tumour growth. As already 
discussed it would be intriguing to know if all methods 
used to achieve prolonged hyperprolactinaemia also block 
oestradiol secretion. This possibility appears to have 
been overlooked in most publications regarding the effect 
of raised plasma prolactin levels on mammary tumour 
growth and indeed it has been suggested, without evidence, 
that prolactin may enhance oestradiol secretion (Cole, 
1974; Welsch s Nagasawa, 1977). In view of the fact, 
that in both intact and ovariectomised rats given per - 
phenazine, plasma prolactin levels were raised equally, 
and plasma oestradiol levels were barely detectable, it 
is necessary to examine the possible reasons for the 
marked difference in tumour growth seen in these two 
groups. 
One possibility is that oestradiol present in the 
plasma of intact rats given perphenazine, although re- 
duced to a level which was difficult to estimate, was 
sufficient to permit a stimulatory action of prolactin 
on tumour growth. A daily dose of oestradiol as low as 
0.01 µg was sufficient to stimulate tumour growth after 
DMBA administration (Huggins, Grand E Brillantes, 1961), 
or to stimulate the growth of regressed tumours in ovari- 
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ectomised- plus- adrenalectomísed rats receiving prolactin 
(Leung, Sasaki e Leung, 1975). This quantity is far be- 
low the daily dose of 3.75 ug considered as appropriate 
replacement therapy in ovariectomised rats (Barnes e 
Eltherington, 1973). 
An alternative possibility is that the other major 
ovarian hormone, progesterone, plays a role in tumour 
growth and may account for the difference between the 
two groups. Although not measured in the present study, 
it has been reported that the progesterone levels in the 
blood of intact female rats 24 hours after the last of 5 
or 6 daily doses of perphenazine (5 mg /kg body weight) 
were significantly elevated compared to those of control 
rats (Chatterton, Chien, Ward s Miller, 1975; Wynn, 
Harris s Chatterton, 1976). Treatment started in oest- 
rus resulted in an 18 -fold increase in plasma progester- 
one levels compa ±ed to a 4 -fold increase when started in 
proestrus. The authors concluded, that the raised pro- 
gesterone levels were due to an increased secretion of 
the steroid from the corpus luteum brought about by the 
luteotrophic action of prolactin (Astwood, 1941; Evans, 
Simpson, Lyons s Turpeinen, 1941; Everett, 1956). From 
these results it is probable that progesterone levels of 
intact rats in the present study were also elevated by 
perphenazine for at least the first half of the treat- 
ment period. 
After ovariectomy progesterone levels fall to about 
one tenth of those in the intact rat (Feder, Resko s Goy, 
1968; Resko, 1969; Piva, Gagliano, Motta e Martini, 1973). 
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The residual levels result from the adrenal production 
of progesterone (Holzbauer, Newport, Birmingham E 
Traihou, 1969; Mann E Barraclough, 1973; Shaikh E 
Shaikh, 1975; Brown, Courtney e Marotta, 1976; Campbell, 
Schwartz e Firlit, 1977), which can be stimulated by 
ACTH and prolactin (Feder E Ruf, 1969; Resko, 1969; 
Pïva, Gagliano, Motta E Martini. 1973). However, the 
degree by which progesterone levels can be stimulated in 
the ovariectomised rat appears to be considerably less 
than in the intact rat. From the evidence available it 
is probable that during perphenazine treatment progest- 
erone levels were considerably higher in intact than in 
ovariectomised rats. 
Although the role of progesterone in the growth of 
established DMBA- induced tumours has received little 
attention there is some evidence that it may have a 
Stimulatory effect. DMBA- induced mammary tumours con- 
tain specific cytoplasmic receptors for progesterone 
(Terenius, 1973; Asselin, Labrie, Kelly, Philibert E 
Raynaud, 1977), the levels of which appear to be under 
the control of oestradiol and prolactin (Kelly, Asselin, 
Labrie e Raynaud, 1977), and are greatly teduced by com- 
bined ovariectomy- plus- adrenalectomy or hypophysectomy 
(Asselin, Melançon, Moachon é Bélanger, 1980). Progest- 
erone has been reported to increase DNA synthesis in 
organ culture of DMBA- induced tumours (Pasteels, Heuson, 
Heuson -Stiennon E Legros, 19 76). Treatment of rats with 
progesterone after DMBA administration has been shown to 
stimulate subsequent mammary tumour development (Huggins, 
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Moon c Morii, 1962; Jabara c Harcourt, 1970; Kelly, 
Asselin, Labrie c Raynaud, 1977). It has been proposed, 
that progesterone exerts its stimulatory effect at tumour 
level (Jabara, Marks, Summers c Anderson, 1979). It has 
also been proposed that progesterone may play an import- 
ant role in regulating the growth of DMBA- induced mam- 
mary tumours, during pseudopregnancy, pregnancy and the 
postpartum period (Dao, 1964; McCormick c Moon, 1965 c 
1967; Leung, 1977). 
Recent reports suggest that progesterone is essen- 
tial in maintaining the growth of the transplantable, 
hormone dependent MTW -9 mammary tumour in rats. The in- 
hibition of the growth of this tumour by prostaglandin 
Fla has been attributed to a fall in progesterone levels 
since progesterone administration restores tumour growth 
(Jubiz, Frailey s Smith, 19 79). Progesterone also pre- 
vents ovariectomy- induced regression of MTW -9 tumours 
grown in rats with elevated prolactin levels induced by 
perphenazine (Diamond, Koprak c Hollander, 1980). 
SThe fact that progesterone secretion is enhanced by 
perphenazine in intact rats and the likelihood that pro- 
gesterone has a stimulatory effect on mammary tumour 
growth raises the possibility that progesterone could 
support the stimulatory effect of prolactin at tumour 
level when oestradiol secretion is reduced in intact 
rats given perphenazine. When progesterone was given to 
ovariectomised rats tumour regression was not prevented 
(Kelly, Asselin, Labrie s Raynaud, 1977), but since pro- 
gesterone does not share the capacity of oestradiol to 
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stimulate prolactin secretion (Chen s Meites, 1970), 
it would be necessary to repeat this study in rats whose 
prolactin levels were maintained artificially. 
Although it is widely accepted that prolactin is 
essential for the growth of the majority of DMBA- induced 
mammary tumours in the rat and that an increase in plasma 
prolactin levels stimulates tumour growth by a direct 
action at tumour level, from the information now avail- 
able two highly speculative propositions may be made con- 
cerning an indirect stimulatory effect of prolactin on 
tumour growth in intact rats. It was suggested above 
that, in place of oestradiol, progesterone may act syn- 
ergistically with prolactin but it is possible that the 
raised plasma progesterone,-levels in hyperprolactinaemic 
rats could have a direct stimulatory effect at tumour 
level and account in part for the increase in tumour 
growth rate attributed to prolactin. In addition, it is 
possible that if the raised plasma levels of oestradiol 
at proestrus in the cycling rat are similar to those 
achieved when tumour growth is inhibited by high doses 
of oestradiol (Huggins e Yang, 1962; Meites, Cassell s 
Clark, 1971), then abolition of the proestrus surge of 
oestradiol in hyperprolactinaemic animals would reduce 
this cyclic inhibitory effect of oestradiol, and thus 
permit faster tumour growth. 
Statistical analysis of the metabolism of testo- 
sterone and its conversion to 5a- dihydrotestosterone 
and 5a- androstanediol by the tumours from the five treat- 
ment groups was performed using variance analysis plus 
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Dunnett's test or Student -Newman -Keuls test. The 
Wilcoxon rank test, which was used to compare results 
from control and perphenazine- treated groups in two 
publications (Buchan, Fraser s Miller, 1976; Buchan c 
Miller, 1978), was inappropriate for the larger number 
of intercomparisons made between the five groups. 
To compare the effects of different treatment 
regimes on a given parameter it is preferable that all 
groups should be alike in every respect at the start 
of treatment. However, on allocation, significant inter- 
group differences occurred in two parameters. It was 
found that, purely by chance, the mean time between 
carcinogen administration and allocation to a treatment 
group was greater in the group of intact rats given per - 
phenazine than in the intact control group and that 
means of initial tumour sizes of both intact rats given 
CB 154 and the ovariectomised control group were greater 
than those of the other groups. This second difference 
was deliberately made in order to obtain sufficient 
tumour mass after treatments which were expected to 
cause tumour regression. Although it is less than ideal 
to have differences between groups before starting treat- 
ment, neither the time between DMBA and start of treat- 
ment nor the size or growth rate of tumours showed any 
correlation with the metabolism of testosterone by tumours 
in any of the five groups. It is therefore assumed that 
the differences in the metabolism of testosterone by 
tumours from the various groups were due to the specific 
treatments and not to these initial differences in age 
and tumour size. 
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The basic observation made was that the in vitro 
metabolism of testosterone by established tumours from 
intact rats given perphenazine for two weeks was higher 
than that of tumours from intact control rats. 5a- 
Reduction, which accounted for most of the testosterone 
metabolism, was also significantly higher in tumours 
from the perphenazine -treated rats, as was the net form- 
ation of the individual metabolites, 5a- dihydrotesto- 
sterone and 5a- androstanediol. These results extend the 
earlier work of Miller (19 76 a), which demonstrated that 
tumours from a group of rats given perphenazine continu- 
ously from 30 days of age exhibited higher 5a- reduction 
of testosterone than those of a control group. From 
that study it was not possible to determine whether the 
treatment acted at the stage of tumour induction to pro- 
mote the development of a tumour with different properties, 
or whether it exerted an effect upon the growing tumour. 
The results of the present study show that it is poss- 
ible to stimulate 5a- reductase activity in established 
tumours. 
Since the present investigation of plasma oestra- 
diol levels and reports in the literature have revealed 
that perphenazine treatment cannot raise plasma pro - 
lactin levels without altering the levels of other 
hormones the increase in 5a- reduction of testosterone by 
tumours from perphenazine- treated rats may have been 
caused by one or more different factors. Testosterone 
metabolism was therefore measured in tumours from rats 
which had undergone other hormonal manipúlations in an 
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attempt to determine which factors may be involved in 
the control of tumour 5a- reductase activity. 
The possibility that perphenazine itself may act 
directly at tumour level to increase 5a- reductase act- 
ivity was not supported by the results from in vitro 
studies in which there was no evidence of a stimulation 
of 5a- reductase activity in tumours incubated in the 
presence of perphenazine. However, this type of study 
is insufficient to discount a direct action of perphena- 
zine on the tumour in vivo and despite the fact that per - 
phenazine is always assumed to act on the mammary gland 
and mammary tumours via an effect on hormonal secretion, 
it is very difficult to eliminate the possibility of the 
drug working directly. It would be informative to 
assess the effect of elevating plasma prolactin by some 
other means, preferably without the use of drugs, on 
tumour 5a- reductase activity. 
The observation that in both intact and ovariecto- 
mised rats the perphenazine- induced elevation of plasma 
prolactin levels was accompanied by an increase in 
tumour 5a- reductase activity compared to the respective 
controls suggests that the two parameters may be pos- 
itively related. The diminished levels of plasma pro - 
lactin and lower levels of testosterone metabolism by 
tumours in ovariectomised controls compared to intact 
controls is in general agreement with such a relation- 
ship. However prolactin levels were similarly reduced 
by the administration of CB 1,54 to intact rats, but 
testosterone metabolism parameters did not differ from 
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those of the control group. Moreover,although per - 
phenazine elevated plasma prolactin levels to the same 
extent in ovariectomised and intact rats the level of 
tumour 5a- reduction was significantly lower in the 
former group. On the basis of these observations the 
differences between tumours of the five treatment groups 
in their ability to metabolise testosterone cannot be 
accounted for solely by differences in plasma prolactin 
levels. It is nevertheless possible to propose a purely 
stimulatory role for prolactin in tumour 5a- reductase 
activity which is dependent on the growth of new tumour 
tissue during the treatment period. 
In other target tissues prolactin appears to have a 
mainly inhibitory effect. The formation of 5a- dihydro- 
testosterone from testosterone by canine prostate was in- 
hibited in dogs given prolactin and stimulated in those 
given CB 154 (Helmerich s Altwein, 1976). However the 
total turnover of testosterone by the prostate was not 
inhibited by prolactin administration. The administra- 
tion of CB 154 to humans also increased the relative 
formation of 5a- dihydrotestosterone from testosterone by 
carcinoma of the prostate but a significant reduction in 
androstanediol formation was also observed (Kurth, 
Jacobi, Sinterhauf s Altwein, 1977). It has been shown, 
that prolactin has an inhibitory effect on the 5a- 
reduction of 4- androstenedione and corticosterone by the 
adrenal cortex (Witorsch e Kitay, 19 70 e 1972; 
Gustafsson e Stenberg, 1975; Witorsch e Edwards, 1976). 
Inhibition of adrenal 5a- reduction of testosterone and 
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4- androstenedione has been reported following prolactin 
administration to male, female and pseudohermaphrodite 
rats (Goldman e Shapiro, 1977). In pregnant rats, 5a- 
reduction of progesterone by the ovary increased when 
ergocornine was administered alone, but not when accom- 
panied by prolactin administration (Zmigrod, Lindner e 
Lamprecht, 19 72). Hypophysectomy decreases, and sub- 
sequent prolactin administration increases, 5a- reduction 
of testosterone by rat liver (Schriefers, Keck, Klein e 
Schroder, 1975). 
When the report that oestradiol administration to 
ovariectomised rats reduced the capacity of DMBA- induced 
tumours to convert testosterone to 5a- dihydrotestosterone 
and 5a- androstanediol (Miller, 1976 c) and the present 
observation that plasma oestradiol levels in intact rats 
were drastically lowered by perphenazine administration 
are considered together, it is possible to postulate, 
that the increased 5a- reduction of testosterone by DMBA- 
induced tumours from intact rats given perphenazine was 
due to the removal of the inhibitory effect of oestra- 
diol. However other intergroup differences cannot be 
attributed to inhibitory effects of oestradiol. Although 
tumour 5a- reductase activity was greater in ovariect- 
omised rats given perphenazine than in ovariectomised 
control rats, there was no difference between the 
extremely low levels of oestradiol in both groups. The 
5a- reduction of testosterone by tumours of the intact, 
CB 154- treated rats was greater than that of the ovari- 
ectomised control group which had, in fact, lower plasma 
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oestradiol levels. Moreover, in the present study, 
tumours from the ovariectomised control group metab- 
olised significantly less testosterone than tumours 
from the intact control group. However, the formation 
of 5a- reduced products was only numerically and not 
significantly lower in the ovariectomised group. The 
results from ovariectomised and intact control groups 
in the present study are at variance with the results 
of Miller (1ß76 c), who found that ovariectomy caused a 
numerical increase in tumour 5a- reduction and a signif- 
icant increase in the formation of 5a- androstanediol. 
The differences between the two sets of results lie 
mainly with the relative amounts of 5a- androstanediol 
formed by tumours from the control groups. The two 
hour incubation period of the earlier study as opposed 
to the one hour incubation period used in the present 
study may have contributed to this difference. So also 
may the fact that all intact control rats in the present 
study were in dioestrus at sacrifice whereas those of 
the earlier study were not killed in any specific stage 
of the cycle. 
Alterations in the levels of circulating oestrogens 
have been reported to affect 5a- reductase activity in 
other tissues. However it is sometimes difficult to 
determine whether the effects observed are due to the 
direct action of oestrogens or due to secondary changes 
in the levels of other hormones such as prolactin. The 
administration of oestrogens to humans, dogs or rats has 
been shown to result in a general inhibition of the net 
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formation of 5a- dihydrotestosterone from testosterone 
by prostatic tissues (Farnsworth, 1970; Griffiths, 
Harper, Groom, Pike, Fahmy e Pierrepoint, 1970; Beiham 
e Neal, 1971; Leav, Morfin, 'fner, Cavazos e Leeds, 
1971; Danutra, Harper e Griffiths, 1973; Fencl e 
Villee, 1ß ?3; Jenkins d McCaffery, 19 74; Yamanaka, 
Shimazaki, Imai, Sugiyama e Shida, 1975). Castration 
was found to stimulate and oestradiol administration to 
inhibit 5a- reductase activity in the rat adrenal whether 
measured using 11- substituted,C -21 precursors (Kitay, 
Coyne e Swygert, 1970), or C -19 precursors (Maynard e 
Cameron, 1973). In male rats, oestrogen administration 
has been reported to stimulate hepatic 5a- reductase act- 
ivity (Schriefers, 1967; Dieringer, Lamartiniere e 
Lucier, 1979), but the higher 5a- reductase activity in 
the liver of female rats was only slightly lowered by 
ovariectomy... and unaffected by the administration of 
oestrogens (Dieringer, Lamartiniere s Lucier, 1979). 
Pituitary hormones appear to be more important than sex 
steroids in the control of hepatic 5a- reductase activity. 
Plasma progesterone levels were not measured during 
these studies since attention was directed towards the 
two main hormones thought to be important for the growth 
of DMBA- induced mammary tumours, prolactin and oestra- 
diol. The probable effects of perphenazine on progest- 
erone levels in intact and ovariectomised rats have al- 
ready been discussed in connection with tumour growth, 
but are also of interest in connection with the results 
of testosterone metabolism by tumours. 
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The increase in plasma progesterone levels induced 
by perphenazine in intact rats (Chatterton, Chien, Ward c 
Miller, 1975; Wynn, Harris e Chatterton, 1976), and the 
decrease following ovariectomy (Feder, Resko e Goy, 1968; 
Resko, 1969; Piva, Gagliano, Motta E Martini, 1973) cor- 
respond with an increase and a decrease respectively in 
the in vitro metabolism of testosterone by tumour 
similarly treated groups in this study. It is probable 
that perphenazine increased plasma progesterone levels in 
ovariectomised rats, as these animals have raised plasma 
prolactin levels, which in turn stimulate the release of 
progesterone from the adrenal (Piva, Gagliano, Motta e 
Martini, 1973). Since most of the progesterone released 
during perphenazine treatment of intact rats appears to 
be of luteal origin (Chatterton, Chien,Ward e Miller, 1974), 
and prolactin only caused a threefold increase in the 
low levels of progesterone in the ovariectomised rats 
(Piva, Gagliano, Motta e Martini, 1973), it is unlikely 
that the progesterone levels in ovariectomised rats 
given perphenazine were elevated to the same extent as 
those in intact rats. If this were the case then pro- 
gesterone levels would again correspond well with the 
5a- reductase activity in tumours from ovariectomised 
rats given perphenazine, which was higher than that of 
tumours from the ovariectomised control group but not as 
high as that in tumours from intact rats given perphena- 
zine. 
The administration of CB 154 in doses similar to 
those used in the present study was found to reduce 
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plasma prolactin levels throughout the cycle and prevent 
pregnancy despite repeated mating ( Wuttke E Döhler, 1973; 
Döhler E Wuttke, 1974). In these rats the peak levels 
of progesterone which occur in proestrus were suppressed 
but the levels at other points in the oestrous cycle re- 
mained fairly constant, at or slightly above those of un- 
treated cycling rats. The apparent ability of CB 154 to 
reduce the cyclic variation of plasma progesterone 
levels without causing much of a change in overall out- 
put may be pertinent to the present discussion since 
mean tumour 5a- reductase activity was similar in control 
and CB 154- treated rats but the variation in 5a- reductase 
levels was markedly less in tumours of the CB 154- treated 
group. 
Therefore, on the basis of these other studies, 
there is a strong possibility that the effect of the 5 
treatment regimes on plasma progesterone levels would 
have paralleled the changes observed in the 5a- reduction 
of testosterone by the tumours in these groups. It 
would have been interesting not only to have compared 
progesterone levels with 5a- reductase activity on a 
group basis, but perhaps also on an individual basis. 
An investigation directed specifically towards examining 
the effects of progesterone on both the growth and 5a- 
reductase activity of DMBA- induced tumours is perhaps 
warranted. 
In the male rat the administration of progestagens 
has been shown to stimulate 5a- reductase in the liver, 
but to be without effect on 5a- reductase of the prostate 
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(Altman, Gordon, Southren, Vittek E Wilker, 1972; Albin, 
Vittek, Gordon, Altman, Olivo e Southren, 19 ?3; Moore 
e Wilson, 1973). 
Testosterone has also been shown to enhance its own 
metabolism in that castration lowers and testosterone ad- 
ministration increases testosterone 5a- reductase activity 
in rat prostate (Shimazaki, Ohki, Matsuoka, Tanaka e Shida, 
1972; Moore a Wilson, 1973; Yamanaka, Kirdani, Saroff, 
Murphy E Sandberg, 1975), and in the coagulating gland 
and seminal vesicles of the mouse (Alison E Wright, 1979). 
Peripheral plasma levels of testosterone in the fe- 
male rat vary with the oestrous cycle from about 80 -90 
pg /ml in oestrus and metoestrus to about 170 -240 pg /ml 
in proestrus (Dupon e Kim, 1973; Rosenfeld, Jones, 
Dupon, Fang E Anderson, 1975; Terranova, Saidapur e 
Greenwald, 1980). Plasma testosterone levels were un- 
altered by adrenalectomy but fell to non -detectable 
levels after ovariectomy (Frankel, Mock, Wright a Kamel, 
1ß75). In agreement with these observations, Terranova, 
Saidapur and Greenwald (1980) have shown that the ovary, 
and in particular corpora lutea, are important in the 
production of both testosterone and its potential pre- 
cursor, 4- androstenedione. However, it has also been 
shown that the adrenal gland of the female rat is cap - 
Able of converting progesterone to testosterone in vitro 
(Vinson, Bell e Whitehouse, 1976). It has been suggested 
that the elevated plasma testosterone levels found in 
pregnant rats were due to a stimulatory effect of pro - 
lactin (Weizenbaum, Adler a Ganjam, 1979). On the basis 
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of these results it is possible that perphenazine, by 
increasing prolactin secretion, may have elevated plasma 
testosterone in intact rats but it is difficult to spec- 
ulate over testosterone levels in ovariectomised rats 
given perphenazine and intact rats given CB 154. How- 
ever it is questionable whether such alterations in 
testosterone levels, if in fact true, could have affected 
5a- reductase activity since the levels of testosterone 
in female rats are relatively low. 
As indicated by the constant dioestrus -type smear 
and other morphological characteristics perphenazine 
treatment appears to inhibit the secretion of gonado- 
trophins in the female rat (Verlardo, 1958; Ben -David, 
1968). Whilst it has been demonstrated that these 
hormones can affect 5a- reductase activity in their class- 
ical target organs (Fblman, Sowell c Eik -Nes, 1972; 
Terakawa, Rondo, Aono, Kurachi E Matsumoto,1978), evidence 
of gonadotrophins having a direct effect on DMBA in duced 
rat mammary tumours appears to be lacking. It has been 
reported that perphenazine does not affect the secretion 
of growth hormone (MacLeod, Fontham c Lehmeyer,1970).. 
Although some evidence for the stimulation of ACTH 
release by phenothiazines has been presented (Smith, 
Maickel e Brodie, 1963), and perphenazine has been re- 
ported to elevate corticosterone levels (Chatterton, 
Chien s Ward, 1974), over short periods of administration, 
others have found no difference in adrenal weight or 
plasma corticosterone levels after more prolonged admin- 
istration of either perphenazine or CB 154 (Cameron e 
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Scarisbrick, 1973). More recently Vasquez and Kitay 
(1978) have shown that although prolactin autlents Stress - 
induced changes in plasma corticosterone levels it has 
no effect on resting levels. 
It is also necessary to consider the possibility, 
that the measurement of 5a- reductase activity was affected 
by the presence of hormones in the tumour after excision. 
The concentrations of hormone present in the DMBA- 
induced mammary tumours after their removal were not 
measured in the present study and there appears to be no 
relevant information available regarding the possible 
effect of these treatment regimes on hormone levels in 
tumours. 
It is possible that hormones present in the tumour 
could have a direct effect on the 5a- reductase enzyme or 
affect NADFH availability by altering the activity of 
endogenous and added glucose -6- phosphate dehydrogenase. 
Several steroids have been shown to reduce glucose -6- 
phosphate dehydrogenase activity in vitro (Raineri E 
Levy, 1970; Benes E Oertel, 1970). 
The in vitro addition of prolactin has been re- 
ported to inhibit 5a- reductase activity in DMBA- induced 
rat mammary tumours (Miller, 1976 d), and in rat and 
guinea -pig prostate (Mawhinney, Belie E Lloyd, 1975; 
Manandhar E Thomas, 1976). There is evidence that in 
several tissues both progesterone and testosterone 
serve as substrates for 5a- reductase and, in common 
with other 4- ene,3- ketosteroids which are unsubstituted 
at the 11- position, competitively inhibit 5a- reductase 
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(Voigt, Fernandez e Hsia, 1970; Frederiksen e Wilson, 
1971; Hsia, 1971; Voigt e Hsia, 1973; Mauvais- Jarvis, 
Kuttenn e Wright, 1975; Patwardhan e Lanthier, 1975; 
Smethurst e Williams, 1975; Saksena, Lau e Chang, 1976; 
Eckstein e Nimrod, 1977; Krauze k Karavolas, 1978). It 
has recently been proposed, on the basis of the close 
similarity between the 5a- reduction of testosterone and 
progesterone, that both are metabolised by the same 
enzyme in DMBA- induced rat mammary tumours.(Mori, 
Tominaga c Tamaoki, 1978; Tamaoki, Mori, Kitamura e 
Tominaga, 1978). However, if the concentrations of 
hormones in DMBA -induced mammary tumours are directly re- 
lated to their plasma levels, it seems unlikely that the 
presence of these hormones in, the excised tumours could 
have accounted for the differences in tumour 5a- reductase 
activity between the groups, since the increase in 5a- 
reductase activity of tumours from perphenazine- treated 
animals was in fact associated with raised plasma levels 
of prolactin and probably also progesterone and testo- 
sterone. 
An inhibitory effect of oestrogens on the 5a- 
reduction of testosterone by human, dog and rat prostate 
in vitro has been described by several workers (Farnsworth, 
1969; Baulieu e Robel, 1970; Belham e Neal, 1971; 
Groom, Harper, Fahmy, Pierrepoint e Griffiths, 1971; 
Jenkins e IVicCaffery, 1974; Patwardhan e Lanthier, 1975; 
Bard s Lasnitzki, 1976 s 1977). Although the concentra- 
tions of oestradiol used in these studies were higher 
than that expected physiologically, Eckstein and Nimrod 
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(1977) have demonstrated the non -competitive inhibition 
of 5a- reductase of the rat ovary with a concentration 
of oestradiol which may be of physiological relevance 
in the ovary. In the DMBA- induced rat mammary tumour, 
oestradiol was also found to have an inhibitory effect 
on 5a- reductase activity in vitro (Miller, 1976 b). 
Despite the fact that differences between the five treat- 
ment groups could not be accounted for by alterations in 
plasma oestradiol levels, two trends were observed which 
indicate that plasma oestradiol levels at sacrifice may 
be inversely related to tumour 5a- reductase levels 
measured in vitro. All r values for the simple co- 
efficient of correlation between plasma oestradiol at 
sacrifice and tumour 5a- reduction in the three groups of 
intact animals and in the cycle study were high and neg- 
ative suggesting a possible inverse relationship between 
the two parameters. Furthermore in the intercomparison 
of groups at different stages of the cycle all but one 
of the tumours from the rats killed in proestrus (the 
stage with the high plasma oestradiol concentrations) 
showed below average 5a- reductase activity. However, 
the difference between the different stages of the cycle 
did not attain significance at the 5% level. Although 
neither of these observations were in themselves stat- 
istically significant, the trend in these results is in 
agreement with the inhibitory effects of oestradiol on 
5a- reductase activity of DMBA- induced mammary tumours in 
vitro (Miller, 1976 b), and also that attributed to oest- 
radiol after its administration in vivo (Miller, 1976 c). 
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When comparing the results of the intact perphenazine- 
treated rats with those of the intact control group it 
could be argued, that the increased metabolism of testo- 
sterone by tumours from the former group simply reflects 
the increased tumour growth rate resulting from hormonal 
changes. The reduced levels of testosterone metabolism 
by tumours from ovariectomised control rats would sup- 
port the argument of tumour growth being related to 
testosterone metabolism. However tumours of both intact 
rats given CB 154 and ovariectomised rats given per - 
phenazine, which were on average regressing at the time 
of sacrifice, showed no difference in their ability to 
metabolise testosterone when compared with the growing 
tumours of the intact control group. Moreover within 
groups there was no obvious correlation between tumour 
size or growth and any of the parameters of testosterone 
metabolism. This observation is of particular signif- 
icance in the group of intact rats given CB 154 and in 
the group of ovariectomised rats given perphenazine, 
since in both of these groups tumour growth ranged from 
rapidly growing to rapidly regressing at the time of 
sacrifice. King, Panattoni, Gordon and Baker (1965) 
were also unable to find a relationship between tumour 
growth and the metabolism of testosterone. The observa- 
tion, that in fast growing tumours of perphenazine- 
treated rats the 5a- reduction of testosterone was in- 
creased whilst the metabolism of DHA. was unaltered 
(Miller, 1976 a), also provides evidence that the in- 
crease in 5a- reductase activity is specific and not just 
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a reflection of a general increase in metabolic activity* 
It may, however, be interesting to compare 5a- reduction 
in growing, static and spontaneously regressing DIVTBA- 
induced tumours of otherwise untreated rats. 
Although there appears to be no direct correlation 
between the growth of a tumour and its ability to metab- 
olise testosterone, this does not dismiss the poss- 
ibility that the growth of new tumour tissue must occur, 
in order that an increase in 5a- reductase due to another 
stimulus may be observed. It was shown that the induc- 
tion of hepatic 5a- reductase by progesterone was due to 
the synthesis of new enzyme protein (Altman, Gordoi., 
Southren, Vittek s Wilker, 1972), and that the rise in 
prostatic 5a- reductase by testosterone coincided with 
maximal increase in RNA and DNA content(Moore s Wilson, 
1973). 
It has been claimed that in cancer of the prostate, 
5a- reductase activity is lower in poorly differentiated 
tissues (Morfin, Charles s Floch, 19 79). In normal and 
benign human prostate 5a- reductase activity resided pre- 
dominantly in stroma with very little in epithelium 
(Cowan, Cowan s Grant, 19 76; Cowan, Cook, Cowan, Grant, 
Sirett s Wallace, 19 79). Possible relationships between 
steroid metabolism and histological features of the DMBA- 
induced mammary tumours were not investigated in this 
study, but the lack of correlation between tumour DNA 
Qäntent and parameters of testosterone metabolism sug- 
gests that the latter are unrelated to cellularity. 
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The effects of 5a- dihydrotestosterone, 5a- androst- 
ane- 3a,17ß -diol and 5a- androstane -3ß,170-diol on the 
size and numbers of growing, static or regressing DMBA- 
induced tumours have been measured and compared with 
those of a control group given only injection vehicle. 
No regressing tumours were present in the control 
group at the pretreatment period, but a significant num- 
ber spontaneously regressed during the study period. 
Overall proportions of growing, static and regressing 
tumours were similar to those reported by Heise and 
Gorlich (1966), Teller, Stock, Stohr, Merker, Kaufman, 
Escher and Bowie (1966), but not to those reported by 
Young, Cowan and Sutherland (1963), who observed a lower 
percentage of growing tumours. 
Both 5a- dihydrotestosterone and 5a- androstane- 3a,17ß- 
diol (1 mg daily over a period of approximately 12 days) 
strongly inhibited tumour growth both in terms of mean 
tumour size and the proportions of growing, static and 
regressing tumours. Over ?5% of the tumours in these 
groups underwent regression. In contrast, 5a- androstane- 
3ß,17ß -diol, administered in the same manner, did not 
cause tumour regression. 
Such effects of these free steroids on the growth 
of DMBA- induced mammary tumours have not been previously 
reported. However, administration of 5a-dihydrotesto- 
sterone, in similar doses but given over a longer period, 
caused regression of transplanted hormone dependent mam- 
mary tumours (Huggins e Mainzer, 1957) and 3 -MC- induced 
rat mammary tumours (Huggins, Briziarelli s Sutton, 1959). 
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About 78% of 3 -MC- induced tumours regressed, a propor- 
tion which is similar to the value found in the present 
study. 
Administration of 5a- androstane- 3a,17P -diol as the 
dipropionate has been reported to inhibit the growth of 
DMBA -induced rat mammary tumours (Griswold, Skipper, 
Laster, Wilcox s Schabel, 1966; Teller, Stock, Stohr, 
Merker, Kaufman, Escher s Bowie, 1966), but no informa- 
tion regarding the effect of 5a- androstane- 30,17ß -diol 
on DMBA- induced rat mammary tumours appears to have been 
published. However in a study of a series of androgens, 
which did not include 5a- androstanediols, Huggins and 
Mainzer (1957) found that, compared with 3a- isomers, 
steroids with 3ß- hydroxyl groups were far weaker in- 
hibitors of the growth of a transplanted mammary fibro- 
adenoma. 
Several groups have reported that doses of testo- 
sterone propionate, similar to those used for its 5a- 
reduced metabolites in this study, had an inhibitory 
effect on the growth of DMBA- induced mammary tumours 
(Griswold, Skipper, Laster, Wilcox s Schabel, 1966; 
Heise e Gorlich, 1966; Teller, Stock, Stohr, Merker, 
Kaufman, Escher s Bowie, 1966; Costlow, Buschow s 
McGuire, 1976). 
In general the cessation of treatment with 5a- 
dihydrotestosterone or 5a- androstane- 3a,17ß -diol halted 
tumour regression, and after a delay growth was obeerved 
in some tumours, although not at the rate displayed by 
the control group. The recovery appeared to be more 
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restricted in the 5a- androstane -3a,17ß -diol- treated 
rats, but the difference between the two groups was 
slight. These findings agree with those of Quadri, 
Kledzik and Meites (1974), who measured tumour size 
over a three week recovery period after the inhibition 
of tumour growth by dromostanolone propionate (2a- methyl- 
17ß- hydroxy -5a- androstan -3 -one propionate). During the 
recovery period some resumption of mammary tumour growth 
was observed but it did not attain that of the control 
rats. In contrast it had previously been found that com- 
plete mammary tumour regrowth had occurred following the 
termination of treatment with doses of oestradiol 
benzoate and ergot drugs which had inhibitory effects on 
tumour growth (Meites, 1972 a s b). The conclusion 
reached was that the difference in recovery could be due 
to differences in the mechanism action of the three 
agents or to dosage effects. 
In addition to tumour size two other parameters 
were measured in the androgen -treated rats. The oest- 
rous cycle was assessed from daily vaginal smears and 
plasma prolactin was assayed in blood samples taken be- 
fore and at the end of treatment and at the end of the 
recovery period. 
5a- Dihydrotestosterone and 5a-androstane-3a,17ß- 
diol, both of which induced extensive tumour regression, 
also arrested the oestrous cycle as indicated by the per- 
sistent dioestrus- pattern of vaginal smears. On average 
there was a delay of about six days after the cessation 
of treatment before cycling resumed. The oestrous cycle 
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appeared to be unaffected by 5a- androstane- 35,17ß -diol 
treatment which did not induce tumour regression. 
Plasma prolactin levels in the non -cycling rats 
treated with 5a- dihydrotestosterone and 5a- androstane- 
3a,17ß -diol were similar to those obtained in cycling 
control rats in the dioestrus stage of the cycle. How- 
ever it has been shown that plasma prolactin levels in 
cycling rats are much lower in dioestrus, than during 
the oestradiol- induced surge of prolactin in proestrus 
(Neill, Freeman s Tillson, 1971; Butcher, Collins s 
Fugo, 1974). If, in comparison, the plasma prolactin 
levels remained constant in the non -cycling rats and 
the value obtained at the end of treatment was rep- 
resentative of the levels throughout the treatment 
period, then this result implies that the net output 
of prolactin was in fact considerably lower in the non - 
cycling rats of the 5a- dihydrotestosterone - and 5a- 
androstane- 3a,175-diol- treated groups than in the 
cycling rats of the control group. 
In other situations where constant dioestrus smears 
are exhibited such as ovariectomy, perphenazine admin- 
istration (this thesis), and pseudopregnancy (Welschen, 
Osman, Dullart, de Greef, Uilenbroek1c de Jong, 1975), 
plasma oestradiol levels are extremely low. Indeed, the 
fact that very small amounts of oestradiol are required 
to break the constant dioestrus pattern in ovariectomised 
rodents has been used as a highly sensitive and specific 
bioassay for oestrogens (Allen s Doisy, 1923; Emmens, 
1962). Furthermore androgen treatment has been shown to 
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induce atrophy of the ovary which was associated with a 
pattern of vaginal smears whose description resembled 
that of constant dioestrus (McEuen, Selye E Collip, 1937; 
Huggins E Mainzer, 1957). These effects are probably 
attributable to the ability of androgens to block gonado- 
trophin release from the anterior pituitary (Beyer, 
Jaffe E Gay, 1972; Swerdloff, Grover, Jacobs E Bain, 
1973; Zanisi, Motta E Martini, 1973; Döhler, Wong, von 
zur MUhlen E Döhler, 19 77). 
In view of these observations it seems probable 
that treatment with 5a- dihydrotestosterone and 5a- 
androstane- 3a,17ß -diol but not with 5a- androstane- 30,17ß- 
diol resulted in an inhibition of the cyclic release of 
oestradiol by the ovaries. Since oestradiol is the 
usual physiological stimulus for prolactin release in 
the rat (Neill,, Freeman s Til.lson, 1971), it is likely 
that the cyclic release of prolactin was also inhibited. 
Such a situation would account for plasma prolactin 
levels in the 5a- dihydrotestosterone - and 5a- androstane- 
diol- treated rats similar to the low levels found in the 
dioestrus stage of normal cycling rats. As has already 
been discussed, both prolactin and oestradiol appear to 
be important in maintaining the growth of DMBAtinduced 
mammary tumours. The possibility, therefore, arises 
that a reduction in the levels of these hormones may 
play a role in tumour regression induced by 5a- dihydro- 
testosterone and 5a- androstane -3a,175-diol. The finding 
that 5a- androstane -30,17ß -diol did not apparently in- 
hibit the hormonal changes of the oestrous cycle and did 
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not induce significant tumour regression is in keeping 
with this hypothesis. 
Although the inhibitory effects of androgens on 
the growth of DMBA- induced mammary tumours in the rat 
may be accounted for simply on the basis of alterations 
in the circulating levels of hormones, a direct effect 
at tumour level cannot be dismissed. In fact most 
results appear to have been interpreted on the basis of 
androgens acting directly on the tumour. From the ob- 
servation that concommitant prolactin administration 
completely abolished the inhibitory effects of dromo- 
stanolone propionate on the growth of DMBA- induced mam- 
mary tumours, it was concluded that the androgen acted, 
by blocking the stimulatory effects of prolactin at 
tumour level (Quadri, Kledzik e Meites, 1974). This 
conclusion stimulated a study of the effect of androgen - 
induced tumour regression on prolactin receptor levels, 
in which it was found that, although the quantity of pro - 
lactin receptors was reduced in most tumours by androgen 
treatment, the reduction was insufficient to account for 
the androgen -induced tumour regression (Costlow, Buschow 
s McGuire, 1976). 
That androgen -induced tumour regression may be med- 
iated via a reduction in plasma levels of prolactin ap- 
pears to have been overlooked by these workers, on the 
basis of observations that in male rats testosterone 
could produce small increments in prolactin secretion in 
vivo ( Meites s Clemens, 1972; Kalra, Fawcett, Krulich e 
McCann, 1973; Shin., Akin, Roberts s Howitt, 1974). 
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This effect has been attributed to the conversion of 
testosterone to oestradiol, which is a more potent stimu- 
lator of prolactin secretion (Herbert, Cisneros a Rennels, 
1977; Nolin, Campbell, Nansel e Bogdanove, 1977; Döhler, 
Wong e von zur Mühlen, 1978). If this were the case, 
then the results obtained with testosterone could not be 
extrapolated to androgens, such as the 5a- reduced C -19 
steroids, which are i 9apable of forming oestradiol. 
Moreover in the castrated female rat no elevation of 
plasma prolactin was detected after the administration 
of a range of doses of testosterone and 5a-dihydrotesto- 
sterone (Döhler, Wong s von zur Mühlen, 1978). It seems 
likely that, in female rats, an inhibition of the ovar- 
ian release of oestradiol would have an overriding 
effect and cause an overall decrease in prolactin se- 
cretion. It is, therefore, possible that prolactin re- 
versed the androgen -induced tumour regression (Quadri, 
Kledzik e Meites, 1974), by restoring plasma prolactin 
levels, which had been lowered as a result of a decrease 
in oestradiol secretion. It is possible also that the 
diminished prolactin receptor levels in tumours of 
androgen -treated rats reported by Costlow, Buschow and 
McGuire (1976) were in part due to decreased plasma 
levels of oestradiol and prolactin. Both of these 
hormones have been associated with a stimulation in the 
levels of prolactin receptor in other tissues (Posner, 
Kelly s Friesen, 1974 e 1975; Gelato, Marshall, Boudreau, 
Bruni, Campbell s Meites, 1975; Costlow, Buschow e 
McGuire, 1975; Kelly, Posner e Friesen, 1976; Hammond 
e Krall, 1979). 
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In so far as receptor sites which specifically 
bind 5a- dihydrotestosterone have recently been charac- 
terised in the cytosol from DMBA- induced tumours (Ip, 
Milholland, Kim e Rosen, 1978; Asselin, Melançon, 
Moachon e Bglanger, 1980), it seems probable that andro- 
gens can act directly at tumour level. These receptors 
have a high affinity and low capacity for binding 5a- 
dihydrotestosterone and resemble those identified in 
classical androgen target tissues. In common with other 
tissues which possess specific receptors for 5a- dihydro- 
testosterone the DMBA- induced mammary tumour also has a 
large capacity for the conversion of testosterone to 5a- 
dihydrotestosterone (Gloyna e Wilson, 1970). However in 
these tissues the interaction between 5a- dihydrotesto- 
sterone and its specific receptors leads to a stimula- 
tion of growth. It remains to be seen whether the spec- 
ific 5a- dihydrotestosterone receptors found in DMBA- 
induced rat mammary tumours mediate the inhibitory effects 
of pharmacological doses of androgen on tumour growth. 
It may be more relevant that androgens have been 
shown to bind to oestrogen receptors which are present 
in substantial concentrations in most DMBA- induced tumours 
(Powell- Jones, Davies, Wilson e Griffiths, 1976; Garcia 
e Rochefort, 1978). Androgens can induce nuclear trans - 
location of the oestrogen receptor complex and the init- 
iation of certain post -transcriptional events character- 
istic of receptor binding with oestradiol or synthetic 
anti -oestrogens (Garcia e Rochefort, 1978; Nicholson, 
Davies e Griffiths, 1978). Although androgens exhibit a 
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lower affinity for oestrogen receptors than does oestra- 
diol itself it must be taken into account that androgens 
are given in milligram quantities to ellicit tumour re- 
sponses whereas only microgram quantities of oestradiol 
are required to reverse ovariectomy- induced tumour re- 
gression. The relationship between the competitive bind- 
ing of androgens to oestradiol receptors and their ant- 
agonistic and possibly agonistic properties, relative to 
oestrogen action, however requires further elucidation 
(Rochefort, Capony s Garcia, 1979). 
It is interesting to note that of the steroids 
tested 5a- androstane- 3ß,17ß -diol, in common with another 
3ß,17ß- hydroxylated steroid, androst- 5 -ene- 30,17ß -diol, 
showed a much greater affinity towards the oestrogen re- 
ceptor than other C -19 steroids (Davies, Powell- Jones, 
Nicholson s Griffiths, 1977; Rochefort, Capony s Garcia, 
1979). The present finding that, in comparison with the 
other two 5a- reduced steroids, 5a- androstane- 30,17ß -diol 
was ineffective in causing tumour regression does not 
lend support to the theory that androgens inhibit the 
growth of DMBA- induced rat mammary tumours by directly 
binding to oestrogen receptors (Ip, Milholland, Kim s 
Rosen, 1978; Nicholson, Davies s Griffiths, 1978). 
This observation has the reservations that 5a- androstane - 
30,17ß -diol was only tested at one dose and that its 
distribution and metabolism are largely unknowns 
A striking feature of the present results was the 
difference in activity between the two isomers of 5a- 
androstanediol which differ only in the orientation of 
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the hydroxyl group at the 3- position. The 3a- isomer 
arrested the oestrous cycle and caused rapid tumour 
regression, whereas the corresponding 35- hydroxysteroid, 
given at the sane dose, was without significant effect 
on either parameter. A similar phenomenon was observed 
with the transplanted mammary fibroadenoma model where 
different series of steroids with 3 -keto and 3a- hydroxyl 
groups showed a much greater ability to induce regres- 
sion of both mammary tumours and ovaries than their 304- 
hydroxylated counterparts (Huggins E Mainzer, 1957). 
Certain features of the metabolism of 5a- reduced 
steroids may have a bearing on the differences observed. 
5a- Dihydrotestosterone is metabolised to 5a- androstane- 
3a,175-diol in preference to the 35- isomer by most tissues 
and it has been shown that the former conversion but not 
the latter is readily reversible in 
pituitary (Baulieu, Le Goascogne, Groyer, Feyel -Cabanes 
s Rebel, 1975; Pïlven, Thieulant, Ducouret, Sampérez E 
Jouan, 1976; Plasse, Revel E Lisboa, 1977). The results 
of the time -course studies in this thesis suggest that 
this pattern of metabolism also occurs in the DMBA- induced 
mammary tumour. If the female rat pituitary and.DMBA- 
induced mammary tumour are capable of interconverting 5a- 
dihydrotestosterone and 5a- androstane- 3a,173 -diol but in- 
capable of transforming 5a- androstane -35,17R -diol to 
either of the former steroids, it is possible that the 
3a- hydroxylated, but not the 35- hydroxylated, steroid 
could exert its action at pituitary or tumour level via 
the production of 5a- dihydrotestosterone. This assumes 
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that 5a- dihydrotestosterone is the active form required, 
but the same argument would hold if in fact 5a- androstane- 
3a,170-diol is the ultimately active steroid. 
The relative importance of direct and indirect 
effects in androgen -induced inhibition of tumour growth 
could be largely answered by administering a series of 
androgens over a range of doses to tumour -bearing rats, 
in which tumour growth rate could be related to changes 
in plasma levels of prolactin and ovarian hormones through- 
out treatment and recovery periods. 
Based on the observations that androgens cause re- 
gression of DMBA- induced mammary tumours (Heise E Gorlich, 
1966), and that these tumours contain 5a- reductase (King, 
Gordon E Helfenstein, 1964; Miller, Forrest E Hamilton, 
1974), an enzyme which is implicated in the expression 
of many of the effects of testosterone on its target 
tissues (King E Mainwaring, 1974), it was hypothesised 
that the levels of tumour 5a- reductase activity might in- 
fluence mammary tumour growth by controlling the conver- 
sion of testosterone to its active metabolites capable 
of inhibiting mammary tumour growth. To test this hypo- 
thesis, and to examine the possibility that some of the 
effects of hormones on tumour growth might be mediated 
by alterations in tumour 5a- reductase activity, tumour 
growth and 5a- reductase activity were measured in rats 
subjected to different hormonal manipulations. Accord- 
ing to the hypothesis, it was expected that 5a- reductase 
activity should decrease in tumours whose growth was 
stimulated and should increase in regressing tumours. 
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With the assumption that the relative capacities of 
tumours to perform 5a- reduction in vitro reflected the 
relative rate of formation of 5a- reduced products in 
vivo, the changes observed in 5a- reductase activity 
were the opposite of what was predicted - namely that 
the faster growing tumours of perphenazine- treated animals 
in fact exhibited higher 5a- reductase activity than 
control tumours. It is therefore necessary to examine 
the basis of the hypothesis in more depth and to examine 
the strength of the relationship between in vitro and in 
vivo 5a- teductase activity. 
Although the observations of androgen- induced tumour 
regression and the presence of tumour 5a- reductase are 
without dispute and were readily confirmed in the pres- 
ent studies, the following fundamental assumptions must 
also hold for the validity of the hypothesis that tumour 
5a- reductase activity influences tumour growth by the 
local conversion of testosterone to its 5a- reduced metab- 
olites. 
1. The ability of testosterone to inhibit mammary 
tumour growth is mediated by its conversion to 
5a- reduced products at tumour level. 
2. In the female rat there are sufficient levels 
of testosterone or other androgenic precursors 
available which, after local 5a- reduction, could 
induce tumour regression. 
3. The critical factor controlling the action of 
testosterone at tumour level is 5a- reductase 
activity and not substrate availability or re- 
ceptor protein concentration. 
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With regard to the first assumption the present 
studies have illustrated that the two major 5a- reduced 
products of testosterone metabolism by DMBA- induced 
mammary tumours, 5a- dihydrotestosterone and 5a- androst- 
ane- 3a,17ß -diol, are very effective inhibitors of mam- 
mary tumour growth. Whilst this demonstrates the capa- 
bility of 5a- reduced metabolites to induce tumour re- 
gression, it has yet to be proven that 5a- reduction of 
testosterone is obligatory for tumour regression and 
that 5m-reduced metabolites formed at other sites do 
not play a role in tumour regression. Furthermore the 
results of the present study have raised the possibility 
that androgen -induced tumour regression may be due, at 
least in part, to a reduction in the secretion of both 
oestradiol and prolactin. Until it can be conclusively 
demonstrated that androgens can induce tumour regression 
without altering the levels of other hormones, the first 
assumption cannot be made. 
The second assumption is basically concerned with 
the comparison between the levels of androgen precursor 
in the normal female rat and the levels achieved follow- 
ing the administration of a minimally effective dose of 
androgen. In the normal female rat peripheral plasma 
levels of testosterone vary from about 80 -90 pg /ml in 
oestrus and metoestrus to about 170 -240 pg /ml in proest- 
rus (Dupon E Kim, 1973; Rosenfeld, Jones, Dupon, Fang s 
Anderson, 1ß75; Terranova, Saidapur s Greenwald, 1980). 
Dupon and Kim (1973) reported that plasma levels of 4- 
androstenedione, a potential precursor of testosterone, 
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were similar or slightly above those of testosterone 
throughout the cycle, whereas Terranova, Saidapur and 
Greenwald (1980) found higher peak levels of 1.4 ng /ml 
in proestrus. DHA and its sulphate are present only 
in low concentrations in the circulation of the rat 
(Cutler, Glenn, Bush, Hodgen, Graham s Loriaux, 1978). 
The milligram quantities of androgen which require to 
be administered to observe tumour regression (Huggins, 
Briziarelli s Sutton, 1959; Griswold, Skipper, Laster, 
Wilcox s Schabel, 1966; Heise s Gorlich, 1966) will al- 
most certainly have resulted in far higher levels of 
androgen than those found in the normal rat. However, 
there appears to be no data on the critical blood levels 
of androgen required for inhibition of tumour growth. 
Although the rat prostate and the DMBA :induced rat 
mammary tumour show opposite responses to androgen treat- 
ment it is useful to draw an analogy between the two for 
consideration of the third assumption. On the basis of 
the high levels of 5a- reductase activity and co- factor 
availability in the rat prostate and the plasma levels 
of testosterone (2 -5.5 ng /ml) in the male rat (Corpgchot, 
Eychenne s Robel, 1977), it was reasoned that the avail- 
ability of testosterone in the cell and not the level of 
5a- reductase activity was critical for the expression of 
androgenic effects of testosterone on the prostate 
(Frederiksen s Wilson, 1971). Incubation of testosterone 
with homogenates of DMBA- induced mammary tumour under 
the standard conditions of the present study resulted on 
average in a little less than half of the precursor 
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undergoing 5a- reduction. This represents an enzyme 
activity of approximately 350 ng /0.5 g homogenate /hour, 
which is approximately equivalent to 250 pmoles /100 mg 
homogenate /hour. This value, which is an underestimaté 
of the initial rate of reaction, is approximately half 
that quoted for the rat prostate, is similar to that of 
the rat epidiis and is higher than that of homogenates 
from a variety of other tissues (Gloyna s Wilson, 1969). 
In view of the extent of 5a- reduction by the tumour in- 
cubated without the addition of an NADPH -generating sys- 
tem and the demonstration in RIBA- induced mammary tumours 
of enzymes required for NADPH production (Hilf, Goldenberg, 
Gruenstein, Meranze s Shimkin, 1970; Cohen s Hilf, 1974), 
it seems likely that endogenous co- factors are also 
readily available in the DMBA- induced mammary tumour. 
Plasma levels of testosterone in female rats (80 -240 pg /ml) 
are much lower than those given above for the male rat 
( Dupon s Kim, 1973; Rosenfeld, Jones, Dupon, Fang c 
Anderson, 1975; Terranova, Saidapur c Greenwald, 1980). 
Although there is insufficient information available to 
draw comparisons between the uptake and concentrations 
of testosterone in the two tissues it would appear that 
the total 5a- reductase capacity of the DMBA- induced mam- 
mary tumour is excessive in comparison with the quantity 
of testosterone available for metabolism. 
However, as mentioned earlier, progesterone and 
testosterone serve as common substrates, and compete for 
metabolism by 5a- reductase in several tissues (Frederiksen 
s Wilson, 1971; Hsia, 1971; Saksena, Lau s Chang, 1976; 
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Eckstein E Nimrod, 1977), including the D12BA- induced 
mammary tumour (Mori, Tominaga E Tamaoki, 1978; Tamaoki, 
Mori, Kitamura E Tominaga, 1978). Moreover it has been 
reported that the enzyme has a preference for progest- 
erone over testosterone (Frederiksen E Wilson, 1971; 
Eckstein E Nimrod, 1977; Mori, Tominaga g Tamaoki, 1978). 
In the female rat, progesterone levels which vary from 
about 10 -50 ng /vYtl (Piva, Gagliano, Motta E Martini, 
1973; Shaikh E Shaikh, 1975; Brown, Courtney E Marotta, 
1976; Miller E Riegle, 1980) are at least 100 times 
those of testosterone quoted above. The relative con- 
centrations of testosterone and progesterone in the 
tumour, which are more pertinent to the discussion, can- 
not be extrapolated from plasma levels because the two 
steroids may differ in their binding to carrier proteins 
in blood and in their rate of uptake into the tumour. 
Nevertheless, the extent of the difference between 
plasma levels of testosterone, the likelihood that pro- 
gesterone will be readily taken up into the tumour (pro- 
gesterone receptor levels are high in the cytoplasm of 
DMBA- induced mammary tumour (Asselin, Melançon, Moachon 
E Bélanger, 1980), and the concentration of progest- 
erone in normal rat mammary gland was reported to be 
approximately 20 times greater than the corresponding 
serum concentrations (Wynn, Harris E Chatterton, 1976)), 
and the preference of 5a- reductase for progesterone, 
suggest that only a fraction of the 5a- reductase capac- 
ity measured in vitro is available for the 5a- reduction 
of testosterone in vivo. From the data presently avail- 
D- 6 4 
able it is not possible to determine the extent of the 
limitations, if any, imposed by progesterone on the 5a- 
reduction of testosterone available to the tumour in vivo. 
Several imponderable factors surround any discussion 
of the adequacy of receptor levels for mediating androgen - 
induced tumour regression. Although the degree of 5a- 
dihydrotestosterone binding to cytoplasmic receptor pro- 
tein of DMBA- induced mammary tumours is lower than that 
of other steroids (Asselin, Melanion, Moachon c Bglanger, 
1980), it is not known whether androgen -induced tumour 
regression is mediated by attachment to this receptor or 
to another, such as the oestradiol receptor; nor is any- 
thing known about the degree of binding required for 
such an effect. More importantly, it has yet to be con - 
elusively demonstrated that androgen -induced tumour re- 
gression is, in fact, mediated by attachment to any 
form of receptor in the DMBA- induced mammary tumour. 
If the assumptions listed above were valid and 5a- 
reduction of testosterone by tumours played a regula- 
tory role in tumour growth certain relationships should 
naturally follow. The level of 5a- reductase activity 
should be directly related to androgen sensitivity and 
inNev --s e-ly related to tumour growth and inhibitors 
of 5a- reductase should stimulate tumour growth. The 
relationship between 5a- reductase activity and androgen 
sensitivity was not included in the present study. How- 
ever, although perhaps not directly comparable, the 
hormone independent transplantable mammary tumour TG 5, 
derived originally from a DMBA- induced tumour, shows 
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extremely high 5a- reductase activity (Miller, Stewart s 
Hawkins, 1979), but appears to be unresponsive to either 
testosterone or 5a- dihydrotestosterone (Appendix II). 
It was found that in transplantable mouse mammary tumours, 
androgen dependency is more closely related to the cap- 
acity for androgen binding in the cytoplasm, than to 
tumour 5a- reductase activity (Yamaguchi, Kasai, Minesita, 
Kotoh e Matsumoto, 1974). No relationship between 5a- 
reductase activity and rate of tumour growth was observed 
in any of the five treatment groups or in untreated rats 
killed at different stages of the oestrous cycle. The 
effect of inhibitors of 5a- reductase on the growth of 
DMBA- induced mammary tumours does not appear to have 
been studied. In such a study the effect of 5a- reductase 
inhibition in tissues other than the DMBA- induced tumour 
would have to be considered. 
Taken as a whole it is apparent that much more in- 
formation is required, in order to determine if the 5a- 
reduction of testosterone by DMBA -induced mammary tumours 
is important in relation to tumour growth. In particular 
three fundamental questions require to be answered: - 
Are androgen levels in the female rat sufficient, if con- 
verted to an active form, to induce tumour regression? 
What is the rate of 5a- reduction of testosterone by the 
tumour in vivo in relation to blood and tissue levels? 
How do androgens exert their inhibitory effect on tumour 
growth? 
With regard to in vitro measurements of 5a- reductase 
activity as a reflection of the relative levels of 5a- 
D-66 
reduction occurring in vivo certain reservations must 
be made. If co- factor availability restricts 5a- reduct- 
ase activity in vivo, then alterations in the production 
of co- factors would alter 5a- reductase activity in vivo, 
without necessarily affecting the in vitro measurement 
of 5a- reductase activity in the presence of an added 
NADRH- generating system. Ovariectomy has been reported 
to decrease, and the administration of oestradiol or pro - 
lactin to increase, tae activity of glucose -6- phosphate 
dehydrogenase which converts NADP} to NADFH (Dao, 1964; 
Lerner, 1964; Wiest E Kidwell, 1969; Hilf, McDonald, 
Sartini, Rector E Richards, 1972). 
It is possible that without altering 5a- reductase 
activity the 5a- reduction of testosterone may be spec- 
ifically affected by alterations in its access to the 
enzyme. It has been shown that prolactin can stimulate 
the uptake of testosterone into accessory sex glands 
(Grayhack E Lebovitz, 1967; Resnick, Walvoord E Grayhack, 
1974), and progesterone may compete with testosterone 
for cellular uptake mechanisms (Orestano, Altwein, 
Knapstein E Bandhauer, 1975; Smethurst E Williams, 1975). 
As already mentioned progesterone can also inhibit the 
access of testosterone to 5a- reductase by direct compet- 
ition for the enzyme. 
These effects on 5a- reductase activity and on the 
5a- reduction of testosterone in particular occur through 
hormonal changes and therefore, if occurring also in the 
DMBA- induced tumour, may have been more marked in one 
treatment regime than in another. However the method used 
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to measure 5a- reductase activity capacity in vitro would 
probably obscure such changes. It is plausible that al- 
though the total capacity for 5a- reduction was higher in 
tumours from perphenazine -treated rats the net 5a- 
reduction of testosterone in vivo was lower because of 
increased competition for uptake and metabolism from 
raised levels of progesterone in the circulation in 
these animals. It has been suggested that in the rat 
ovary high local concentrations of progesterone and 20a- 
hydroxy-4- pregnene -3 -one may protect against the metab- 
olism of testosterone and 4- androstenedione (Koninckx, 
Verhoeven, Heyns s de Moor, 1979). 
The possibility of progesterone involvement in the 
control of 5a- reductase activity in the DMBA- induced rat 
mammary tumour has already been discussed. If progest- 
erone does, in fact, increase 5a- reductase, activity and 
is the major substrate for the enzyme, it might be worth- 
while investigating whether the enzyme level is controlled 
by a form of substrate induction. 
No information could be found regarding the effect 
of 5a- reduced metabolites of progesterone on DMBA- induced 
mammary tumours. Although it is generally considered 
that, for progestational activity, progesterone itself 
is in a biologically active form (Wiest, 1971), 5a- 
reduced metabolites have been reported to bind to pro- 
gesterone receptors (Pollow, labbert, Boquoi, Kreuzer c 
Pollow, 1975; Coty, Schroder s O'Malley, 1979), and 
have been implicated in some of the biological actions 
of progesterone (Armstrong s King, 1971). 
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When this thesis was begun there were already 
several reports in the literature concerning factors 
which play a regulatory role in the induction of rat 
mammary tumours by DMBA. Factors studied included 
hormonal manipulation, age at DMBA administration and 
strain difference (Welsch s Nagasawa, 1ß77). However, 
no report appeared to have been published on factors 
which might be associated with tumour incidence within a 
colony of untreated rats, all given DMBA at a similar 
age. It was therefore proposed that in addition to the 
main study, the stage of oestrous cycle and plasma pro - 
lactin levels at the time of DMBA administration should 
be recorded and related to subsequent tumour incidence. 
Because this study was of secondary importance and the 
tumours developed were required for other purposes, cert- 
ain limitations had to be imposed on the measurements 
taken. The stage of the oestrous cycle was assessed 
from a single vaginal smear and because several rats 
were given DMBA consecutively stress- induced alterations 
in prolactin may have occurred. The only tumour para- 
meter which could be measured was the presence or ab- 
sence of tumours within 120 days of DMBA administration. 
Since it is possible for first tumours to arise beyond 
this period, this measurement can be considered as a com- 
bination of incidence and latency. Although not all of 
the tumours recorded were examined histologically, it has 
been reported that non -adenocarcinomatous tumours, such 
as fibroadenomas and nodular adenoses, have a long latent 
period and are not usually seen within the observation 
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period used in this study (Gruenstein, Meranze, Thatcher 
s Shimkin, 1966). This agrees with the findings in the 
tumours which were examined histologically, namely, that 
nearly all tumours were classified as adenocarcinoma. 
One strong point of the study was the large number of 
animals included. 
Two significant observations were made. The first 
was that the distribution of rats over the different 
stages of the cycle at the time of DIVIBA administration 
was different between those which subsequently bore 
tumours and those which did not. This difference was 
due to the number of tumour -bearing rats being lower 
than expected in the group which was in dioestrus at the 
time of carcinogen administration and being higher than 
expected in the group which was in proestrus. The second 
observation was that tumour- bearing rats had higher 
levels of plasma prolactin at the time of DIVIBA administ- 
ration. 
As reviewed in the INTRODUCTION the common link 
between factors which affect tumour induction appears to 
be the rate of DNA synthesis in the mammary gland at the 
time of DMBA administration. The susceptibility of the 
mammary gland to carcinogenic attack is greatest when 
DNA synthesis is highest (Nagasawa s Yanai, 1974; Janss 
s Hadaway, 1977), and in particular during the period of 
differentiation of terminal end buds, the structures 
from which the tumours arise (Russo 6 Russo, 1978 b). 
In rats of 50 days of age, overall DNA synthesis in the 
mammary gland was found to be fourfold higher in proestrus 
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than in dioestrus (Nagasawa, Yanai E Taniguchi, 1976), 
and it was recently stated that DNA synthesis in the 
terminal end bud structures of 55- day -old rats was high 
in proestrus and early oestrus and low in dioestrus 
(Dulbecco, 1980). 
Since the stages of the oestrous cycle in which 
high and low DNA synthesis occurs are the stages in 
which DMBA administration resulted in a high and low 
tumour incidence respectively it is tempting to conclude 
that the two factors are related. This conclusion is 
only valid if the initial step in the carcinogenic act- 
ion of DMBA occurs shortly after it is administered. 
Indeed it has been demonstrated that peak levels of DMBA 
were found in the mammary gland 6 -16 hours after intra- 
gastric administration (Gammal, Carroll, Muhlstock c 
Plunkett, 1965; Wieder, Thatcher e Shimkin, 1967), and 
that 16 hours after feeding 3H -DMBA a high amount of 
radioactivity was bound to DNA of parenchymal cells of 
the mammary gland (Janss, Moon c Irving, 1971). When 
pieces of mammary gland were transplanted from rats 
given DMBA to untreated recipients, tumour incidence was 
highest in the grafts removed when DMBA content was high- 
est (Dao, King c Gawlak, 1968). 
However the clearance of DMBA or its metabolites 
from the mammary gland is slow and trace amounts remain 
in the tissue several days after administration (Wieder, 
Thatcher e Shimkin, 1967; Dao, King e Gawlak, 1968). 
The compound N- nitroso -N- methylurea, which has recently 
been reported to induce breast cancer in rats in a sim- 
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ilar manner to DMBA, but which can only be detected 
in mammary tissue for a short time after its administra- 
tion, may offer a superior approach to this question of 
the variation in susceptibility to carcinogenesis through- 
out the oestrous cycle (Gullino, Pettigrew s Grantham, 
1975). 
While these data were being collected a report on 
the same subject was published in which DMBA was given 
to 37 rats in proestrus and 27 rats in dioestrus (Nagasawa, 
Yanai s Taniguchi, 1976). Over a follow -up period of 26 
weeks no significant difference in the mammary tumour in- 
cidence between the two groups was found b,xt the percent- 
age of progressive tumours, growth rate and the number 
and the weight of tumours per tumour- bearing rat were 
significantly higher in those given DMBA at proestrus 
than in animals given it at dioestrus. The lack of 
noticeable effect on incidence is not surprising since 
it was extremely high, between 95 and 100/ in both groups. 
Despite the differences between the study of Nagasawa, 
Yanai and Tanaguchi (1976) and the one presented in this 
thesis both arrive at the same conclusion, that the sus- 
ceptibility of the mammary gland to the carcinogénic 
effects of DMBA is greater when the carcinogen is given 
in proestrus than when given in dioestrus. 
Irrespective of the stage of oestrous cycle, the 
levels of plasma prolactin were higher in rats which sub- 
sequently developed tumours than in those which did not. 
It has been reported that 'normal' prolactin levels are 
required at the time of DMBA administration for the 
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development of tumours (Nagasawa, Chen E Meites, 1973), 
and that a reduction in plasma prolactin levels by hypophys- 
ectomy (Huggins, Grand E Brillantes, 1959), and by ergot 
alkaloids (Clemens E Shaar, 1972; Nagasawa, Yanai E 
Taniguchi, 1976) led to a decreased incidence of mammary 
tumours. Plasma prolactin levels have also been found to 
be lower in strains of rats which have a lower tumour in- 
cidence (Boyns, Buchan, Cole, Forrest E Griffiths, 1973; 
Hawkins, Drewitt, Freedman, Killen, Jenner E Cameron, 1976). 
(The difference in incidence between strains could how- 
ever be due to the levels of plasma prolactin being too 
low to support tumour growth. It would be interesting 
to artificially raise plasma prolactin before and /or 
after DMBA administration in a strain exhibiting abnorm- 
ally low tumour response to carcinogens.) However the 
present report appears to be the first to indicate that 
within a single colony of unmanipulated rats tumour in- 
cidence is related to plasma prolactin levels at the 
time of DMBA administration. 
Both in vivo and in vitro studies have shown that 
prolactin plays an important role in the development of 
the mammary gland and that it has a stimulatory effect 
on the role of DNA synthesis by this tissue (Lyons, Li E 
Johnson, 1958; Meites E Nicoll, 1966; Dilley, 1971; 
Hallowes, Wang E Lewis, 1973; Stoudemire, Stumpf E Sar, 
1975). It is possible therefore that the rats which 
bore tumours were more susceptible to a carcinogenic 
attack than their non -tumour- bearing counterparts be- 
cause of a greater DNA synthesis rate in their mammary 
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glands caused by higher prolactin levels at the time 
of DMBA administration. A correlation between the rate 
of DNA synthesis and plasma prolactin levels at each 
stage of the oestrous cycle would have to be demonstrated 
to support this possibility. 
An alternative possibility which was not invest- 
igated was that the rats which developed tumours may 
have continued to exhibit higher prolactin levels than 
non -tumour- bearing rats after DMBA administration. If 
this were the case then relationships between plasma pro - 
lactin levels and tumour incidence may have resulted 
from a stimulatory effect of prolactin on development as 
well as induction of tumours. 
Attempts to relate the results of the present study 
on the DMBA- induced rat mammary tumour to the human situ- 
ation are hindered by differences between both the pro- 
perties of human and ?gat mammary tumoursand the endocrin- 
ology of the respective host species. 
Although both human breast cancer and the DMBA- 
induced tumour convert testosterone to 5a- dihydrotesto- 
sterone and 5a- androstanediol, the ability to do so is 
greater in tumours of the rat (Miller, Forrest c Hamilton, 
19 74). In view of the observation that 5a- dihydrotesto- 
sterone is a potent inhibitor of the aromatisation sys- 
tem (Scharrzel, Kruggel s Brodie, 1973; Siiteri c 
Thompson, 1975; Hillier, van den Boogaard, Reichert s 
van Hall, 1980), the higher production of this steroid 
by rat mammary tumours in vitro may account for the fact 
that oestradiol synthesis has never been conclusively 
D- 71, 
demonstrated in the DMBA- induced mammary tumour, whereas 
it has been demonstrated in approximately half of the 
human tumours (Li, Chandra, Foo, Adams E McDonald, 1976; 
Miller c Forrest, 1976; Abul -Hajj, Iverson c Kiang, 
1979 a). Much of the metabolism of testosterone by 
human mammary tumours remains unaccounted for. It may 
be worthwhile investigating the formation of steroid 
allyl alcohols which has now been shown to take place 
in the DMBA -induced tumour. 
In relation to the stimulation of tumour 5a- reduct- 
ase by administration of perphenazine to rats it is int- 
eresting that exceptionally high 5a- reductase activity 
has been observed in a small number of breast cancers 
from patients who had been receiving the prolactin- 
releasing drug, methyl -dopa, for some time (Miller, 
personal communication). Whereas it was possible to 
postulate that in the rat the increase in 5a- reductase 
activity could be mediated by a stimulation in plasma 
progesterone levels, prolactin does not appear to per- 
form the same luteotrophic role in the human (Nicoll, 
1974). However it may be relevant that chronically 
elevated levels of plasma prolactin have been associated 
with an increased secretion of C -19 androgen precursors 
from the adrenal of postmenopausal women (Ando c Vermeulen, 
1977; Murru, Romagnino, Genazzani s Fioretti, 1977; 
Vermeulen, Suy s Rubens, 1977). It would be of interest 
to know if there was a relationship between their plasma 
levels and tumour 5a- reductase activity. 
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On account of the high level of 5a- reductase in 
the DMBA -induced mammary tumour and the relatively low 
levels of circulating C -19 steroids in the female rat, 
the role of 5a- reductase in controlling the action of 
androgens on this tumour has been questioned. However, 
the higher levels of C -19 steroids in the blood of 
women and the relatively lower tumour 5a- reductase act- 
ivity mean that the level of 5a- reductase may be of 
more significance in controlling the sensitivity of 
human breast cancer to androgens. 
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SUMMARY 
In common with certain human breast cancers, rat 
mammary adenocarcinomas induced by DMBA regress on the 
administration of pharmacological doses of androgen. 
Mammary cancers of both species convert testosterone 
by 5a- reduction to 5a- dihydrotestosterone and 5a- androst- 
anediol. This conversion plays an important role in 
mediating the androgenic effects of testosterone in 
target organs. The relationship between plasma hormone 
levels, tumour growth and metabolism of testosterone 
by DMBA- induced tumours has been investigated in rats 
of differing endocrine status. 
Female Sprague -Dawley rats bearing actively grow- 
ing tumours, induced by a single intragastric adminis- 
tration of 30 mg DMBA at 50 days of age, were allocated 
to one of the following treatment groups:- 1) Intact 
Control, 2) Intact + Perphenazine, 3) Intact + CB 154, 
4) Ovariectomised Control, 5) Ovariectomised + Perphen- 
azine. Animals received a daily s.c. dose of drug 
(5 mg /kg body weight) or corn oil vehicle (control groups) 
over an average treatment period of 12 days. Tumour 
size and the stage of the oestrous cycle, assessed from 
daily vaginal smears, were monitored before and during 
treatment. The effects of the treatment regimes on 
plasma prolactin and oestradiol levels, the two hormones 
considered of major importance in the growth of DMBA- 
induced mammary tumours, were measured in individual 
tumour -bearing rats and also in greater detail in par- 
allel studies in non- tumour -bearing rats. At the end 
of treatment (on the day of dioestrus in cycling animals) 
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a portion of tumour (0.5 g) was minced, sonicated and 
incubated for one hour at 37 °C with 50 x 106 d.p.m. 
[7a-311i-testosterone in Krebs -Ringer phosphate buffer, 
pH 7.4, containing an NADFH- generating system. Steroid 
interconversions were determined by measuring radioact- 
ive label in individual metabolites after extraction 
and purification by thin layer chromatography. 
Under these conditions tumour preparations from 
the intact control group metabolised slightly more than 
half of the testosterone precursor, mainly by 5a- reduct- 
ion (determined as the sum of 5a- dihydrotestosterone 
and 5a- androstanediol production). The major isomer 
of 5a- androstanediol was the 3a,17p -diol. In comparison 
with the intact control group, the administration of 
perphenazine to intact rats raised plasma prolactin 
levels, lowered plasma oestradiol levels, arrested the 
oestrous cycle in dioestrus and stimulated mammary tumour 
growth. Tumours in this group showed a greater capacity 
for testosterone metabolism and had significantly 
elevated levels of 5a- reduction. Administration of 
CB 154 depressed plasma prolactin levels but did not 
decrease plasma oestradiol levels, nor did it arrest 
the oestrous cycle. In these rats tumour growth was, 
in general, inhibited but the metabolism of testosterone 
did not differ significantly from that of the intact 
control group. Ovariectomy caused a fall in plasma 
oestradiol and plasma prolactin levels, a constant di- 
oestrus -type vaginal smear, and rapid tumour regression° 
Although the mean level of 5a- reduction in tumours from 
this group was numerically lower than that of the intact 
control group, the difference did not attain signific- 
ance. Plasma prolactin levels in ovariectomised rats 
given perphenazine were elevated to the same extent as 
in intact rats given perphenazine but tumour growth was 
not maintained. Whilst the level of 5a- reduction in 
tumours from ovariectomised rats given perphenazine was 
significantly higher than in tumours from the ovari- 
ectomised control group, it did not differ significantly 
from that of tumours from the intact control group and 
was significantly lower than that of tumours from intact 
rats given perphenazine. It is concluded that tumour 
growth is largely dependent on plasma prolactin levels 
and on the presence of ovaries. Although tumour 5a- 
reduction was increased in rats with elevated plasma 
prolactin levels other intergroup comparisons indicate 
that ovarian hormones could also be involved in the 
regulation of tumour 5a- reductase activity. In general 
there was no consistent correlation between tumour 
growth rate and tumour 5a- reductase activity. 
A study of testosterone metabolism in actively 
growing DMBA- induced mammary tumours, taken from un- 
treated rats at different stages of a 4 -day oestrous 
cycle, revealed that 5a- reductase was highest in tumours 
removed in metoestrus and lowest in tumours removed in 
proestrus. However the differences in 5a- reduction 
levels in tumours from the four stages of the cycle did 
not attain significance. Of the other parameters 
measured only plasma oestradiol levels varied signifi- 
cantly throughout the cycle, the level being greatly 
raised in proestrus. 
DMBA- induced mammary tumours appear to possess an 
extremely high capacity for 5a- reduction in relation 
to circulating levels of androgen precursor in the 
female rat. On the other hand progesterone, which has 
been reported to be a preferred substrate to testosterone 
for 5a_- reductase, is present in relatively high con- 
centrations in the plasma of female rats. The poss- 
ibility that an important function of tumour 5a- reduct- 
ase in vivo may be the conversion of progesterone to 
5a- reduced products is therefore raised. 
Evidence is presented for the conversion of testo- 
sterone to androst- 4 -ene- 3a,170-diol by DMBA- induced 
rat mammary tumours. The formation of this metabolite 
appeared to be inversely related to the formation of 
5a- reduced products and was responsible for a large 
part of the metabolism of testosterone otherwise un- 
accounted for by 5a- reduction. 
The daily administration (1 mg s.c. /rat) of 5a- 
dihydrotestosterone and 5a- androstane- 3a,17ß -diol for 
about 12 days resulted in constant dioestrus -type smears 
and profound regression of DMBA- induced mammary tumours. 
In contrast, the same dose of 5a- androstane- 3ß,17ß -diol 
was without effect on either parameter. Plasma pro - 
lactin levels in the two groups of non -cycling, 
androgen- treated rats were similar to those of control 
cycling rats in dioestrus. It is therefore plausible 
that, in addition to a direct effect at tumour level, 
androgen- induced tumour regression may be mediated by 
an inhibition in the secretion of oestradiol and pro - 
lactin. 
In a total of 861 rats, the plasma prolactin level 
and the stage of the oestrous cycle at the time of DMBA 
administration were related to subsequent tumour ap- 
pearance over an observation period of 120 days. Tumour 
incidence was higher in rats given DMBA in proestrus, 
and lower in those given DMBA in dioestrus. At all 
stages of the cycle the mean plasma prolactin levels 
at the time of DMBA administration were higher in rats 
which subsequently bore tumours than in those which did 
not. These observations may reflect a relationship 
between the rate of cell division in components of the 
breast and susceptibility to carcinogenic attack. 
APPENDICES 
Appendix I 
Testosterone metabolism and oestrogen receptor levels 
Some of the tumours which were incubated for testosterone metabolism 
studies were also assayed for their oestradiol receptor content in 
Dr R. A. Hawkins' laboratory. Although some of the oestrogen receptor results 
have already been published (Hawkins, Hill, Freedman, Killen, Buchan, Miller & 
Forrest, 1977), no data on testosterone metabolism were included. In Table 39 
the percentage 50(-reduction of testosterone is given along with the oestrogen 
receptor content for all tumours on which both assays were performed. The 
dissociation constant (Kd) values of the oestrogen receptors in these tumours 
ranged from 0.08 - 0.86 x 10 -10 M. Since the assay measured unoccupied 
cytoplasmic binding sites whose levels may be affected by the levels of 
oestradiol in the circulation (Hawkins, Hill, Freedman, Killen, Buchan, Miller & 
Forrest, 1977), plasma oestradiol levels are also listed. Further details of rats 
and tumours are given in the tables in Sections III and IV of the RESULTS. 
Although the tumours from intact rats given perphenazine showed high levels 
of 5g-reduction and had a high oestrogen receptor content there did not appear 
to be a correlation between these 2 parameters over the small number of 
tumours within each group. In 5 of the 6 rats from which data on 2 tumours 
were available, the tumour with highest 5 o(- reductase activity also had the 
highest oestrogen receptor content. 
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Table 39 
Oestrogen receptor levels and 5 o(- reductase activity 
















dioestrus 45M RIn 52.94 4.93 0.52 
I C 343L LNk 43.00 1.68 0.81 
LGr 27.17 1.44 
I + P 309E RNk 81.93 3.13 0.10 
LIn 81.36 2.57 
318E RAx 41.66 4.41 0.61 
333E RNk 39.80 4.20 0.24 
343E RIn 64.10 2.22 0.92 
357E LAx 37.19 2.57 0.27 
60H LGr 68.53 2.51 0.23 
87H RGr 70.48 6.05 0.28 
I + B 345L LAx 36.75 0.82 2.02 
LIn 48.45 1.52 
351L LTh 54.27 2.07 0.97 
354L LCh 18.89 1.35 1.08 
361L LTh 39.92 1.06 1.24 
LAn 46.47 1.15 
366L RGr 55.31 1.68 0.60 
384L RAx 41.05 2.49 0.69 
A-Z 
Table 39 (continued) 
5o.- reduction Receptor 
of content (Po) Plasma 
Treatment Rat and testosterone (fmol /mg oestradiol 
group tumour (%) tissue) (ng /100m1) 
OC 306K LNk 15.14 1.10 0.33 
O+P 378E RCh 63.57 1.40 0.22 
RAx 32.13 1.55 
397E RCh 71.54 2.88 0.29 
26H RAx 38.96 0.64 0.06 
297K RAx 38.30 0.92 0.43 
LAx 18.89 0.51 
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Appendix II 
Effect of androgens on a transplantable mammary tumour 
A tumour line, TG -5, which originated from a DMBA- induced mammary 
tumour, was maintained by serial transplantation into an inbred colony of rats 
originally purchased from the Animal Diseases Research Association, Edinburgh. 
With successive transplantations, tumours became ovarian independent and 
displayed high 50(- reductase activity (Miller, Stewart & Hawkins, 1979). Because 
of these features the effect of androgens on tumour growth was investigated. 
Small pieces of tumour from the 31st transplant generation were implanted 
s.c. in the backs of 75- day -old rats. Approximately 2 weeks after the 
appearance of the first tumour, animals were given testosterone or 50(- dihydro- 
testosterone, dissolved in corn oil, in daily s.c. doses of 5mg /kg. Tumour size 
was measured 3 times per week and vaginal smears taken daily before and during 
treatment. Since it was known that all transplant tumours grow continuously no 
control group was included. 
It can be seen from the results in Table 40 that the growth of these 
tumours was not inhibited by androgen treatment. Vaginal smear patterns in 
rats of this colony were less regular than those of the rats used for inducing 
tumours with DMBA. Furthermore the rats of this colony did not exhibit a 
constant pattern of dioestrus -type vaginal smears during androgen treatment. 
Table 40 
The effect of androgens on the growth of a 
transplantable mammary tumour 
Treatment 
5 o( -DHT Testosterone 
Number of rats 5 4 
Number of tumours 9 9 
Pretreatment 
9 9 number growing 
size (cm2) 2.55 ± 0.94 2.54 t 0.85 
growth rate (cm2 /week) 1.38 ±0.52 1.12 ±0.41 
End of treatment 
9 9 number growing 
size (cm2) 5.75 ± 2.86 6.32 t 2.07 
growth rate (cm2 /week) 1.814: 1.28 1.86 ± 0.65 
Values of size and growth rate are means ± s.d.'s. 
Each rat received 12 daily s.c. doses of 5mg steroid /kg body weight. 
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Appendix III 
Standardisation of plasma prolactin results 
Because of the inevitable deterioration of certain of the reagents used in 
the prolactin assay, interassay variations could occur. Therefore, from time to 
time, samples of fresh plasma from male rats were pooled, and divided into 
aliquots for use as quality controls. These were stored in the same manner as 
other samples, and duplicates included in each assay. Quality control values 
were read off the standard curve of each assay, and are listed in Table 41. In 
order to standardise the results of different assays a reference value for Pool E 
was fixed arbitrarily at 2Ong /ml (after this value had been obtained in 3 
consecutive assays), and the sample values obtained from the standard curve of 
each assay multiplied by the correction factor, 
reference value of pool 
quality control value in assay. 
The reference value for a new pool relative to the original 2Ong /ml of Pool 
E was determined from the average ratio of values of the old and new pools run 
in the same assay (Table 41). 
A- G 
Table 41 
Quality control values and calculation of reference values 
in prolactin assays 
Assay 
number Pool E 
Prolactin (ng /ml) 
Pool G Pool P 
63 21 
64 25 
65 20 Pool E 









78 25 62 
79 32 54 
80 27 44 
81 30 60 Ave G/E = 2.12 
82 31 56 Pool G 
83 25 50 ref. value = 20 x 2.12 
84 21 50 
85 19 49 
86 30 
87 24 50 
88 25 55 






Table 41 (continued) 
Assay 
number 
Prolactin (ng /ml) 
Pool E Pool G Pool P 
100 53 
101 50 40 
102 43 
103 44 Ave P/G = 0.80 
107 40 32 Pool P 
108 29 23 ref. value = 42.2 x 0.80 
110 30 










The choice and application of statistical analyses and formulae used 
in this thesis are described in the publications listed below. 
1. Dunnett's test - 
Dunnett, C. W. (1964) 
New tables for multiple comparisons with a control 
Biometrics 20, 482 - 491 
2. Table for d2 in s.d. (est.) = d 2 2 
Grant, E. L. (1952) 
Statistical quality control. 3rd Edition 
New York: McGraw -Hill 
3. All other tests - 
Snedecor, G. W. and Cochran, W. G. (1976) 
Statistical methods. 6th Edition 
Iowa State University Press 
Appendix V 
Publications 
Part of the work carried out for this thesis has been described in the 
following publications:- 
Buchan, P., Fraser, A. T. and Miller, W. R. (1976) 
The effect of perphenazine treatment on testosterone metabolism by 
established rat mammary carcinomas. 
Biochem. Soc. Trans. 4, 1100 - 1102 
Buchan, P. and Miller, W. R. (1978) 
Perphenazine and testosterone metabolism by mammary tumours in 
oophorectomised rats. 
Biochem. Soc. Trans. 6, 135 - 136 
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1100 BIOCHEMICAL SOCIETY TRANSACTIONS 
The Effect of Perphenazine Treatment on Testosterone Metabolism by 
Established Rat Mammary Carcinomas 
PETER BUCHAN, ALISON T. FRASER and WILLIAM R. MILLER 
Department of Clinical Surgery, Medical School, University of Edinburgh, 
Edinburgh EH8 9AG, Scotland, U.K. 
Mammary carcinomas may be induced in female Sprague - Dawley rats by the adminis- 
tration of the carcinogen 7,12 -dimethylbenzanthracene. These tumours metabolize 
testosterone (King et al., 1964), particularly by 5a- reduction to 5a- dihydrotestosterone 
and 5a- androstanediol (Miller, 1976). In a previous study, tumours obtained from ani- 
mals rendered hyperprolactinaemic by giving perphenazine during the period of tumour 
induction and growth showed enhanced conversion of testosterone into 5a- reduced 
metabolites (Miller et al., 1974a). The aim of the present study was to determine if similar 
effects could be elicited by administering perphenazine to animals with established 
tumours and raising plasma prolactin concentrations during the growth period alone. 
Tumours induced in female Sprague - Dawley rats by intragastric administration of 
dimethylbenzanthracene (30 mg in cotton -seed oil) at 50 days of age were measured 
three times weekly by calipers. Animals bearing tumours showing continuous growth 
were allocated to control or treatment groups when the tumour size was about 1.5cm x 
1.5cm. The treatment group received daily subcutaneous injections of perphenazine 
(5 mg /kg body weight) until being killed 12 days later. Control animals did not receive 
the drug over the same time- period. Measurement of tumour size continued during 
treatment until excision at death. The metabolism of testosterone in vitro was then de- 
termined in ten tumours from each group. A portion of each tumour (0.5 g) was finely 
sliced and sonicated in 5 ml of Krebs -Ringer phosphate buffer, pH 7.4. An NADPH- 
generating system (100pmol of glucose 6- phosphate, 15Etmol of NADP+ and 25 units 
of glucose 6- phosphate dehydrogenase) and 20,uCi of [7a- 3H]testosterone were added 
to give a final volume of 7.5 ml. The incubations were then shaken in an atmosphere of 
02 at 37 °C for 1 h. 
The steroid interconversions were determined by measuring the percentage incorpora- 
tion of radioactive label into the individual metabolites after extraction and purification 
by t.l.c. Details of the methods of steroid purification and characterization have been 
described by Miller et al. (1974b). 
When sufficient tumour material was available, the DNA content was measured by 
the method of Burton (1956). 
All but one of the tumours from the perphenazine -treated group showed an accelera- 
tion of growth during the treatment period, whereas those from control animals showed 
no significant change. 
The results from the incubations with [7a- 3H]testosterone are summarized in Table 1. 
Tumours from perphenazine- treated animals showed significantly higher metabolism of 
testosterone than those from control animals. The major metabolites of testosterone in 
tumours from both control and perphenazine- treated animals were 5a- dihydrotesto- 
sterone and 5a- androstanediol. The conversion into both 5a- dihydrotestosterone and 
5a- androstanediol was, however, significantly higher in tumours from the perphenazine- 
treated group. The increase in 5a- reduction alone accounts for the higher concentrations 
of testosterone metabolized by tumours from this group. These effects of perphenazine 
are unlikely .to be mediated by an increase in tumour cellularity, as the tumour DNA 
content was similar in both groups of animals. 
It is concluded that short -term administration of perphenazine stimulates growth 
and testosterone metabolism in dimethylbenzanthracene- induced rat mammary carci- 
nomas. Preliminary results show that these changes were accompanied by an increase in 
plasma prolactin. 
Burton, K. (1956) Bioche,n. J. 62, 315 -323 
King, R. J. B., Gordon, J. & Helfenstein, J. E. (1964) J. Endocrinol. 29, 103 -110 
Miller, W. R. (1976) Br. J. Cancer 33, 474 -477 
Miller, W. R., Buchan, R. & Forrest, A. P. M. (1974e) Biochem. Soc. Trans. 2, 312 -314 





















































































































































































































































































































































































































572nd MEETING, LONDON 135 
Perphenazine and Testosterone Metabolism by Mammary Tumours in 
Oophorectomized Rats 
PETER BUCHAN and WILLIAM R. MILLER 
Department of Clinical Surgery, Medical School, University of Edinburgh, 
Edinburgh EtH8 9AG, Scotland, U.K. 
Rat mammary tumours induced by the carcinogen 7,12 -dimethylbenzanthracene in 
female rats metabolized testosterone, particularly by 5a- reduction to 5a- dihydrotesto- 
sterone and 5a- androstanediol (Miller, 1976). It has also been shown that these conver- 
sions were significantly elevated in tumours from animals treated with perphenazine 
( 2-{ 4-[ 3-( 2- chlorophenothiazin- 10- yl)propyl]piperazin -1 -yl; ethanol) (Buchan et al., 
1976). Additionally, perphenazine stimulated tumour growth, raised plasma prolactin 
concentrations and interrupted the normal oestrous cycle. To determine the relative 
influence of prolactin and ovarian hormones on tumour growth and steriod metabolism, 
the effects of perphenazine have been studied in oophorectomized animals. 
Female Sprague- Dawley 50- day -old rats were given 7,12- dimethylbenzanthracene 
(30 mg in cottonseed oil) intragastrically. Tumours subsequently induced were measured 
three times weekly by calipers throughout the study. Animals bearing tumours that 
showed cow intious growth were allocated to the treatment or the control group 
when the tumour size exceeded 2cm x 2cm. The allocation was performed on the day of 
dioestrus when all animals were bled from the tail vein and bilaterally oophorectomized. 
The treatment group of rats additionally received daily subcutaneous injection of 
perphenazine (5 mg /kg body wt.) from the day of oophorectomy until death 14 days 
later. Control animals received daily doses of the injection vehicle (corn oil) over the 
same period. Immediately before death, blood was taken for plasma prolactin 
determination by radioimmunoassay, and tumours taken for steroid metabolism 
studies in vitro. Ten tumours from both animal groups were investigated: 0.5g of each 
tumour was finely sliced and incubated at 37 "C for 1 h in 5ml of Krebs -Ringer phos- 
phate buffer, pl-l7.4, containing 20,uCi of [7a -'H] testosterone and NADPH -generating 
system (Buchan et al., 1976). Methods for purification and characterization of testo- 
sterone and its metabolites have been described in detail previously ( Miller et al., 1974). 
The effects of the treatment regimes on plasma prolactin concentrations are shown in 
Table 1. Both groups of animals had similar prolactin values at the time of allocation. 
However, whereas oophorectomy alone resulted in a fall in plasma prolactin concen- 
tration in each animal, oophorectomy in combination with perphenazine treatment 
produced an increase in prolactin in all animals. The difference between pre- and post- 
treatment values was significantly for both animal groups. 
Oophorectomy alone produced an immediate regression of all tumours. In the 
oophorectomy- plus - perphenazine group, however, there was a variable response in 
tumour growth, certain tumours increasing in size throughout the time of study whereas 
others regressed, usually after a short period of continued growth. 
The metabolism of [7a- 3H]testosterone by tumours from both groups of animals is 
shown in Table 2. Tumours from animals given perphenazine in addition to oophorect- 
Table 1. Erect of oophorectomy and subsequent perphenazine administration on plasma 
prolactin concentrations 
Animal group 





Oophorectomy alone 37.1 ± 11.4 6.7± 1.0 P <0.01 
Oophorectomy and perphenazine 
administration 
37.3 ± 10.8 87.9 ± 10.6 P <0.01 
* Significance was measured by paired Student's t test. 
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Table 2. Metabolism of [7a- 3H]testosterone by tumours from the animal groups studied 
Significance, by Wilcoxon -Rank test, of perphenazine- treated animals paired with 
oophorectomy -alone group for each conversion was: $, not significant; f, P<0.I ; 







Metabolism into 5a -di- Conversion 
of testos- hydrotestos- into 5a- andro- 5a- Reduction 
terone ( %) terone ( %) stanediol ( %) 
40.09± 5.43 4.53 ±0.66 22.96 ±3.40 27.49 ±3.74 
57.65 ± 4.83* 8.97 ±2.32$ 33.22 ±4.43$ 42.17 ±6.13f 
omy showed significantly higher metabolism of testosterone than tumours from rats 
subjected to oophorectomy alone. In all tumours, irrespective of the animal group from 
which they were derived, the major metabolites of testosterone were 5a-dihvdrotesto- 
sterone and 5a- androstanediol. Although the mean conversions into both metabolites 
were greater in tumours from animals given perphenazine, the differences from the 
oophorectomy alone -group were not significant. 
The present results contrast with effects in intact animals where perphenazine, 
although producing a similar elevation in plasma prolactin values, stimulates tumour 
growth and causes a highly significant increase in tumour 5a- reduction of testosterone 
(Buchan et al., 1976). 
In summary, perphenazine failed to reproduce, in animals deprived of ovarian 
hormones, the marked stimulatory effects on mammary- tumour growth and steroid 
metabolism that it produces in endocrine -intact animals. 
Buchan, P., Fraser, A. T. & Miller, W. R. (1976) Biochem. Soc. Trans. 4, 1100 -1102 
Miller, W. R. t 'Y76) I?,. J. Cancer 33,474-477 
Miller, W. R., Forrest, A. P. M. & Hamilton, T. (1974) Steroids 23, 379 -395 
A-14. 
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